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LDL-receptor mutations and familial defective apolipoprotein 
B-100 (codon 3500) (FOB), the known causes of monogenic 
hypercholesterolemia (MH), have similar clinical features. 
The nature of the mutations responsible for MH in South 
Africans of Indian origin was previously unknown. Similarly, 
the mutations in the LDL-receptor gene of a South African 
Black FH homozygote had also not been characterised. The aim 
of this thesis was to identify and analyse the LDL-receptor 
mutations in the Indian homozygotes NS, D, AV and AA and in 
the Black homozygote JL. In addition, the possible importance 
of FOB as a cause of MH in South Africans was also assessed. 
The patient NS was characterized as having two "Null" LDL-
receptor alleles. His skin fibroblasts expressed no 
detectable LDL-receptor protein and very low levels of LDL-
receptor mRNA of approximately normal size. Since NS' s LDL-
receptor promoter sequence was normal, his alleles are likely 
to harbour exonic point mutations or minor rearrangements that 
cause premature stop codons. 
The patient D was found to be a heteroallelic homozygote. Two 
new point mutations in the LDL receptor, Asp69 -Tyr and Glu119-
Lys, were identified. D's fibroblasts expressed about 30% of 
the normal surf ace complement of receptors that bound LDL 
poorly. This low number could at least be partially explained 
by their decreased stability. These mutations were not 
iv 
identified in any other Indian FH or hypercholesterolemic 
patients. 
Patients AV and AA were both shown to be homoallelic 
homozygotes for the Pro664-Leu mutation. This mutation was 
identified in 4 unrelated Muslim families of Gujerati origin 
suggesting that the mutation arose from this area in India. 
Contrary to previous reports (Knight et al. 1990, Soutar et 
al. 1989), neither LOL nor B-VLOL binding were shown to be 
affected by this mutation. These mutant receptors were 
rapidly degraded. Thus the disease FH in these subjects is 
presumably due to the low steady-state level of mature 
receptors that are functionally normal but exhibit accelerated 
turnover. 
The Pedi FH homozygote, JL, expressed very few LOL receptors 
due to decreased receptor synthesis associated with low mRNA 
levels and not due to enhanced degradation. One of JL's LOL 
receptor alleles has a 3 b.p. deletion in repeat 1 of the 
promoter (G. Zuilani, H. Hobbs and L.F. de Waal, personal 
communication). The nature of the defect in his other allele 
is unknown. 
The importance of FOB as a cause of monogenic 
hypercholesterolemia in the South African Indian, "Coloured" 
and Afrikaner populations was determined by screening 
hypercholesterolemic subjects with or without xanthomata. The 
absence of FOB in such patients, in whom the relevant common 
V 
or founder South African mutations were excluded, suggested 
that this disorder was rarer in these groups than in North 
America and Europe. 
FOB was identified in two different families of mixed British 
and Afrikaner ancestry. One family contained individuals who 
were heterozygous for the FOB mutation, as well as the FH 
Afrikaner-1 and the FH Afrikaner-2 LOL-receptor mutations. In 
addition, 4 compound heterozygotes, who had both FOB and the 
FH Afrikaner-1 mutation and one individual whu inherited all 3 
defects, were identified. This family allowed us to 
characterise the compound heterozygotes with one mutant LOL-
receptor allele and FOB as having a condition that was 
probably intermediate in severity between the FH heterozygote 
and homozygote states. 
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= ammonium persulphate 
= Apolipoprotein 
= Beta migrating very low density lipoprotein 
= Bovine serum albumin 
= Chloramphenicol acetyltransferase 
= Chinese hamster ovary 
= Diethylpyrocarbonate 
= 1, 1' dioctadecyl-3,3,3',3' tetramethylindocyanine 
perchlorate 
= Dulbecco's modification of Eagle's Minimum 
Essential Medium 
= Endoplasmic Reticulum 
= Fetal calf serum 
= Familial defective apolipoprotein B-100. 
= Familial hypercholesterolemia 
= N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic 
acid 
= 3-hydroxymethyl-3-methylglutaryl coenzyme A 
= Herpes simplex virus 
= Intermediate density lipoprotein 
= Luria/Lennox broth 
= Low density lipoprotein 
= Lipoprotein deficient serum 
= Eagle's Minimal Essential Medium buffered with 
Earle's salts 
PBS = Phosphate-buffered saline 
PCR = Polymerase chain reaction 
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SSCP = Single-strand conformational polymorphism 
TEMED = N,N,N',N'-tetramethylethylenediamine 
TK = Thymidine kinase 
TLC = Thin layer chromatography 
VLDL = Very low density lipoprotein 
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CHAPTER 1 
MONOGENIC HYPERCHOLESTEROLEMIA: A REVIEW OF NORMAL AND MUTANT 
LDL-RECEPTOR BIOLOGY AND FAMILIAL DEFECTIVE 
APOLIPOPROTEIN B-100 
1.1 INTRODUCTION TO LIPOPROTEIN METABOLISM AND MONOGENIC 
HYPERCHOLESTEROLEMIA 
1.1.1 NORMAL LIPOPROTEIN METABOLISM 
Cholesterol plays important roles in vertebrate structure and 
metabolism as a constituent of cell membranes and as a 
precursor for steroid hormones and bile acids (Myant 1990). 
Two different pathways transport cholesterol in the blood. 
The "exogenous" pathway delivers dietary cholesterol mainly 
to the liver. Chylomicron particles containing triglycerides 
and cholesterol absorbed from the intestine are secreted into 
the lymphatic system and enter the circulation via the 
thoracic duct. The triglycerides in these large lipoproteins 
are hydrolysed by lipoprotein lipase on the vascular 
endothelium. The resultant smaller chylomicron remnants are 
rapidly removed from the blood mainly by receptors on 
parenchymal liver cells (Shepherd and Krauss 1991). These 
receptors are probably distinct from the LDL receptor since 
chylomicron remnant clearance is unimpaired in FH homozygote 
subjects with severe LDL-receptor deficiency (Rubinsztein et 
al. 1990). The LDL-receptor related protein (LRP), the a 2 
macroglobulin receptor, might be the chylomicron remnant 
receptor (Brown et al. 1991). 
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The "endogenous" cholesterol pathway is concerned with the 
transport in the circulation of apo B-100 containing 
lipoproteins 
initially 
secreted by the liver. These particles are 
known as very low density lipoproteins (VLDL) . 
The nascent VLDL particles contain apo B-100, apo E and a 
small amount of apo c. As soon as the VLDL enters the 
circulation it acquires additional apo E and apo C derived 
from HDL metabolism. The VLDL triglycerides are lipolysed by 
lipoprotein lipase to yield smaller particles called 
intermediate density lipoproteins (IDL). These IDL can 
either be furthur lipolysed by lipoprotein lipase or h~patic 
lipase to form low density lipoproteins {LDL) or can be 
directly removed from the circulation via the interaction of 
apo E with LDL receptors. LDL particles, which carry most of 
the plasma cholesterol, are removed from the circulation 
mainly by hepatic LDL receptors interacting with their sole 
apolipoprotein, apo B-100. Although approximately 70% of LDL 
catabolism is via the liver, the major route of cholesterol 
exit from the body, significant LDL clearance from the blood 
is mediated by the small intestine, skeletal muscle, kidney 
and spleen (Myant 1990). A small proportion of LDL in normal 
individuals is cleared by non-LDL-receptor pathways. 
Although most of the cholesterol eliminated from the body is 
via the hepatic route, some cholesterol is lost in sebum and 
in desquamated intestinal and skin cells. 
1.1.2 MENDELIAN DISEASES THAT RESULT IN IMPAIRED LDL 
METABOLISM 
Two related syndromes have been characterised where defective 
removal of LDL via LDL receptors is the primary defect. 
Familial Hypercholesterol~mia (FH) results from mutations at 
2 
the LDL-receptor gene locus that affect either the number 
and/ or function of the LDL-receptor proteins. This causes 
two different perturbations in the endogenous cholesterol 
pathway that result in hypercholesterolemia. Firstly, an 
overproduction of LDL from IDL results from impaired direct 
IDL removal from the circulation and secondly the rate of LDL 
removal is decreased (James et al. 1989) . The clinical 
severity of this disease is milder in patients with one 
mutant gene (heterozygotes) than in those with two 
(homozygotes). Heterozygotes have approximately 50% of the 
normal number of functional LDL receptors on their cells (a 
simplification). Their plasma cholesterol levels are about 
twice as high as normal and many have evidence of premature 
coronary artery disease: about 50% of FH heterozygote males 
have coronary heart disease by age 50. The situation in 
homozygotes who have two mutant alleles is far more severe: 
Plasma cholesterol concentrations are raised up to 5x the 
normal levels and coronary artery disease often manifests in 
childhood with death from a heart attack occuring frequently 
before the age of 25 (Thompson et al. 1989). 
An alternative gene defect that causes decreased LDL 
clearance is the glutamine for arginine substitution at codon 
3500 of apo B. Apo B-100 is the sole apoprotein on LDL and 
is the ligand on the particle that binds to the LDL receptor. 
The LDL that carry apo B with the arg-gln mutation at codon 
3500 bind very poorly to LDL receptors and are cleared 
abnormally · slowly from the circulation. This condition, 
3 
called familial defective apo B-100 (FOB}, is inherited in an 
autosomal dominant fashion (Innerarity et al. 1990}. FOB in 
its heterozygous state is clinically very similar to 
heterozygous FH (Rauh et al. 1992). 
1.2 THE INTINERARY OF THE LOL RECEPTOR 
LOL-receptor proteins are synthesized on polyribosomes and 
are co-translationally inserted into the endoplasmic 
reticulum where high-m.::innose N-linked glycosylation occurs. 
The receptor is then transported to the smooth endoplasmic 
reticulum where a-linked N-acetyl-galactosamine residues are 
thought to be added to the receptor (Myant 1990). At this 
point the precursor receptor has an apparent MW of 120 kOa. 
After transport to the Golgi, where the high-mannose N-linked 
sugars are trimmed and converted to complex chains and 
galactose and sialic acid residues are added to the 0-linked 
chains, the receptor attains its mature form, MW 160 kOa. 
This process takes 15-30 minutes. It seems that the increase 
of the apparent MW from 120 kOa precursor to the 160 kOa 
mature receptor is largely due to the addition of galactose 
and sialic acid residues to a-linked chains in the trans 
Golgi (Tolleshaug et al. 1982, Cummings et al. 1983). 
Cummings et al. (1983}, in their extensive analysis of the 
glycosylation of the LOL-receptor, demonstrated considerable 
heterogeneity of 0-linked glycosylation. It is likely that 
the 0-linked glycosylation is heterogeneous within each 
receptor but the possibility exists that a-linked 
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glycosylation varies between receptors i.e. receptors have 
different 0-linked chains at homologous sites. These authors 
found that each receptor had only one N-linked sugar chain. 
However, there were more than 2 different types of N-linked 
sugar chains in the mature LDL receptors from each of the 
cell types studied. This suggested that there are 
differently glycosylated populations of LDL receptors 
produced by normal cells. The possibility that functional 
heterogeneity of normal LDL-receptor sub-populations might 
exist has not been investigated. 
FH Afrikaner-1 (Fourie et al. 
Some mutant receptors, e.g. 
1988) , however, do man if est 
functionally heterogeneous sub-populations of receptors that 
might be subtly differently glycosylated. 
The conversion of precursor to mature receptors is 
quantitatively virtually complete in normal cells (Tolleshaug 
et al. 1982, Knight et al. 1989). This implies that hardly 
any precursor degradation occurs. It is possible that a 
"pre-precursor" form of the LDL receptor exists that is not 
immunoprecipitable by anti-LDL-receptor antibodies or is not 
immunoprecipitated at 120 kDa. Alternatively, the steady-
state pool of these pre-precursor receptors could be very 
small. These pre-precursor receptors would possibly include 
proteins that are folding and re-folding in order to attain 
their correct conformation(s). Nobody knows what the kinetics 
of "pre-precursor" to precursor conversion are or whether 
this conversion · is completed for all molecules. It is 
possible that the extent of "pre-precursor" to precursor 
5 
conversion is impaired by some of the many mutations that 
seem to affect normal protein folding. 
From the Golgi the receptor is transported to the cell 
surface, where it can bind lipoproteins that bear its ligands 
apo B-100 and/or apo E. The receptors in fibroblasts are 
particularly concentrated in specific regions of the plasma 
membrane called coated pits that mediate their endocytosis 
(Anderson et al. 1977). 
LDL receptors are internalized into the cell whether or not 
they have bound ligand (Anderson et al. 1982, Basu et al. 
1981). As endocytosis proceeds, the pH in the vesicles is 
lowered by a proton-driven pump (Tycko and Maxfield 1982). 
In the compartment of uncoupling of the receptor and ligand 
(CURL), the pH is sufficiently low for the receptor and 
ligand to dissociate. At this point they part ways. The 
freed receptor can return to the cell surface where it can 
undergo many further rounds of endocytosis (Brown et al. 
1983). Each round trip takes about 12 minutes (Basu et al. 
1981). The ligand is delivered to lysosomes where its 
apoproteins are degraded and the cholesterol esters are 
hydrolysed. The liberated free cholesterol is transported 
out of the lysosome and will have many important regulatory 
consequences in the cells. It inhibits the synthesis of LDL 
receptors (Brown and Goldstein 1975). It stimulates ACAT 
(the enzyme that forms intracellular cholesterol esters) 
(Goldstein · et al. 1974) and inhibits the activity of HMG-CoA 
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reductase, the rate-limiting enzyme in the cell's de novo 
cholesterol synthesis pathway (Brown et al. 1974). 
1.3 THE GENETIC ORGANISATION AND PROTEIN STRUCTURE OF THE 
LDL RECEPTOR 
The 860 amino acid LDL receptor (Yamamoto et al. 1984) is a 
multi-domain protein, with components of diverse evolutionary 
origin (Sildhof et al. 1985). The LDL receptor is an ancient 
protein that is highly conserved across many species ranging 
from Xenopus to humans (Mehta et al. 1991). The 45 kB gene 
(19p 13.1 - p 13.3) (Lindgren et al. 1985), containing 18 
exons and 17 introns, is transcribed into a 5. 3 kB mRNA 
( Stidhof et al. 1985) . The exons are arranged in a modular 
fashion where each exon or group of exons defines a distinct 
domain of the receptor (see Fig. 1.1). 
Exon 1 codes for a short 5' untranslated region and a 21 
amino acid signal sequence that aids in the co-translational 
translocation of the protein into the ER. This region is 
cleaved off during the translocation process to yield a 
mature protein of 839 amino acids. 
• 
Exons 2-6 code for the LDL-receptor's ligand-binding domain. 
This domain consists of 7 40-amino acid repeats homologous 
to the complement factor 9. Each repeat has 6 cysteines that 
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Fig. 1.1: Schematic diagram of the Lot-receptor protein and 
gene showing relationship of exons to specific domains (from 
Esser et al. 1988 and Russell et al. 1989) with permission of 
the authors and the American Socie~ty for ·Biochemistry and 
Molecular Biology. 
Exons 7-14 code for the EGF-precursor homology domain, so 
named because of its DNA sequence similarity to the mouse 
EGF-precursor molecule. Exons 7, 8 and 14 code for 40-amino 
acid repeats of distinct evolutionary origin from those found 
in the ligand-binding domain. These repeats (named A,B and 
C) also contain 6 disulphide-bonded cysteines (Stidhof et al. 
1985). Repeats A and Bare separated from repeat C by 280 
amino acids in which 5 repeats of the motif YWTD are found. 
This EGF-precursor homology domain is thought to have 4 
functions: Repeat A is necessary for optimal LDL (Apo B) 
binding to the receptor (Esser et al. 1988). The domain as a 
whole mediates acid-dependent dissociation of the receptor 
from its ligand in endosomes (Davis et al. 1988) and the YWTD 
repeats are thought to play a role in protecting the receptor 
from rapid degradation (Hobbs et al. 1990). The intactness 
of the domain is crucial for normal folding of the receptor 
and transport from the ER to the Golgi (Hobbs et al. 1990). 
Exon 15 codes for a region of 48 amino acids including 18 
serines and threonines that are potential attachment sites 
for 0-linked sugars (Stidhof et al. 1985). The deletion of 
this region in Chinese hamster ovary cells has no deleterious 
consequences on receptor function (Davis et al. 1986). 
However, there is a natural mutation, FH Tonami-1, where this 
domain is deleted, that manifested slow processing of the 
precursor to the mature form (Mabuchi et al. 1990). 
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Exons 16 and the start of exon 17 code for the membrane 
spanning domain, and the 3' end of exon 17 and the 5
1 end of 
exon 18 code for the cytoplasmic tail of the receptor {Slidhof 
et al. 1985). The cytoplasmic domain contains amino acids 
that are important determinants for the clustering of 
receptors in coated pits. Mutations to crucial amino acids 
in this region result in receptors that bind ligand but do 
not get internalized to any significant extent (Davis et al. 
1987, Chen et al. 1990). In addition to amino acid signals 
that ensure normal clustering in coated pits, the LDL-
receptor tail has distinct sequences that direct the 
receptors to the apical and/or basolateral domains of 
polarised cells (Pathak et al. 1990). 
LDL-receptor expression is largely regulated by the level of 
intracellular unesterified cholesterol. There are, however, 
other hormonal influences that regulate LDL-receptor levels 
that I will not review here {See Soutar and Knight 1990). 
The transcription of the LDL-receptor gene is modulated by 
proteins that bind to DNA sequences within 200 base pairs 
upstream of the translation initiation codon. This promoter 
contains a TATA like sequence and 3 16-base pair imperfect 
direct repeats {Slidhof et al. 1987) that seem to be necessary 
for maximal transcription. Repeats 1 and 3 bind the 
transcription factor Sp-1 (Dawson et al. 1988) . The 2nd 
repeat is the sterol regulatory element that is a positive 
transcriptional element in the absence of sterols {Slidhof et 
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al. 1987) , but is also the site of inhibition of 
transcription in the presence of sterols (Dawson et al. 
1988) • The regulation of steady-state levels of receptors 
was thought to occur almost entirely at the level of 
transcription. Recent work has suggested that sterol 
regulation can take place at a post-transcriptional level as 
well (Tam et al. 1991, Sharky et al. 1990). The details of 
this mechanism have not been further elucidated. 
The degradation pathways of the LDL receptor have not been 
fully characterised. The mature fibroblast receptor has a 
half-life of 10-12 hours that is unaffected by the presence 
or absence of sterols (Casciola et al. 1988). This suggests 
that sterol regulation of receptor levels is occurring almost 
exclusively at the level of .receptor synthesis (transcription 
and maybe translation). Since the degradation of the mature 
receptor was not affected by the lysosomotropic agent 
leupeptin, the initial steps in this process are unlikely to 
be lysosomal (Casciola et al. 1989). The degradation process 
depends on the presence of short-lived proteins since the 
half-life of receptors is increased in cells treated with 
cycloheximide (Casciola et al. 1988). 
1.4 VARIATION IN "NORMAL" LDL-RECEPTOR GENES 
Restriction fragment length polymorphism (RFLP) analysis of 
LDL-receptor genes has yielded 22 different polymorphic sites 
(Hobbs et al. 1990) and 123 different haplotypes (Leitersdorf 
et al. 1989a) . Because there is linkage disequilibrium 
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between many of the sites, the analysis of 5 selected sites 
is probably sufficient as the cumulative heterozygosity index 
of these sites is 84% and the addition of a further 5 sites 
only increases the heterozygosity index to 86% (Hobbs et al. 
1990) . There have been some attempts to link certain RFLPs 
to variation in cholesterol levels in normolipidemic 
populations. In 3 different populations the presence of a 
Pvu II cutting site was correlated with reduced cholesterol 
levels (Pedersen and Berg 1988, Schuster et al. 1990, 
Humphries et al. 1991). This suggests that some factor in 
linkage disequilibrium with the Pvu II RFLP site in the LDL-
receptor gene, that possibly alters LDL-receptor structure or 
expression, results in lower cholesterol levels. 
1. 5 LDL-RECEPTOR MUTATIONS . 
More than 40 different mutant LDL-receptor genes have been 
detected to date (Hobbs et al. 1990). These have been 
classified into 5 classes by the Dallas group depending on 
their phenotypic defect (Hobbs et al. 1990). Class 1 
mutations produce no immunoprecipitable receptors. The null 
alleles that produce no mRNA are often large deletions that 
remove the gene's promoter. Other null alleles produce mRNA 
that is reduced in quantity. This can result from nonsense 
mutations or deletions that create premature stop codons. 
The mRNA levels are thought to be low in these cases due to 
the lack of ribosomal binding to a large stretch of mRNA 
exposing it to increased degradation (Trecartin et al. 1981). 
Null mutations could possibly also result from very rapid 
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degradation of the LDL-receptor precursor (Hobbs et al. 
1990) . 
Class 2 mutations produce proteins that are slowly 
transported from the ER to the Golgi. This is manifested in 
a delay in conversion of the precursor receptor (120 kD) to 
its mature form (160 kD). These mutations have been 
classified into either complete (type 2A) or partial (type 
2B) blocks of transport. The type 2A mutations described 
thus far occur in the EGF-precursur homology domain (Hobbs et 
al. 1990) or result from the deletion of the a-linked sugar 
domain (Mabuchi et al. 1990). Various point mutations and 
small deletions in the ligand-binding domain result in type 
2B mutations (Hobbs 1990). The distinction between type 2A 
and 2B mutations is maybe not such a simple matter. The 
absence of any mature receptors in these 2A mutations might 
be due to a complete block in transport of precursor 
receptors to the Golgi. Alternatively, since it is known 
that many mutations in the EGF-precursor domain also cause 
rapid degradation of the mature receptor (eg FH-Afrikaner-2, 
Fourie et al. 1988, and FH-Cape Town-2, van der Westhuyzen et 
al. 1991), it is possible that the absence of detectable 
mature receptors is a result of very rapid degradation of the 
mature receptors and not due to an absolute block in 
transport. The slow transport phenomenon is fairly 
widespread among human genetic diseases and is probably the 
result of improper folding of mutant proteins in the ER. 
These malfolded molecules get subsequently retained in the ER 
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by proteins such as Bip (Gething and Sambrook 1992). 
Partially impaired transport from the ER to the Golgi is not 
sufficient to cause a lower than normal number of cell 
surface LDL receptors. A low cell-surface receptor 
complement will presumably only manifest if, in addition to 
slow transport, there is either decreased receptor protein 
synthesis or enhanced absolute degradation of either the 
precursor or mature forms of the receptor. If there is a low 
fractional degradation rate of normal precursor receptors 
that is not usually noticeable, it might be a mechanism that 
becomes increasingly prominent in determining mature receptor 
pool sizes in slowly transported mutations. In these cases, 
the absolute precursor degradation rate can be greatly 
increased as the precursor receptor pool expands due to 
impaired transport from the ER to the Golgi, even if the 
fractional degradation rate is unaltered. This scenario is 
probably not operative in all type 2B mutations, since the 
conversion of precursors to mature receptors was 
quantitatively virtually complete in the slowly processed FH 
Zambia mutation (Knight et al. 1989). 
Type 3 mutations exhibit impaired ligand binding. Mutations 
in repeats 2 to 7 of the ligand-binding domain and repeat A 
of the EGF-precursor homology domain affect LDL (apo B) 
binding, while only mutations in repeat 5 in the ligand-
binding domain seem to impair B-VLDL (Apo E) binding (Esser 
et al. 1988, . Russell et al. 1989) . These mutations will be 
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considered in greater detail in a later section: Ligand-
binding requirements of the LDL receptor. 
Mutant receptors that cannot internalise bound ligand 
normally are grouped in Class 4. These mutations are either 
deletions of the transmembrane domain and the cytoplasmic 
tail that result in secretion of the LDL receptor from the 
cell (reviewed by Hobbs et al. 1990) or, more commonly, 
mutations in the cytoplasmic tail that affect the clustering 
of receptors in coated pi ts and subsequent internalisation 
(Davis et al. 1987) The sequence NPVY (Asn-Pro-Val-Tyr), 
starting at amino acid 804, is found in LDL receptors from 6 
species. The NP and Y from this tetrameric sequence and the 
phenylalanine at 802 are the important signals that ensure 
normal receptor clustering in coated pits. A single amino 
acid substitution or deletion at one of these crucial sites 
can result in an internalisation-defective phenotype (Chen et 
al. 1990). This process is mediated by the interaction of 
the receptor tail with adaptor molecules that are in turn 










conformation in the LDL-receptor cytoplasmic tail (Bansai 
1991). It is likely that the aromatic amino acid Tyr (Y) in 
the NPVY motif plays a crucial role in maintaining the 
reverse-turn conformation (Bansai and Gierasch 1991) and that 
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this same Tyr is also recognised by adaptor molecules in the 
context of its tight turn (Eberle et al. 1991). 
In 1990 a fifth class of mutations was added to the above 
four. These were defined as recycling-deficient receptors 
that did not separate from their bound ligands after being 
internalised in endosomes. These receptors are trapped in 
the cell and are unable to return to the cell surface. The 
degradation rate of these (mature) receptors is often 
increased as a consequence of this phenomenon. Certain 
mutations in the EGF-precursor domain manifest this phenotype 
(Hobbs et al. 1990). Perhaps the entrance criteria for this 
class of mutation should be extended to include mutations 
that result in increased degradation of mature and/or 
precursor receptors in the . absence of ligand. The defect 
that results in increased turnover of these mutant receptors 
is not primarily impaired acid-dependent ligand-receptor 
dissociation in endosomes. Mutations that result in unstable 
receptors are probably quite common, since, in the absence of 
a synthetic defect, increased degradation would be the only 
explanation for a decreased surf ace receptor complement in 
class 2B receptor mutants (assuming they have not been 
secreted from the cell). If one assumes that the transport 
of receptors (mutant and normal) from the ER to the Golgi is 
a first order process, then even in a severe type 2B 
mutuation there would be a normal absolute number of 
receptors transported from the ER to the Golgi per unit time, 
as long as · no precursor degradation occurs. At steady-state 
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the number of receptor molecules entering the ER would equal 
the number of those leaving. 
type 2B defect would be 
The ER pool of receptors in a 
greatly increased until the 
concentration of receptors would be high enough to allow a 
normal number of receptors to be transported per unit time to 
the Golgi in spite of the reduced fractional transport rate. 
1.6 LIGAND-BINDING REQUIREMENTS OF THE LDL RECEPTOR 
Apolipo9roteins B-100 and E mediate the binding of 
lipoproteins to the LDL receptor (Goldstein et al. 1985, 
Mahley and Innerarity 1983) . Apo B-100 is responsible for 
LDL binding while apo E containing lipoproteins bind via that 
apoprotein whether apo B-100 is present or not (Innerarity 
1990). Canine HDLc or rabbit B-VLDL, which are both induced 
by cholesterol feeding, are the ligands that are 
traditionally used to measure the LDL receptor's ability to 
bind apo E (Innerarity 1990). 
The interaction of the LDL receptor and its ligands is 
thought to be ionic and ca2+ dependent. At the carboxy-
terminus of each of the ligand-binding repeats is a highly 
conserved triad of negatively charged amino acids (Ser-Asp-
Glu) that are thought to play a major role in binding by 
interacting with positively charged areas of Apo Band Apo E 
(Goldstein et al. 1985). The classic understanding is that 
the stochiometry of LDL to receptor binding is 1:1 while 3-4 
receptors bind to one HDLc particle: 
the fact that each LDL particle 
This is probably due to 
contains one apo B-100 
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molecule, while there are multiple copies of apo E on each 
HDLc molecule. Because each HDLc particle binds to many LDL 
receptors, the affinity of this lipoprotein for the LDL 
receptor is much higher than that of LDL. Studies have 
suggested that the LDL receptor might in fact exist and act 
as a multimer (Reviewed by Innerarity 1990). 
The structural requirements of the LDL receptor that enable 
lipoproteins to bind have been determined largely through the 
observations of the behaviour of natural and artificial 
mutant receptors. The reasoning used in this approach has 
been that if a particular mutation impairs the normal 
function of the receptors, then the area that has been 
altered is important for that function. The converse 
reasoning has also been used.: if the mutation has no effect, 
then the area that has been mutated is not crucial for the 
particular function one is determining. Although this 
approach is traditionally used, I believe one should be very 
circumspect when interpreting its results. The difference or 
similarity in behaviour between a mutated protein (let's say 
for simplicity's sake with a point mutation) and the wild-
type protein can be subjected to many interpretations. The 
point mutation has removed an amino acid that might have had 
a specific function. How does one define the function of an 
amino acid in the LDL receptor? Since this protein has not 
been crystallised and is therefore not amenable to structural 
investigations using X-ray crystallography, one has to look 
at functional characteristics. If the mutation causes a 
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functional aberration by virtue of the amino acid being 
removed, is this because the amino acid being removed has a 
specific role (eg. a glycosylation site) or is it because the 
2° and 3° protein structure has been distorted. This issue 
is particularly problematical in deletion mutations where 
entire domains of the receptor are removed and the 2° and 3° 
structure of the protein are certainly affected. In 
addition, the ability of the LDL receptor to form multimers 
might be affected. 
The other major difficulty in the interpretation of 
mutagenesis experiments is whether the observed effect of the 
mutation is the result of the removal of the wild-type amino 
acid (in the case of a point mutation) or is it the 
consequence of the mutant amino acid that has been 
introduced. This problem can be addressed but not always 
resolved by doing site-directed mutagenesis with more than 
one amino acid substitution at a given site and by ensuring 
that the substitutions that take place are with amino acids 
of similar size and characteristics. Two examples of this 
problem arise in one of the classic papers on mutagenesis of 
the ligand-binding domain of the LDL receptor (Esser et al. 
1988). The substitution of Phe181 with Tyr has minimal 
effects on LDL and B-VLDL binding. However, if one mutates 
the same amino acid to Gly, the binding of both ligands is 
severely impaired. 
19 
An even more dramatic example of this problem is demonstrated 
by point mutations at Asp206 . When Esser et al. (Esser et 
al. 1988) mutated this amino acid to either Tyr or Asn, both 
LDL and B-VLDL binding were almost entirely abolished, but 
transport of the mutant receptor was only mildly affected. 
However, in the naturally occurring mutant where this Asp is 
replaced with Glu, a similar amino acid, the transport is 
markedly delayed, and there is significant LDL and B-VLDL 
binding! (Fourie 1988, AM Fourie, GA Coetzee and D.R. van 
der Westhuyzen, personal communication). 
Another problem with these experiments is that the behaviour 
of mutant receptors has not been studied in hepatocytes, or 
in other polarised cell types. In vitro investigation of the 
LDL-receptor structure-function relationships have been 
almost entirely carried out in skin fibroblasts, cos cells 
and CHO cells, none of which are polarised. The cell type 
is almost certain to affect the control of LDL-receptor 
synthesis (Hep G2 and fibroblasts respond differently to up-
and down-regulation (Tam et al. 1991) ; the rate of LDL-
receptor processing from the precursor to the mature form is 
much slower in COS cells (Esser et al. 1988) than in 
fibroblasts (Tolleschaug et al. 1982), and the degradation 
rate of receptors is faster in HepG2 cells than in 
fibroblasts (D Hendricks, GA Coetzee and DR van der 
Westhuyzen, personal communication). 
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In spite of these problems, two classic papers from the 
Dallas group (Esser et al. 1988, Russell et al. 1989) have 
made a major contribution to the understanding of the 
structure-function relationships in the ligand-binding domain 
of the LDL receptor and will be reviewed in some depth. 
Plasmids containing the LDL-receptor cDNA were engineered 
with various amino acid substitutions and deletions and the 
binding at of antibody, LDL and B-VLDL 
expressing normal and mutant cDNA was determined. 




at two binding (LDL and B-VLDL) was done 
concentrations: One concentration 
levels, while the other was 
concentrations for normal receptors. 
in most cases 
was below saturating 
at saturating ligand 
The binding ability of 
the receptors was normalised to the number of receptors on 
the cell surface by dividing the amount of LDL or B-VLDL 
bound by the amount of antibody bound (Esser et al. 1988, 
Russell et al. 1989) . The actual affinity of the mutant 
receptors for the mutant ligands was only measured in a few 
cases. These studies suggested that repeat 1 was not 
important for ligand binding (Esser et al. 1988). The only 
repeat in the ligand binding domain that was crucial for B-
VLDL binding was repeat 5 (Russell et al. 1989). LDL binding 
was mildly affected by point mutations in or deletion of 
repeat 2, and severely affected by mutations or deletions in 
repeats 6, 7, 3, 4 and particularly repeat 5 (Russell et al. 
1989) . Deletions. or mutations in the EGF-precursor homology 
domain repeats A and/or B did not affect B-VLDL binding while 
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mutations in repeat A alone or i:n both repeats A and B 
affected LDL binding. Mutations in repeat B alone did not 
affect LDL binding (Esser et al. 1988). These results 
implied that the individual repeats operate as semi-
independent modules: 
the same effect as 
a mutation in a repeat very often has 
the deletion of that repeat the 
implication is that a mutation does not have effects outside 
its own repeat. 
The results of Esser et al. (1988) suggest a particularly 
interesting phenomenon (Fourie et al. 1988) that was not 
discussed in that paper: Some of these mutations possibly 
produce at least 2 distinct functional populations of 
receptors from one mutant gene. In these experiments the 
surface number of receptors .has been normalised by comparing 
the antibody binding in the mutant cells to that in normal 
cells. Any LDL or B-VLDL binding to the normal and mutant 
cells was made proportional to the number of surface 
receptors by dividing by the amount of antibody bound. This 
corrected binding was then compared to that of the normal 
receptor and called a percent of normal corrected binding. I 
will give an example: If the normal cells bind 600 ng IgG-
C7 /mg cell protein and 100 ng LDL/mg cell protein and the 
mutant cells bind 300 ng/mg and 10 ng/mg of the respective 
ligands in parallel experiments, then the normal cells bind 
1/6 ng LDL per ng IgG-C7 bound while the mutant cells bind 
1/30 ng LDL per ng IgG-C7 bound. Therefore if one corrects 
for the antibody binding, the mutant receptors bind only 20% 
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the amount of LDL that the same number of normal receptors 
would bind. Two models can explain this result. The one 
possibility is that the affinity of the mutant receptors for 
LDL is lower than that of the normal receptors. 
Alternatively, there are two populations of mutant receptors 
where 20% of the receptors have a normal affinity for LDL and 
80% of the receptors do not see LDL at all. A combination of 
these two models, where there are two or more populations of 
receptors each with abnormally low but different affinities 
for LDL, can also explain these results. 
In cases where the corrected percentage ligand bound by a 
mutant receptor is less than 10% of normal at both non-
saturating and saturating ligand concentrations (for normal 
receptors) , one can assume that the affinity of the mutant 
receptors for the ligand has been grossly impaired. Even if 
there are two receptor populations, the population that 
recognises ligand is insignificant. 
In the scenario where the corrected percentage ligand bound 
is low at the non-saturating ligand concentration but 
increases to approach normality at the saturating 
concentration, one will again assume that the mutant 
receptors have an impaired affinity for the ligand. When the 
corrected percentage ligand bound remains at a significant 
but abnormally low vaiue at both ligand concentrations, one 
must consider the two-population model. It is difficult to 
distinguish between one population of receptors with a 
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decreased affinity for LDL and the 2-population model where 
one population has a normal affinity for LDL, unless one does 
binding isotherms at various ligand concentrations as was 
done in Fig. 8 of the paper by Esser et al. (Fig. 1.2). In 
this experiment the corrected specific binding has been 
plotted over a range of ligand concentrations for 4 mutations 
and compared to the normal binding. The affinities of the 
mutant receptors have been determined to be approximately 
normal. If two different receptors have the same affinity 
for their ligands, one would expect them to show identical 
curves if the corrected binding values are plotted. The 
curves will have similar shapes as the affinities are the 
same and should have the same Bmax (and thus overlap) since 
the corrected binding normalises for cell surface receptor 
expression. Because the affinity of the mutant receptors in 
this experiment were normal but the proportion of mutant 
receptors that see a given concentration of LDL as a 
percentage of antibody binding was less in all cases than the 
same number of normal receptors (as a percentage of antibody 
binding), one has to conclude that there are at least two 
populations of mutant receptors resulting from each of these 
mutant genes. A naturally occurring mutant that exhibits the 
same phenomenon is the FH Afrikaner-1 major founder mutation 
in South Africa (Fourie et al. 1988). This phenomenon should 
not be that surprising since even the normal receptor does 
not exist as a single population of identical molecules. 
There are probably two or more distinctly glycosylated normal 
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surface binding of 125r-LDL in cos cells 
transfected with normal or mutant LDL receptors bearing 
deletions of ligand binding repeats 1 (ARl.) • 1-2 (fi.Rl. 2) . 1-
3 (ARl-3) or 6-7 (~R6-7) (from Esser et al. 1988). Plasmids 
encoding the indicated LDL receptors were transfected into 
COS-MG cells and assayed for binding of 125r-LDL at the 
indicated concentrations. The amount (ng/dish) of 125r-LDL 
bound at each ligand concentration by cells mock-transfected 
with salmon sperm DNA was subtracted from the value obtained 
with a given plasmid. This number was corrected for 
transfection efficiency by dividing it by the amount of 125r-
labeled anti-LDL receptor monoclonal antibody bound to cells 
transfected with the indicated plasmid in the same experiment 
(2 ug/ml 125r-labeled IgG-HLl were incubated with cells for 3 
hat 4°C). Binding constants (inset) were calculated by the 
methods of Lineweaver and Burk using a programmable 
calculator. Reproduced with permission of the authors and 
American Society for Biochemistry and Cell Biology. 
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even behave in subtly different fashions. However, in these 
artificial mutations and in FH Afrikaner-1 (Fourie et al. 
1988) we see how one gene product has produced distinct 
functional populations. 
This phenomenon of multiple receptor conformations with 
different ligand-binding properties produced by a single gene 
has also been offered as a possible explanation for the non-
reciprocal cross-competition of Acetyl-LDL and Oxidised LDL 
for binding tu type I and type II bovine scavenger Ieceptors 
(Freeman et al. 1991, Krieger 1992). 
The effect that 0-glycosylation has on receptor binding was 
demonstrated in a Monensin-resistant CHO cell line that 
produces LDL receptors that lack selected 0- linked sugars 
(Segushi et al. 1991). About a third of the o-glycosylation 
of the receptor occurs outside the 0-linked sugar domain of 
the receptor. If this is interfered with, the receptors do 
not bind ligand normally, suggesting that these sugars play a 
role in ensuring optimal folding of the receptor. 
1.7 MECHANISMS OF MUTATION IN THE LDL-RECEPTOR GENE 
Familial hypercholesterolemia with its heterozygote frequency 
of 1/500 is one of the commonest Mendelian diseases known to 
man (Goldstein and Brown 1989). Three factors determine the 
frequency of a genetic disease: Firstly, the susceptibility 
of a particuiar gene to mutation; 
heterozygote disadvantage or 
secondly, 
advantage 
the extent of 
conferred by 
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mutations; the third factor includes the chance gene-
sampling events like random genetic drift and founder effects 
that can amplify or reduce a gene's frequency. 
The LDL-receptor gene is potentially a highly mutagenic locus 
(Hobbs et al. 1990). Twenty-five percent of the 45 kB LDL 
receptor gene has been sequenced and 28 Alu repeats have been 
found. This is a frequency of about twice that of the 
average human gene. These Alu repeats are the commonest 
••middle repetitive" DNA sequences in humans. They are 
hotspots for recombination events that can occur by at least 
two mechanisms. Two Alu repeats on the same strand can 
recombine and cause a deletion when the repeats are in the 
opposite orientation if the strand forms the approriate stem-
loop structure. Alu repeats in the same orientation at 
different locations but on different chromatids are potential 
sites for unequal crossing over during meiosis. 
Theoretically, this will result in one chromosome having an 
insertion and its homologue having the complementary 
deletion. This type of Alu-Alu recombination event is the 
most prevalent. Alu mediated recombination can also involve 
only a single Alu sequence. Seven of the 8 large deletions 
in the LDL receptor that have been sequenced involve Alu 
repeats at one or both of the endpoints (Hobbs et al. 1990). 
The other mechanism of mutation that seems to be prevalent in 
the LDL receptor is the transition of C to T at CpG 
dinucleotides (Cooper and Krawczak 1990). These transitions 
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are presumably due to the deamination of 5-methyl-cytosines 
at these sites. (Most of the methylation of DNA occurs at 
cytosines in CpG dinucleotides}. Once a 5-mc is mutated to a 
Tit is replicated, while if an unmethylated C is deaminated 
to U it is likely to be repaired to a C by uracil glycosidase 
(Coulandre et al. 1978). Eight of the 18 known LDL-R point 
mutations involve C-T transitions at CpG dinucleotides (Hobbs 
et al. 1990}. In the case of the FH Afrikaner-1 mutation the 
CpG concerned was shown to be methylated (Rideout 1990}. 
This type of hotspot for mutations can give rise to t~1e 
situation where a particular mutation can occur twice e.g. 
the FH Zambia (Pro664 -Leu} mutation has occurred 
independently in India and in England and possibly in Norway 
as well! (King-Underwood et al. 1991). 
In certain diseases where the heterozygous disadvantage 
severely compromises reproductive fitness, the gene frequency 
is low and is maintained almost exclusively by the mutation 
rate. However, in FH it is unlikely that there is any 
significant heterozygote disadvantage since the disease 
usually only manifests in men after the reproductive age and 
about 10 years later in women (Thompson et al. 1989}. NoQody 
has suggested a mechanism or evidence for heterozygous 
advantage in FH. Thus the disease genes are only eliminated 
from the population by homozygote subjects who usually do not 
reproduce. 
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The frequency of FH in most populations is 1/500 but in the 
Afrikaners, French Canadians and Christian Lebanese it has 
been amplified by founder effects and/or random genetic 
drift (Seftel et al. 1980, Moorjani et al. 1989, 
Khachadurian 1964) . The history of the settlement of the 
Afrikaners in South Africa serves as a classic example of the 
workings of the founder effect. The majority of the present 
day population of about 2 million Afrikaners in South Africa 
are descended from about 2000 settlers of Dutch, German and 
French origin who arrived in South Africa in the late 17th 
and early 18th centuries (Theal 1922). These settlers' gene 
pool evidently had a higher frequency of certain disease 
alleles and a lower frequency of other alleles compared to 
their original parent European gene pool. This was the 
result of chance over- or . undersampling of rare alleles. 
(The odds of such occurrences is inversely proportional to 
the size of the settler population). This population 
maintained its altered genetic constitution as it expanded, 
since until recently Afrikaners generally only married 
Afrikaners. These altered allelic frequencies were prone to 
further amplification or reduction by random genetic drift 
which small populations are prone to. The Afrikaner 
population expanded far faster than its European counterparts 
by growing about 1000 fold in 300 years (Dean 1973). Today 
the frequency of FH has been estimated to be 1/70 (Seftel et 
al. 1980) and is very largely accounted for by two founder 
mutations and possibly .a third (Leitersdorf et al. 1989b, 




prevalent in the Afrikaner population are 
familial heart block, Huntington's Chorea, 
variegata, Gauchers disease, cystic fibrosis and 
colonic polyposis (Botha and Beighton 1980). 
familial 
South African Jews of Eastern European (Ashkenazi) descent 
also have a particularly high incidence of FH ( > 1/100) 
(Seftel et al. 1989). The predominant mutation in this 
population is FH Piscataway (Meiner et al. 1991). The 
majority of the South African Jewish population are 
descendents of 40 ooo Lithuanian immigrants who settled in 
the country between 1889 and 1910. In this case it is 
unlikely that a founder effect could have manifested in three 
or four generations from a relatively large starting 
population. Since this mutation also accounts for 35% of FH 
in Ashkenazi (Jews of Eastern European origin) Israelis, it 
is more likely that the founder effect occurred in Lithuania. 
This founder mutation is particularly interesting since 
evidence of its founder origin are visible in many Ashkenazi 
Jewish families throught the world (Meiner et al. 1991). 
Another South African population that seems to have a 
particularly high incidence of FH ( > 1/100) is the Indian 
population (Seftel H., Aswat M, personal communication) that 
is almost entirely descended from 150 000 immigrants who 
settled in South Africa between 1860 and 1911. The majority 
of these people were indentured labourers who originated from 
many different regions on the the South and East Coasts of 
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India. A minority (less than 30 000) were traders and 
artisans who paid their own passage to South Africa. This 
group, known as the "passenger Indians", came from areas in 
the Gujerat province on the west coast of the subcontinent. 
About half of these persons came from the Surat and Valsad 
districts. The other major source of passenger Indians was 
Kathiawar on the Arabian Sea (Bhana and Brain 1990). The 
Indian population of South Africa is of diverse cultural and 
religious origin; the majority (65%) of the population are 
Hindus (many of the castes are represented) and there are a 
significant number of Muslims (21%) and Christians (7. 5 %) 
(Lazarus 1972). 
1.8 FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100 
1.8.1 Historical 
One of the major roles of Apo B-100 is to serve as the ligand 
on LDL for its binding to the LDL receptor. The possibility 
that a binding-defective apo B could be of pathological 
consequence was strongly suggested by the discovery of a 
group of hypercholesterolemic patients who manifested delayed 
clearance of autologous LDL but not of heterologous LDL (Vega 
and Grundy 1986). Subsequently, LDL from these patients was 
shown to bind poorly to the LDL receptor (Innerarity et al. 
1987). The binding site of apo B was the region most likely 
to harbour a mutation that would have these consequences. 
Thus, LDL from these patients and normal controls was 
examined with respect to its antigenicity to 4 different 
antibodies whose epitopes are in the putative binding domain 
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of apo B-100. Three of the antibodies showed no difference 
in binding but the antibody MB47 showed preferential binding 
to the LDL from the patients (Weisgraber et al. 1988) . A 
large region of the apo B-100 DNA from the patients was 
sequenced and a single point mutation was detected at 
position 3500. This resulted in the codon for arginine being 
replaced by glutamine (Soria et al. 1989). Although the 
functional consequences of this mutation have not been 
confirmed by the classical techniques of site directed 
mutagenesis, there is convincing epidemiological and physical 
chemistry evidence to suggest that the Arg-Gln mutation is 
responsible for impaired apo B-100 binding in these subjects 
(Innerarity et al. 1990). 
The prevalence of this disorder has been estimated to be 
around 1/500 in North American and Western European 
populations (Innerarity et al. 1990), which would make it one 
of the most common Mendelian disorders. Since this mutation 
is a C to T transition at a CpG dinucleotide and was possibly 
caused by deamination of a methyl-cytosine, the mutation 
could have occurred more than once. Ten different Apo B 
allelic markers were analysed in 8 subjects with the Apo B-
3500 mutation in order to determine the haplotypes of the 
mutant alleles. The mutant alleles of 7 of the subjects were 
the same. The 8th subject's mutant allele was concordant 
with those from the other subjects for 9 of the markers. The 
only difference in this subject was that he had 46 instead of 
48 repeats in the 3' VNTR of the apo B gene. This difference 
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could have arisen either from slippage or recombination. A 
further 6 subjects with this mutation were found to have 
mutant genes with the same haplotype as the 7 subjects that 
were initially examined. These findings suggest that the apo 
B-3500 mutation is a founder mutation (Ludwig and McCarthy 
1990) . One should thus not expect this mutation to be 
equally prevalent in all populations. Indeed, this mutation 
was not detected in more than 500 Finnish 
hypercholesterolemic subjects suggesting that this is not a 
common cause of raised plasma cholesterol in this population 
(Hamalainen et al. 1990). 
1.8.2 Clinical 
There has been some controversy as to the severity of the 
hypercholesterolemic and atherogenic consequences FOB 
compared to FH. This problem was initially exposed by the 
difference between a moderately hypercholesterolemic North 
American group of FOB patients (Innerarity et al. 1990) and 
an English and Scandinavian cohort (Tybj aerg-Hansen et al. 
1990) who were practically indistinguishable from FH 
heterozygotes. Innerarity et al. (1990) suggested that there 
was a danger of equating the severity of this disease to FH 
if one looks for it in an FH-like population from the start. 
It was possible that there were less severely affected 
individuals who were not being detected because they did not 
have an FH phenotype. This debate has not been entirely 
resolved but it would seem that FOB is often clinically 
indistinguishable from FH with respect to its degree of 
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hypercholesterolemia and frequency of xanthomata, arcus 
cornealis and premature atherosclerosis (Rauh et al. 1992). 
Conflicting reports exist as to the effect of drugs that 
upregulate LDL-receptor function on the hypercholesterolemia 
resulting from FOB. Al though an initial report suggested 
that FOB was perhaps refractory to such therapy (Corsini et 
al. 1991), Maher et al. (1991) showed very similar responses 
to cholystyramine and/or simvastatin in 11 FOB subjects and 
FH controls matched for age, apo E phenotype and starting 
LDL-cholesterol concentrations. 
Dunning et al. (1991) recently presented evidence that this 
mutation at codon 3500 might not be the only apo B mutation 
that causes hypercholesterolemia. They examined the apo B 
gene sequence encoding amino acids 3130-3630 in 8 
hypercholesterolemic individuals who were selected either on 
the basis of delayed clearance of autologous LDL or impaired 
binding of their LDL to normal LDL receptors. Since no 
sequence abnormalities were detected in the area of the gene 
examined, they concluded that mutations outside the putative 
binding domain of the apo B gene were affecting its 
interaction with the LDL receptor. Thus, there are possibly 
mutations in apo B-100 other than that at codon 3500 that can 
cause hypercholesterolemia. 
1.9 THE AIMS OF THIS THESIS 
The clinical picture of familial hypercholesterolemia can 
result from mutations at either the LDL-receptor gene locus 
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or at codon 3500 in the apo B gene (Rauh et al. 1992). Thus, 
at the risk of being pedantic, a patient with clinically 
defined familial hypercholesterolemia should be provisionally 
labelled as having monogenic hypercholesterolemia until the 
defect has been localised to either the LDL receptor or apo B 
genes. The Afrikaner (Seftel et al. 1980), Jewish (Seftel et 
al. 1989) and Indian populations in South Africa (Seftel H, 
Asvat M, personal communication) have particularly high 
frequencies of clinically defined monogenic 
hypercholesterolemia. Founder LDL-receptor mutations have 
been shown to account for most of this disease in the Jewish 
and Afrikaner groups (Leitersdorf et al. 1989, Meiner et al. 
1991) . 
The nature of the mutations that result in this disease in 
South African Indians was unknown. Skin fibroblasts were 
received from the 4 clinically diagnosed FH homozygotes that 
attended the various lipid clinics in the country, so that 
their mutations could be studied. The behaviour of the 
mutant proteins was initially investigated in order to allow 
us to predict the site of the mutations from the type of 
defects. 
These mutations were also examined at the DNA level. 
Knowledge of the exact nature of the mutations is a vital 
part of the puzzle that allows one to consider 
structure/function relationships. The definition of a 
mutation at the DNA level would also allow one to screen 
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likely FH patients in the Indian population. The possibility 
existed that familial hypercholesterolemia in this group 
might have been caused by one or two predominant mutations. 
If this were the case, the discovery of these mutations would 
allow for rapid and confident diagnosis of LDL-receptor 
mutations in Indians with definite or possible clinical 
monogenic hypercholesterolemia. 
Although FH does not seem to be common in the South African 
"Black" population (Marais and Berger 1986), two different FH 
homozygotes had been discovered (van Wingerdin 1981, 
Leitersdorf et al. 1988). The nature of the mutations that 
resulted in low cell-surface receptor-numbers in the one 
subject, JL, was not known (Coetzee et al. 1985). 
Preliminary investigations into the behaviour of the mutant 
LDL-receptor proteins were undertaken in order to direct us 
to the possible nature of the gene defect(s) in this subject. 
The detection of point mutations can be very laborious if one 
relies entirely on sequencing DNA. Orita and co-workers 
(1989a, 1989b) described a rapid and easy method to detect 
point mutations by comparing the electrophoretic mobility on 
non-denaturing gels of single-stranded DNA from mutant and 
wild-type genes. The sensitivity and utility of this so-
called single-strand conformational polymorphism ( SSCP) 
technique was investigated. 
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Although founder LOL-receptor mutations have been shown to 
account for the majority of clinical FH in Afrikaners and 
Jews, a significant number of patients in these groups 
remained that do not have these mutations (Graadt van Roggen 
et al. 1991, Meiner et al. 1991). Both of these populations 
and the so-called Coloured population ( of mixed European, 
Indonesian and native African descent) have European 
ancestry. Since the familial defective apo B-100 mutation 
has a prevalence of 1/ 500 in European and North American 
populations (Innerarity et al. 1990, Schuster et al. 1990, 
Tjaeberg-Hansen et al. 1990), these populations were 
screened for this mutation. 
The FOB mutation seems to have arisen once on an ancestral 
chromosome (Ludwig and McCarthy 1990) and although quite a 
number of groups have identified it in populations of 
presumably European origin, the incidence of this mutation 
had not been investigated much in non-European/North American 
or non-causasian populations (Ludwig and McCarthy 1990). The 
availability of a number of hypercholesterolemic Indian 
patients from lipid clinics around South Africa allowed us to 
look for FOB in such a population. 
In summary, the main aim of this thesis was to try and gain 
an understanding of the LOL-receptor mutations that cause 
familial hypercholesterolemia in the South African Indian 
population. An additional aim was to determine whether or 
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not the FDB mutation was a common cause of monogenic 
hypercholesterolemia in the Afrikaners, Jews, so-called 
Coloureds and Indians in South Africa. 
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CHAPTER 2 
SECTION A: GENERAL METHODS 
2A.1 Patients 
Blood and fibroblast specimens from the patients used in 
these studies were kindly provided by physicians at Lipid 
Clinics in Johannesburg (Prof. H. Seftel, Dr D. Raal), Cape 
Town (Dr A.O. Marais), Durban (Dr I. Jialal, Prof. G.M. 
Berger) and Potchefstroom (Prof. E. Vorster). 
2A.2 DNA isolation from blood or tissue culture cells 
DNA isolation was performed either by conventional Proteinase 
K treatment of cells followed by phenol/chloroform extraction 
(blood and tissue culture cells) (Method 1) or by using a 
rapid method (blood only) described by Talmud et al. (1991) 
(Method 2) . 
2A.2.1 METHOD 1 (Strauss 1987) 
Fibroblasts (about cells) were trypsinised 
resuspended in ice-cold phosphate-buffered saline (PBS). 
and 
The 
cells were then pelleted by centrifuging for 5 minutes at 
500 g, resuspended in PBS and repelleted. Fibroblasts or 
huffy layers were resuspended in 300 µl of digestion buffer 
containing 100 mM NaCl, 10 mM Tris-Cl pH 8. o, 25 mM EDTA 
pH 8.0, 0.5% sos and 0.1 mg/ml Proteinase K (Boehringer 
Mannheim, Mannheim, Germany) and placed in a 1.5 ml 
microfuge tube. This digestion buffer was freshly prepared. 
The cells were digested overnight at 50°C. After digestion 
the samples were extracted with 300 µl 
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phenol/chloroform/isoamylalcohol (25:24:1). The aqueous 
phase was then re-extracted with 300 µl 
chloroform/isoamylalcohol (24:1). The aqueous phase was 
transferred to a new microfuge tube to which 150 µl 7. 5 M 
ammonium acetate and 600 µl 100% ethanol was added. The DNA 
was precipitated by centrifugation at 12 ooo g for 2 minutes. 
The pellet was rinsed with 70% ethanol, air-dried in a 
Speedvac (Savant Instruments Inc.) and resuspended in H2o or 
TE pH 8.0 (Strauss, 1987). 
2A.2.2 METHOD 2 (Talmud et al. 1991) 
DNA from whole blood for PCR amplification was frequently 
prepared by this rapid procedure: 100 µl whole blood 
anticoagulated with EDTA (1.5 mg/ml) was mixed with 400 µl 
freshly prepared 0.17 M ammonium chloride and left for 20 min 
at room temperature. This was then washed three times by 
first centrifuging the contents at 12 000 g for 30 sec, then 
adding 1 ml 0.9% NaCl to the pellet, vortexing and re-
centrifuging. The pellet left after centrifuging for 30 sec 
after the third wash was resuspended in 200 µl o. 05 M NaOH 
and boiled for 10 min with occasional agitation. This was 
then neutralized with 25 µl lM Tris pH 8.0. Three to five µl 
of this preparation was used per PCR (Talmud et al. 1991). 
2A.3 RNA Isolation 
RNA isolation from tissue culture cells was performed 
essentially as described by Chomczynskj and Sacchi (1987). 
Fibroblasts were seeded at 120 ooo cells per 10 cm Petri dish 
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and grown in Dulbecco's MEM (DMEM} with 10% fetal calf serum 
for 5 days with a medium change on day 3. On day 5 the 
medium was changed to DMEM containing lipoprotein deficient 
serum (LPDS} (5 µg/protein/ml). The cells were then 
harvested on day 6. The dishes were washed three times with 
ice-cold phosphate buffered saline. Six hundred microlitres 
of a digestion solution containing 4 M guanidinium 
thiocyanate, 25 mM sodium citrate pH 7.0, 0.5% sarcosyl and 
0.1 M 2-mercaptoethanol was added to each dish. The digested 
cells were "scraped" from their dishes and collet.:ted in 1. 5 
ml microfuge tubes to which 60 µl sodium acetate pH 4.0 was 
added and the contents were mixed by inversion. Then 600 µl 
phenol (water-saturated) and 120 µl chloroform/isoamylalcohol 
( 49: 1) were sequentially added and mixed in the tubes by 
inversion. The tubes were left on ice for 15 minutes and 
then centrifuged at 4 °C in a microfuge ( 12 000 g) for 20 
minutes. The aqueous phase was then transferred to a fresh 
tube to which 600 µl cold isopropanol was added. The tube 
was placed at -20°c for at least 1 hour. The tube was then 
centrifuged at 12 000 g for 20 minutes at 4°C to pellet the 
RNA. The pellet was air-dried and resuspended in 600 µl of 
the digestion buffer that was initially used and the RNA was 
precipitated again with 300 µl isopropanol at -20°c for at 
least 1 hour. The RNA was pelleted by centrifugation at 
12 ooo g for 10 minutes at 4°C. The pellet was washed once 
with 75% ethanol, sedimented and air-dried. Care was taken 
not to over-dry the pellet. The pellet was then dissolved in 
H2o. RNA preparation was always carried out with gloves on. 
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In some cases diethylpyrocarbonate (DEPC)-treated solutions, 
microfuge tubes and pipette tips were used to prevent RNAse 
activity. DEPC treatment was done according to Gilman 
(1987): 0.2 ml of diethylpyrocarbonate (DEPC) was mixed into 
100 ml of the solution to be treated. This was autoclaved to 




first strand synthesis was carried out using the 
kit and protocol (Perkin Elmer Cetus, GeneampR RNA PCR 
Norwalk, CT) with the random hexamers provided. A 20 µl mix 
was made containing the RNA, 5 mM Mgcl2 , 50 mM KCl, 10 mM 
Tris-HCl pH 8.3, 1 mM of each dNTP, 1 u/µl RNAse inhibitor, 
2. 5 µM random hexamers and 2. 5 u/ml reverse transcriptase. 
This mix was overlaid with . mineral oil and placed at room 
temperature for 10 minutes. The tubes were then incubated at 
42°C for 15 minutes, 99°C for 5 minutes and placed on ice for 
5 minutes. Three to five µl of this reaction was used in 
subsequent PCR reactions that generated double-stranded cDNA. 
2A.5 Kinasing of Oligonucleotides 
Oligonucleotides were kinased in a final volume of 10-50 µl 
containing 10-50 pmol of oligonucleotide, 140 µCi of [r-32p]-
ATP (made using the gammaprep kit (Promega, Madison WI)), 8µ 
T4 polynucleotide kinase (Promega) and 1/ 10 volume of lOx 
polynucleotide kinase buffer (Promega). This was incubated 
at 37°C for at least 30 minutes. 
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2A.6 Isolation of DNA fragments from Gels: 
2A.6.1 Polyacrylamide Gels 
DNA was electrophoresed on polyacrylamide gels of the 
appropriate percentage and the gel was stained in ethidium 
bromide ( Sambrook et al. 1989) . The bands were visualised 
with a UV lamp and the bands were cut out using a new 
surgical blade. Each gel slice was broken up with a sterile 
pipette tip in a 1.5 ml microfuge tube to which 350 µl of a 
solution of 0.5 M ammonium acetate, 10 mM magnesium acetate, 
1 mM EDTA, pH 8, was then added. The tubes were incubated at 
37°C in a 
centrifuged 
rotary mixer 
at 12 ooo g 
overnight. The samples were 
for 1 minute to pellet the 
acrylamide. The solution was then transferred to a new 
microfuge tube and recentrifuged at 12 ooo g for 1 minute. 
The solution was transferred to a fresh microfuge tube and 
the DNA was precipitated by adding 1/10 volume of 3M sodium 
acetate pH 5.2 and 2.5 volumes 100% ethanol and then placing 
it at -70°C for at least 1 hour. The DNA was pelleted by 
centrifugation for 30 minutes at 12 ooo g at 4 °C and was 
washed with 70% ethanol. The sample was recentrifuged at 
12 000 g for 20 minutes, the ethanol was removed and the DNA 
was vacuum dried in a SpeedVac (Savant Instruments Inc.). 
The DNA was resuspended in an appropriate volume of TE pH 8.0 
or H2o. 
2A.6.2 Agarose Gels 
DNA electrophoresed on agarose gels (Sambrook et al. 1989) 
was also visualised on a UV box after ethidiurn bromide 
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staining and the correct bands were cut out. DNA was eluted 
from the agarose slices using Geneclean II {Bio 101, La 
Jolla, CA, USA). 
2A.7 DNA Sequencing 
DNA sequences were determined by one of three different 
methods. Direct sequencing of PCR products was done either 
with {2A.7.1) the Maxam and Gilbert system {NEMR DU PONT) or 
{2A. 7 .2) with a modification of the Sanger method using a 
thermal cycler, the fmol TM uNA Sequencing system { Promega, 
Madison, WI). {2A.7.3) DNA sequencing of cloned material was 
done with the Tag Track™ sequencing system, a modification 
of the Sanger method that uses Tag polymerase as the 
extension enzyme. 
2A.7.1 Maxam and Gilbert sequencing: 
Maxam and Gilbert sequencing {Maxam and Gilbert 1980) was 
carried out essentially as described in the kit's booklet 
{NEN, DUPONT). The following changes were made to the 
prescribed method. 
primer that had 
unlabelled primer. 
PCR reactions were performed using one 
been kinased with (r-32p]-ATP and one 
The PCR product was electrophoresed on a 
6% polyacrylamide gel, and the correct bands were eluted from 
the gel {see section 2A.6.1). G modification with OMS was 
performed for 4 minutes while the other three modification 
reactions {A+G, T+C and C) 
After modification of the 
precipitated with tRNA, 
were performed for 10 minutes. 
appropriate bases the DNA was 
ammonium acetate and ethanol 
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according to the protocol but the pellet was washed three 
times (as opposed to twice) with cold 75% ethanol prior to 
piperidine cleavage. 
2A.7.2 Direct sequencing of PCR products with the fmol kit 
(Promega, Madison, WI) 
Direct sequencing of PCR products was also performed using 
the fmol sequencing kit (Promega, Madison, WI). The PCR 
products were electrophoresed on 1% agarose gels and the 
appropriate bands were cut out of the gel. DNA was extracted 
from the gel using the Geneclean II kit (BIO 101 Inc, La 
Jolla, 
with 
CA). Sequencing was performed using primers kinased 
[r-32pJ-ATP (see section 2A.5) according to the 
protocol. This method of sequencing is a modification of 
Sanger di-d~oxy sequencing (Sanger et al. 1977) that uses Taq 
Polymerase on a thermal cycler to accomplish many cycles of 
sequencing. The linear amplification of the resultant 
sequence reduces the amount of template needed. The high 
temperatures used have certain theoretical advantages: 
alkali denaturation of double-stranded DNA is not needed; 
there is reduced re-annealing of double stranded templates; 
there is increased stringency of primer-template annealing 
and the secondary structure of the DNA templates is reduced. 
We sequenced exactly according to the kit's protocol. We 
initially denatured our sample at 93.5°C for 2 minutes before 
sequencing with 42 cycles of 93.5°C for 35 seconds, 62.5°C 
for 30 seconds and 72 °C for 30 seconds. After the cycles 
terminated _· we employed the following procedure to extract the 
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mineral oil that tended to cause smears on the gels if not 
removed completely. Ninety-five µl H2o were added to each 
tube to which 300 µl of the following stop buffer containing 
0.01 M Tris pH 7.5, 4 mM EDTA pH 8.0, 258 mM sodium acetate 
pH 5. 2, 67 µg/ml yeast tRNA, was added. The PCR microfuge 
tube was centrifuged for 30 seconds at 12 000 g and the 
contents were transferred to a 1.5 ml microfuge tube, 
extracted with 400 µl phenol/chloroform/isoamylalcohol 
(25:24:1) and precipitated with 940 µl 100% ethanol. After 
washing the pellets with 70% ethanol and drying, the DNA was 
resuspended in 3-8 µl of loading dye from the kit. 
2A.7.3 Sequencing of cloned material with Tag Track Kit 
(Promega, WI, Madison) 
Sequencing of cloned DNA was performed with the Tag Track Kit 
(Promega WI, Madison), a variation of the Sanger (Sanger et 
al. 1977) sequencing system. Oligonucleotides were kinased 
with (T-32PJATP (see section 2A.5) and the plasmid template 
was alkali denatured, ethanol precipitated and sequenced 
exactly as described in the protocol. 
Sequences generated by all of the above methods were 
denatured at 95°C (Tag Track, Maxam-Gilbert) or 75°C (fmol 
Kit) prior to electrophoresis on 6% or 8% acrylamide, 7 M 
urea sequencing gels (Slatko and Albright 1989). 
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Table 2A,1; oligonucleotides, reaction conditions and gene regions amplified by PCB 
Oligo- Gene and gene 
nucleotide region amplified 

























Ex<'>ns sand 6 + 
Ii of 7 
LDL Receptor ONA 
LDL-R promoter 
Amplification conditions 
lx(94•c for 10 min, Add 
Taq, 6a•c for 12 min) 
35x(93°C for 1.5 min+ 
68°C for s min) 
1X68° for 10 minutes 
(9s•xsmin add Taq) 
37x (93°C for 35sec, 
62.5° x 3 mini 
lx93° for JS sec+ 
62.5° for 6 min 
35x(93°C for JSsec, 59°C 
for 2min, 12•c for 2min) 
oliqonucleotida sequences cs'-3') 
ATA GGA TCC AAA TTG CGC TGG ACC GTC GCC TTG C 
ATA GCA TGC TCG TCA GGG CGA CAG GTG GCC ACA G 
ATA GGA TCC GAC AAA TCT GAC GAG GAA AAC TGC G 
ATA GCA TGC GTG AAG AAG AGG TAG GCG ATG GAG C 
ATA GGA TCC CAC ACG AAG GCC TGC AAG GCT GTG G 
ATA GCA TGC TGA TAT CTG TCC AAA ATA CTT TGT C 
CGC GGA TCC CCC CTT CTC CTT GGC CGT CTT TGA G 
CGC GGA TCC CCT CTG CCA GCA ACG TCG CCC AGA G 
CGC GGA TCC GAG ATA GTG ACA ATG TCT CAC CAA G 
CGC GGA TCC CAG GAA GGG '1"l'C TGG GCA GGG GCG G 
TAT GTC GAC ACT GCC TGG CAG AGG C 
GAT CAA GCT TCC CAT CGT GGC AGC GA 
ATA TCT AGA CGA GCA AGG CTG TCC CC 
GAG GAA TTC G'1'C AGG GCG ACA GG 
ATA GAA T'l'C CAG CTG GCG CTG TGA TG 
AAA GTC GAC TCG TAG CCG ATC T'l'A AGG 
'l"l'C TCT GGG ACA GG'r CAG ACC AGT 














Exon 4 (5' end) 
Exon lJ, 
intron lJ 
and Exon 14 
Taq 1 RFLP 
Cintron 4) 
Stu 1 RFLP 
(Exon 8) 
Ava II RFLP 
(Exon lJ) 
Nco 1 RFLP 
(Exon 18) 
LDL-R exon 4 
Apo E gene for 
genotyping 
Apo B gene for 
diagnosing 3500 
mutation 
for 2min, 12•c for lOain) 
40x(93•c for 1 min, 53•0 
for 1 min, 12•c for lmin) 
1X(9J•c for 1 min, 55°C 
for 1 min, 12•c for lmin) 
35x(93°C for 35 sec, 
6o•c for 3 min) 
lx(93°C x 35 sec, 60°C 
for 6 min) 
30x(93°C for 1 min, 
65°C for 4 min) 
J5x(9J 0 c for 1 min, 
ss•c for 2 min, 
72 x 2 min) 
35x(9J°C for JS sec, 
60°C for J min) 
lx(93°C for JS sec, 
60°c for 6 min) . 
95°c for s min, Add Taq; 
35x(94.s•c for 25 sec, 
· 60°~ for 1 min) 
· (include SI DMSO in PCR mix) 
40x(93•c· for JS sec, 
S6°C for 1 min, 12•c 
for 4 min) · 
ACT TAC GAC AGC CTT GCT CG 
CTG TCT CTT CTG TAG TGT CT 
CAT CCA TCC CTG CAG CCC CC 
GGG GTC GTT G'1'C GCA GGC CC 
AAT GTC GAC GTC ATC T'l'C CTT GCT GCC TGT 
TAT GTC CAG AAA CAA GGC GTG TGC CAC 
ATC TGA CGA GGA AAA CTG CGG 
GGC CAC AGC TGG AAA ACA GGA 
ATC GAT GAG TGT CAG GAT CC 
CCC GCC GCC TTC CCG TGC TGA 
AGT GCC AAG CGC CTC ACA GG 
CCT CTC ACA CCA GTT CAC TC 
CAC CTA GTG C'l"l' CCA CTT CTA 
TCC CGT CAA ACG ATC CAG ACT 
CCC CAG CTG TGG GCC TGC GAC AAC G 
CGC CCA TAC CGC AGT T'1'T CC 
TAA GCT TGG CAC GGC TGT CCA A GGA 
ACA GAA T'l'C GCC CCG GCC TGG TAC AC 
CCA ACA C'l"l' ACT TGA ATT CCA AGA GCA CCC 








2A. 8 PCR 
Each 50 µl PCR reaction mix contained genomic DNA or cDNA 
(1st strand), 2.5 u Sequencing grade Taq polymerase (Su for 
amplification of cDNA) (Promega, Madison, WI, USA), 5 ul of 
lOx Taq polymerase buffer (Promega), 100 µM of each dNTP, 20 
pmol of each primer and 500 ng genomic DNA or 3 to 5 µl of 
rapid preparation DNA. Acetylated BSA (100 µg/ml) (Promega) 
was added to some of the reactions. The exact conditions and 
oligonucleotides used in each PCR reaction are shown in Table 
2A.1. Oligonucleotides were synthesised on an AUTOGEN™ 
machine (Milligene Corporation, U.S.A.) 
2A.9 Diagnosis of Mutations by PCR with/without restriction 
enzyme analysis 
2A.9.1 FH Zambia {Pro664 to. Leu) 
This mutation was detected according to the method of Soutar 
et al. (1989). Exons 13 and 14 were amplified using 
oligonucleotides 541 and 542 (kindly provided by Dr A Soutar, 
MRC Lipoprotein Team, Hammersmith Hospital, London, UK) as 
described in Table 2A.1. After analysing 15 µl of the 
product by electrophoresis in 1% agarose, the remaining 35 µl 
was digested overnight at 37°C with 10 U Pst I (Boehringer 
Mannheim, Mannheim, Germany) in a final volume of 40 µl 
containing 4 µl lOx H buffer (Boehringer Manhheim). This was 
then analysed by electrophoresis on a 6% acrylamide gel. 





81 -1 - 82 
Msp I restriction site is created 
in normal allele by PCR with the 
mutagenic oligonucleotide 81 . 




Fig. 2A.1: Assay for the FOB ·mutation. Genomic DNA was 
amplified in a .· PCR reaction containing oligonucleotides Bl 
and B2 (see table 2A.l) and 2 µCi (a-32P] dCTP. PCR products 
were digested with 20 u Msp I and were electrophoresed on 12% 
Acrylamide. The gels were dried· and exposed to X-ray film 
overnight. 
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2A.9.2 Familial Defective Apolipoprotein B-100 
~3500 - Gln) 
This mutation was detected exactly according to the method 
described by Hansen et al. (1991). This assay uses an 
oligonucleotide (Bl) with a single base pair mismatch 2 bp 
from its 3 1 end that introduces an Msp I cleavage site in the 
PCR product (generated with B2, see Table 2A.1) of the normal 
allele. The normal alleles are digested by this enzyme but 
the mutant alleles are not since they do not have the 
recognition sequence (Fig. 2A.1). It was difficult to 
achieve 100% digestion of our PCR products even if they were 
phenol/chloroform extracted and ethanol precipitated prior to 
digestion with 20 u MspI. A subject was considered normal if 
the digestion was clearly more than 50%. The diagnosis of 
FOB in subjects where there was obviously abnormally little 
digestion was confirmed by repetition of the experiment or by 
digestion of a small amount of [a-32P]dCTP-labelled normal 
PCR product in the same tube as unlabelled suspect DNA. The 
suspect DNA was confirmed to be FDB since there was clearly 
more digestion of normal DNA as judged by autoradiography of 
the sample run on a 12% acrylamide gel than of the mutant 
sample as judged by ethidium bromide staining of our gel. 
(The converse situation was also used to confirm the 
mutation). 
2A.9.3 LDL-receptor Haplotypes 
The LDL-receptor RFLPs were determined using PCR 
amplification with oligonucleotides flanking the variable 
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restriction sites for Taq 1, Stu 1, Hine II, Ava II and Nco 1 
(Leitersdorf and Hobbs 1989, Leitersdorf et al. 1989a, Meiner 
et al. 1992} (see Table 2A.1). Some of the haplotyping was 
done in the laboratory of Dr E. Leitersdorf (Lipid Research 
Laboratory, Haddassah University Hospital, Jerusalem, Israel} 
and some was done by me. 
2A.9.4 Diagnosis of 'D' mutation in exon 4 (Glu119-Lys) 
This mutation eliminates a Mnl I site in exon 4. The 5 1 end 
of exon 4 was amplified using oligonucleotides &31 and 4.3 as 
described in Table 2A.1. Each PCR mix was spiked with 2 µCi 
[a-32p] dCTP. Four microlitres of each sample were digested 
in a final volume of 30 µl containing 3 µl Buffer 2 (New 
England Biolabs, Beverly, MA}, 3 µl acetylated BSA (1 mg/ml, 
Promega}, and 4 u Mnl I (New England Biolabs}. The digested 
products were electrophoresed on 12 % Polyacrylamide gels. 
The gel was dried and exposed to X-ray film overnight (See 
Fig. 4. 12} . 
2A.9.5 Diagnosis of Lithuanian Jewish mutation, FH 
Piscataway (deletion of Gly197l 
Part of exon four spanning Gly197 was PCR-amplified with 
oligonucleotides Dl and 02 (Table 2A.l}. The heteroduplexes 
formed between amplification products of the normal and 
mutant alleles run with a slower mobility than homoduplexes 
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Fig. 2A. 2: Diagnosis of the FH Piscataway LDL-receptor 
mutation. Genomic DNA was amplified by PCR using 
oligonucleotides D1 and D2 that span part of exon 4 of the 
LDL-receptor gene . ( see table 2A. 1) . The PCR products were 
electrophoresed on 6% Acrylamide and the heteroduplexes 
formed were characteristic in heterozygotes of this mutation, 
a 3 b.p. deletion of Gly197• 
2A.9.6 Detection of FH Afrikaner-1 and FH Afrikaner-3 LDL-
receptor mutations 
. 
These mutations, both in exon 4, were screened for by PCR-
amplification of a 220 b.p. region of that exon using 
oligonucleotides Dl and D2 (see PCR Table 2A.1) and by 
subsequent restriction digestion with Ode 1, the site created 
by the FH Afrikaner-1 mutation, or Mbo II, the site abolished 
by the FH Afrikaner-3 allele. These assays were performed 
essentially as described (Graadt van Roggen et al. 1991) . 
Each PCR reaction was spiked with 2-4 µCi [a32p]-dCTP. Ten 
microlitres of the amplified product were digested overnight 
at 37°C with Ode I (Promega 4u) or Mbo II (New England 
Biolabs 2.Su) without the addition of any additional buffers 
to the PCR mix. The digested products were electrophoresed 
on 12% Polyacrylamide (Ode I) or 10% Polyacrylamide (or 2 % 
Agarose) (Mbo II). Ode 1 digests normal alleles into two 
fragments of 130 and 90 b.p. and FR-Afrikaner 1 alleles into 
130, 64 and 26 b.p. (Fig. 2A.3). Mbo II digests normal 
alleles into 171 and 49 b.p. fragments and the FH Afrikaner-3 
alleles are resistant to digestion (Fig. 2A.4). 
2A.9.7 Detection of FH Afrikaner-2 mutation (and familial 
defective Apo B-100) 
This method was devised by E. Langenhoven and M. Kotze 
(Department of Human · Genetics, Faculty of Medicine, 
University of Stellenbosch) and was kindly conveyed to us. 
The ARMS (Amplification Refractory Mutation system) PCR 
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Fig. 2A.3: Assay for diagnosis of the FH Afrikaner-1 
mutation. Genomic DNA was amplified by PCR using 
oligonucleotides 01 and 02 that span part of exon 4 of the 
LDL-receptor gene (see Table 2A.1). PCR products were 
digested overnight at 37°C with 4 u Ode I and then 
electrophoresed on 12% Acrylamide. This mutation creates a 
new Ode I site (Ode I-m) that results in the formation of a 
64 b.p. fragment. {The band just above 90 b.p. in the uncut 
sample that persists in the cut samples is probably a primer 
dimer-type PCR artefact that is unrelated to the LDL-R 
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Fig. 2A.4: Assay for diagnosis of the FH-Afrikaner-3 
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mutation. Genomic DNA was amplified by PCR using 
oligonucleotides Dl and D2 that span part of exon 4 of the 
LDL-receptor gene (see table 2A.1). The PCR products were 
digested overnight at 37°C with 2.5 u Mbo II and the products 
were electrophoresed on 2% Agarose. This mutation abolishes 
an Mbo II site and the persistence of a 220 b.p. fragment 
after Mbo II digestion is diagnostic for this mutation. 
the same PCR tube also contains oligonucleotides that amplify 
the apo B gene which serves as an internal control for the 
PCR. The apo B PCR product can be used for detection of FDB 
by differential oligonucleotide hybridisation {Tybjaerg-
Hansen et al. 1990). Each sample is placed into two 
different PCR mixes for analysis by ARMS. Each mix contained 
the oligonucleotides AB-1 {5'-GGAGCAGTTGACCACAAGCTTAGC-3 1 ) 
and AB-2 (5 1 -CAGGGTGGCTTTGCTTGTATGTTC-3 ') that amplify a 345 
b.p. region of the apo B gene. The oligonucleotide 9.5 (5'-
GCTCACCTGCAGATCATTCTCTGGG-3') was the common distal primer 
for amplification of exon 9 of the LDL receptor and was added 
to both tubes that contained either one of the allele 
specific oligonucleotides 9.3 (5'-AGCCTCATCCCCAACCTGAGG~ACG-3 
normal allele) or 9.4 (5'-AGCCTCATCCCCAACCTGAGG~ACA, mutant 
allele). The underlined base was deliberately destabilized 
(it should have been A) in order to ensure allele-
specificity. Three to five µl of rapid prep DNA {Talmud et 
al. 1991, see 2A.2.2) was added to 50 pmol of each of the 
appropriate primers, 100 µmol of each deoxynucleoside 
triphosphate, 5 µl of lOx Mg2+-free Tag DNA polymerase buffer 
{Promega) supplemented with 15 mmol Mgcl2 and 2 units 
sequencing grade Tag {Promega) in a final volume of 50 µl. 
Samples were overlaid with light mineral oil(Sigma) and 
cycled 30 times (93°C for 1 min, 70°C for 1 min, 72°C for 2 
min). Half of each PCR product was analysed on 6% acrylamide 
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Fig. 2A.5: ARMS assay for the detection of the FH-Afrikaner-3 
mutation. Genomic DNA was amplified with oligonucleotides 
AB-1 and AB-2 (internal controls for PCR reaction that 
amplify the Apo B gene) and 9.5 with either 9.3 (that 
hybridises to the normal LDL-receptor) or 9. 4 (that 
hybridises to this mutation in exon 9 of the LDL-receptor. 
PCR products were electrophoresed on ·6% Acrylamide). N = 
normal, HET = heterozygote for FH-Afrikaner-3 mutation, HOM= 
homozygote for FH-Afrikaner-3 mutation. 
The advantage of this assay is that it provides amplified apo 
B-100 product that can be analysed for the apo B-3500 
mutation (FDB) by allele-specific oligonculeotide 
hybridisation exactly as described by Tybjaerg-Hansen et al. 
(1990). This assay was used to screen the Afrikaner and 
Coloured patients for FDB. 
2A.9.8 Restriction isotyping of apolipoprotein E 
polymorphisms 
This assay was carried out as described by Hixson and 
Vernier(1990). A region of the apo E gene flanking the 
polymorphic codons 112 and 158 was amplified with 
Table 2A.1). Forty olignucleotides G23 and G24 (see 
microlitres of the PCR product were digested overnight at 
37°C with Hha I (6u, Promega) without the addition of any 
buffers and was electrophoresed on 10% polyacrylamide gels. 
Hha I digests the 244 b.p. PCR product at 3 invariant sites 
in the E2 allele but cleaves in addition at codon 158 in the 
E3 allele, and at codons 112 and 158 in the E4 allele (Fig. 
2A. 6) . 
2A.10 CLONING 
2A.10.1 Preparation of Competent cells 
JM 85 cells were kindly provided by Prof. D. Botes 
(Department of Biochemistry, UCT). 40 ml of LB were 
innoculated with 2 ml of an overnight culture of JM 85 cells. 
These cells were grown for 2 hours till they reached an 00550 
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Fig. 2A.6: Assay for Apo E genotyping with Hha I. Genomic 
DNA was amplified by PCR using oligonucleotides G23 and G24 
that span the polymorphic codons 112 and 158 of the apo E 
gene (see table 2A.1). PCR products were digested overnight 
at 37°c with Hha I (6 u) and were electrophoresed on 10% 
polyacrylamide gels. The enzyme Hha I differentiates the 
polymorphisms at codons 112 and . 158. 
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3000 rpm at 4°C in a Beckman JA-20 rotor. This pellet was 
resuspended in 20 ml ice-cold solution of 60 mM cac12 , 10 mM 
Pipes, pH 7. 2, left on ice for 3 o min then re-pelleted by 
centrifugation at 3000 rpm at 4°C for 5 min. This pellet was 
resuspended in 4 ml 60 mM cacl2 , 10 mM Pipes pH 7.2 and left 
on ice for at least 30 minutes prior to using for 
transformation. 
2A.10.2 Restriction digestion and ligation of PCR product 
and vector 
Exons 1 to 4 of the LDL-receptor cDNA, prepared as described 
earlier (2A.4), were amplified using AR12 and AR13 (see Table 
2A.1, Fig. 4.8). The PCR products were electrophoresed on a 
6% acrylamide gel and the appropriate bands were cut out of 
the gel and eluted as described earlier ( 2A6. 1) . This 
fragment and pUC 118 were both simultaneously digested with 
Barn HI ( 11 u) (Boehringer Mannheim, Mannheim, Germany) and 
Sph I (12 u) (Boehringer Mannheim) in the Boehringer Mannheim 
Buff er B. The digested pUC 118 was separated from the 
released insert on 1% agarose and the vector was eluted from 
the gel with Geneclean II (Bio 101, La Jolla, CA, USA). 
The digested products were ligated overnight at 16°C using 3u 
T4 DNA ligase (Promega Madison, WI, USA) in the supplied T4 
ligase buffer. 
10 µl of the ligated product was mixed with 40 µl of a 10 mM 
Tris-HCl, pH 8.0, 25 mM cacl2 solution and this mix was added 
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to 100 µl ice-cold competent cells. These cells were then 
heat-shocked at 42°C for three minutes and left to cool at 
room temperature for 10 min. After adding 850 µl LB 
(Sambrook et al. 1989), this mix was placed at 37°C in a 
rotary shaker for 45 min. 40 µl of X-gal (20 mg/µl in 
dimethylformamide) was spread on premade LB plates (Sambrook 
et al. 1989) containing Ampicillin (50 µg/ml) and placed at 
37°C for about 1 hour prior to plating (JM85 cells only need 
the addition of X-gal for a-complementation). 
200 µl aliquots of the cells were spread onto LB plates 
containing Ampicillin and incubated at 37°C overnight. 
White colonies were picked and minipreparations of DNA for 
sequencing were obtained by alkali-lysis exactly as described 
(Sambrook 1989, pp 1.25-1.28). DNA from colonies was tested 
for the presence of insert by digesting about 20% of each 
minipreparation with Eco Rl (14 µ) (Promega Madison, WI) and 
Hind III (11 µ Boehringer Mannheim) in Buffer B (Boehringer 
Mannheim) to see if the appropriate size insert was released. 
2A.11 Northern Blots 
Northern transfer and hybridization was performed essentially 
as described (Selden 1989). The following minor alterations 
were introduced. 40 ug of each sample of total RNA was 
electrophoresed on 1% Agarose gels containing 1 x MOPS and 
1.1% formaldehyde. RNA was blotted as described onto 
HYBOND™-N (Amersham, Buckinghamshire, UK). The filter was 
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baked at 80°C for 2 hr. The blot was prehybridised at 42°C 
for 2 hr and hybridised overnight at 42 °C in the described 
solutions with pLDLR-2HH1 (Taylor et al. 1988) that had been 
random primed (Multiprime DNA labelling system, Amersham) . 
Membranes were exposed to X-ray film to visualise the bands. 
2A.12 Oligonucleotide purification 
Some of our oligonucleotides that were size-degenerate were 
purified with the following method for use in sequencing. 
Oligonucleotides were dissolved in 200 µl sterile d H2o and 
dried down in a Speedvac (Savant Instruments Inc). The dried 
oligonucleotides were resuspended in 500 µl H2o and dried. 
This was repeated again. (This process removes the ammonium 
as the oligonucleotides are initially prepared in 
concentrated ammonium hydroxide). The pellet was redissolved 
in 400 µl deionized formamide. 300 µl of this solution was 
stored for future use at -20°c and 100 µl was electrophoresed 
on a 20% acrylamide 7% urea preparative gel. The gel was 
pre-electrophoresed for 30 minutes at 200 V then the samples 
were loaded and electrophoresed at 300 V for 4 hours. The 
oligonucleotides were localized on the gel by UV shadowing on 
TLC paper. The band was cut out from the gel with a new 
steel blade and crushed through a 5 ml syringe into a 10 ml 
sterile tube. The oligonucleotides were extracted from the 
gel by incubating it with 10 ml 0.3 M sodium acetate pH 5.6, 
1 µM EDTA at .37°C overnight. The slush was then centrifuged 
at 2000 rpm for 10 min. The liquid was carefully poured off 
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and the oligonucleotides were desalted and concentrated using 
C18 Sep-pack columns (Waters Associates, Mifford 
Massachusetts USA). 
with 10 ml HPLC 
These columns were charged by washing 
grade acetonitrile (Rathburn Chemicals 
Limited, Walkerburn, Scotland) followed by 10 ml sterile H2o. 
The aqueous solutions containing the oligonucleotides were 
loaded onto the column and the column was then washed with 10 
ml H2o. The oligonucleotides were eluted with 60% methanol; 
4 ml 60% methanol was passed through the column and 1 ml 
aliquots were col~ected. The first 2 aliquots were dried and 
resuspended in water. After confirming that most of the 
oligonucleotide was in the first aliquot by measuring the 
00260 , the oligonucleotides were freeze dried and 
reconstituted in tt2o in 20 µM stocks. 
2A.13 Lipoprotein preparation and iodination 
Human LDL (Goldstein et al. 1983), Rabbit B-VLDL (Kovanen et 
al. 1981), IgG C7 (Beisigel et al. 1981) and human 
lipoprotein deficient serum (Goldstein 1983) were prepared as 
described. Iodination of LDL, B-VLDL (Goldstein et al. 1983) 
and IgG-C7 (Beisigel et al. 1981) with 125r was performed as 
described. The specific activity of LDL, IgG-C7 and B-VLDL 
ranged from 214-748 cpm/ng, 480-1442 cpm/ng and 618-1581 
cpm/ng respectively. Detailed descriptions of the above can 
be found in the thesis of A.M. Fourie (1989). 
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2A.14 Cell Culture 
Skin fibroblasts were usually seeded at 50 000 or 60 000 
cells per 60 mm Petri dish ( ligand binding experiments and 
some immunoprecipitation experiments) or at 20 000 cells per 
35 mm diameter Petri dish (some immunoprecipitation 
experiments) in Dulbecco' s MEM (DMEM) {Flow Laboratories, 
Ayrshire, Scotland, UK) containing 10% (v/v) fetal calf serum 
(day O). On day 3 this medium was replenished. On day 5, 
the medium was changed to Dulbecco' s MEM containing 
lipoprotein-deficient serum {LPDS) (5 mg protein/ml). This 
medium was replenished on day 6. Experiments were performed 
on day 7. Occasionally the number of cells seeded per dish 
or the number of days of cell growth in DMEM containing fetal 
calf serum were varied in order that cells were subconfluent 
and thus s _till rapidly dividing at the time that they were 
placed in lipoprotein-deficient medium so that maximal 
upregulation of LDL receptors should occur. 
2A.15 LDL binding and metabolism in fibroblasts as assessed 
with DiI-LDL 
The fluorescent dye 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine perchlorate (Di!) was 
incorporated into LDL {Pitas 1981). One mg of LDL in 2 ml of 
LPDS was vortexed for 10-15 sec with 50 µl of a 3 mg/ml Di! 
solution in dimethylsulphoxide. Di! was incorporated into 
the lipid phase for 15 hr at 37°C. The density of the 
incubation mixture was raised to 1.063 g/ml and DiI-labelled-
lipoproteins were isolated by ultracentrifugation at 40 000 
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rpm for 24 hr (Beckman SW40Ti Rotor). The LDL in the top 6 
mm was collected and dialyzed against 0.9% NaCl, 0.01% EDTA 
for 48 hr. The DiI-LDL was sterilised by filtration through 
a 0.22 µM filter (Millex GU, Millipore) prior to storage at 
4°C. The protein concentration of the DiI-LDL was determined 
(Lowry et al. 1951). 
DiI-LDL (20 µg/ml) was incubated with upregulated cells for 4 
hours at 37°C and visualised by fluorescence microscopy 
(Sanan 1985). 
2A.16 surface binding of 125r-B-VLDL to fibroblasts at 4°C 
Surface binding of 125r-B-VLDL at 4°C was performed at 
1 µg/ml 125r-B-VLDL with or without the simultaneous addition 
of 100 µg/ml unlabelled B-VLDL. Fibroblast monolayers were 
washed once with Dulbecco's phosphate buffered saline (ca2+ 
and Mg2+-free) (PBS), then the B-VLDL was added to the cells 
in MEM, buffered at pH 7.4 with 20 mM HEPES, containing LPDS 
( 5mg protein/ml) for 2 hr at 4°C. After the medium was 
collected the cells were washed 4 times with PBS containing 
O. 2% bovine serum albumin (Boehringer Mannheim, Mannheim, 
Germany) followed by 3 washes with PBS at 4°C. Six hundred 
µl PBS was added to each 60 mm dish and the cells were 
scraped off the dishes with cell scrapers and collected into 
1.5 ml microfuge tubes. The cells were centrifuged at 12 ooo 
g for 5 minutes in a microfuge. The 125r-B-VLDL bound to the 
cells was considered to be associated with the pelleted cells 
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that were counted after the supernatant was carefully 
removed. 
2A.17 surface Binding of 125I-IgG-C7 or 125I-LDL to 
fibroblasts at 4°C 
Surface binding of 125I-IgG-C7 (Fourie et al. 1988) and 125I-
LDL (Grant et al. 1989) was performed at 4 °C using the 
indicated concentrations of the respective ligands. Prior to 
adding ligands to the dishes the cells were washed once with 
Dulbecco' s Phosphate buffered sal-lne (PBS) (ca2+ and Mg2+_ 
free). Incubations were done in MEM, buffered at pH 7.4 with 
20 mM HEPES, containing LPDS (5mg protein/ml) After 2 
hours incubation the cells were washed 4 times with PBS 
containing o. 2% bovine serum albumin followed by 3 washes 
with PBS at 4°C. In the 125I-LDL binding experiments 2 ml of 
heparin (4 mg/ml) were added to the cells for 40 minutes at 
4°C and the 125I-LDL released was taken as the bound 
fraction. In the 125I-IgG-C7 experiments, the cell-
associated radioactivity was quantitated after the cells were 
dissolved in 1 N NaOH. 
2A.18 B-VLDL affinities at 4°C 
The affinities of the LDL receptors for Apo E were estimated 
by measuring the ability of unlabelled B-VLDL to compete for 
125I-LDL binding at 4°C. Rabbit B-VLDL was added at the 
indicated concentrations to 2 µg/ml 125I-LDL in MEM, buffered 
at pH 7.4 with 20 mM HEPES, containing LPDS (5mg protein/ml). 
These premixes were added to dishes and 125I-LDL binding was 
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determined as above. The B-VLDL concentration required for 
half-maximal inhibition of 125r-LDL binding was taken to 
reflect the affinity of the receptors for B-VLDL. This value 
was determined by non-linear regression analysis (Enzfitter; 
Elsevier Biosoft, Cambridge, U.K.). 
2A.19 125r-LDL and 125r-B-VLDL metabolism in fibroblasts at 
37°c 
The ability of cells to bind, internalize and degrade 125r-
LDL and 125r-B-VLDL at 37°C was measured at the indicated 
ligand concentrations as described previously (Goldstein et 
al. 1983). Prior to adding ligand to the dishes, the cells 
were washed once with PBS. After the cells were incubated 
with the desired concentration of 125r-LDL or 125r-B-VLDL in 
DMEM/LPDS at 37°C for 4 hours, they were put on a cold metal 
tray in the 4°C cold room. The medium was immediately 
harvested so that its content of non-iodide trichloroacetic 
acid-soluble radioactivity could be measured for LDL or 
B-VLDL degradation. The cells were washed four times with 
PBS-albumin and three times with PBS. The cells that had 
been incubated with LDL were then treated with heparin as 
described in the 4°C LDL binding assay. The cells that had 
been incubated with B-VLDL were treated with 10 mM suramin 
(Germanin, Bayer-Miles, South Africa), 50 mM NaCl, 3 mM 
cacl2 , 10 mM Hepes pH 7.4 for 1 hour at 4°C. The heparin- or 
suramin-releasable radioactivity was taken as the bound 
fraction. The cells were then solubilized in 1 M NaOH and 
the radioactivity quantitated (intracellular 125r-LDL or 
67 
1251-B-VLDL). Cellular protein in the solubilized extract 
was also determined (Lowry et al. 1951). Degraded 1251-LDL 
or 1251-B-VLDL in the medium was determined in the following 
way: The protein was precipitated from the medium by the 
addition of 0.3 volumes 50% (w/v) trichloroacetic acid and by 
incubation at 4°C for 30 minutes. The precipitate was 
sedimented by centrifugation at 2000 rpm (Beckman TJ-6 
centrifuge) for 30 minutes at 4°C. An aliquot of the 
supernatant (1 ml) was mixed with 20 µl 40% potassium iodide 
and 50 µl 30% hydrogen peroxide that converts free iodide to 
iodine. The free iodine was extracted with 2 volumes of 
chloroform and the radioactivity in the aqueous phase was 
considered to represent the degraded lipoprotein ligand. 
2A.20 Calculation of Bmax and Kd_values 
The Bmax and Kd values were calculated from binding curves 
using a commercial software package (Enzfitter; Elsevier 
Biosoft, Cambridge UK) for non-linear regression analysis 
assuming one saturable site plus non-saturable processes. In 
some cases specific values were determined by subtracting 
from the total activity the non-specific values obtained 
either in the presence of excess unlabelled LDL (200 µg/ml) 
or in cells in which LDL receptor activity had been fully 
downregulated by treatment with 1 µg/ml 25-0H cholesterol for 
48 h. The resultant curves of specific high-affinity 
activity were analyzed using Enzfitter assuming only one site 
of specific binding. 
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2A.21 135s1-Methionine pulse-chase experiments 
These experiments were done essentially as described 
{Tolleshaug et al. 1982). On day 7, upregulated cells were 
pre-incubated for 30 minutes in methionine-free Eagles MEM 
containing LPDS (5mg protein/ml) at 37°C, after which cells 
were pulse-labelled at 37°C for the required time with [35s1-
methionine (50 - 100 µCi/ml; Methionine, L-[35s1-, Dupont, 
Wilmington, DE, USA) . The medium was then changed to 
. DMEM/LPDS containing 200 µM unlabelled methionine and the 
cells were chased for varying times. The cells were then 
washed and solubilized. Post-nuclear supernatants were 
incubated for 1 hour at 4°C with a preformed immune complex 
containing IgG-C7 (mouse monoclonal anti-LDL receptor 
antibody) coupled to a goat anti-mouse antibody {Organon 
Teknica Corp. West Chester, PA, USA). The immunoprecipitates 
were pelleted by centrifugation at 2000 rpm for 5 minutes. 
The supernatant was discarded or kept aside for subsequent 
transferrin receptor immunoprecipitation. The pellets 
containing the immunoprecipitates were washed through a 4-
step sucrose density gradient where each layer contained a 
different combination of detergent and ionic strength. 
Immunoprecipitates were electrophoresed on 7% SOS 
polyacrylamide gels which were enhanced with salicylate, 
dried and exposed to X-ray film (Kodak X-OMAT-AR). The 35s 
radioactivity in the mature and precursor LDL receptors was 
quantified by densitometric scanning of the fluorograms 
{Cliniscan, Helena Laboratories, Beaumont, Texas, USA). 
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In some experiments, transferrin receptors were 
immunoprecipitated in addition to LDL receptors to serve as a 
control for protein synthesis in different cell types. The 
transferrin receptors were immunoprecipitated from the 
supernatant left after LDL-receptor immunoprecipitation with 
a mouse anti-transferrin antibody-goat anti-mouse antibody 
complex in exactly the same way as the LDL receptors. 
2A.22 Determination of r35sJ-methionine incorporation into 
total trichloroacetic acid-precipitable protein 
In some experiments we needed to determine r35s]-
radioactivity incorporated into t6tal trichloroacetic acid-
precipitable cell protein during a pulse-labelling period as 
a measure of total protein synthesis. We used the filter 
disc method outlined briefly below (Mans and Novelli 1961, 
Bester 1973). An aliquot of the (35s]-labelled post-nuclear 
supernatant from the cell-lysate obtained as described in 
2A.21 (Tolleshaug et al. 1982) was diluted in 9 volumes H2o 
and then applied to a Whatman GF/C filter. This filter was 
successively immersed in 10% trichloroacetic acid (TCA) at 
4°C for 30 minutes, 5% TCA for 15 minutes at room 
temperature, 5% TCA at 90°C for 20 minutes, 5% TCA at room 
temperature for 5 minutes, ethanol: diethyl ether (1:1) for 
5 minutes, and diethyl ether for 5 minutes. The 35s-labelled 
TCA-precipitable protein on the filter disc was then measured 
by scintillation counting (Beckman Ready-Solv™ EP 
scintillation cocktail, Packard 4690 Scintillation counter). 
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SECTION B: AN EXPLORATION OF THE SINGLE STRAND 
CONFORMATIONAL POLYMORPHISM (SSCP) METHOD FOR 
THE DETECTION OF POINT MUTATIONS. 
2B.1.1 Introduction: Techniques other than SSCP that are 
used to detect point mutations. 
The ability to detect point mutations has become very 
important in genetic research. Techniques that can screen 
large stretches of DNA or RNA for mutations without having to 
resort to sequencing have the potential to easily detect new 
mutations, to screen populations for new and previously 
detected mutations, and can be used to detect new markers for 
gene mapping independent of the sequence constraints imposed 
by restriction endonuclease sites. 
Many different approaches have been developed to solve this 
problem. Some methods have relied on the susceptibility to 
chemical modification and/or enzyme digestion of exposed 
unpaired bases, formed by annealing a mutant to a normal 
sequence . Earlier techniques included attempts to cleave 
DNA: DNA mismatches with the single-strand specific nuclease 
Sl (Shenk et al. 1975, Dodgson and Wells 1977) or by the 
cleavages of RNA:DNA mismatches by ribonuclease A (Myers et 
al. 1985). The problem with these methods was that they only 
detected about 50% of mutations (Myers et al. 1985). Recent 
variations of this approach have relied on the abilities of 
hydroxylamine and osmium tetroxide to modify mismatched C's 
and T's, respectively, and make them susceptible to 
piperidene cleavage (Cotton et al. 1988) . Theoretically, 
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this technique could be virtually 100% sensitive to point 
mutations (Rossiter and Caskey 1990). However, the chemical 
method has been unable to detect some mutations that have 
been detected by other methods (Theophilus et al. 1989). 
Another group of techniques involve denaturing gradient gel 
electrophoresis. This method relies on the principle that 
different DNA sequences, even those that differ by only one 
base pair, have different melting temperatures. Normal and 
mutant duplex fragments migrate through acrylamide gels 
containing a gradient of formamide, urea, or temperature with 
a constant mobility as a function of their molecular weight, 
while they are double stranded. When they reach the region 
of the gel that has sufficient denaturant to cause melting, 
the rate of migration is suddenly slowed. Theoretically, at 
least, the differences in melting temperature between two 
sequences differing by a single base pair or a native double-
stranded sequence and a heteroduplex with a single base-pair 
mismatch, should allow resolution of single base-pair changes 
on denaturing gradient gels (Rossiter and Caskey 1990). A 
problem with this method was that it did not pick up 
mutations in regions of the sequence that melted latest, 
because at that stage the strands had already started to 
separate and the electrophoretic mobility had been arrested 
to some extent. To circumvent this and improve the 
sensitivity of the technique a GC-rich region was placed at 
one end of the sequence to be analysed in order that this so-
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called GC clamp should be the last area of the sequence to 
denature. 
The immunomicroscopy technique (Ganguly et al. 1989) relies 
on the binding of carbodiimide to the point of mismatch in a 
heteroduplex. The carbodiimide is then detected with a 
polyclonal anti-carbodiimide antibody which is itself 
recognised by a second antibody linked to an electron dense 
marker. This complex is ultimately visualised by electron 
microscopy. The advantage of this technique is that it -ean 
identify mutations in large lengths of DNA (e.g. 7 kB) but 
can only locate mutations with an accuracy of 0.1 kB to 0.3 
kB. This technique seems to be quite finnicky and time-
consuming as there are difficulties in detecting A:C/G:T or 
G:G/C:C mismatches. In addition, false positives from non-
specific labelling of molecules have to be ruled out (Ganguly 
et al. 1989) . 
The altered electrophoretic mobility of heteroduplexes as 
opposed to homoduplexes can often be detected on Hydrolink 
gels (AT Biochem. Inc., Malvern, PA, USA) (Keen et al. 
1991). This is another way to screen PCR products for point 
mutations or small deletions (Keen et al. 1991). 
Heteroduplexes form in heterozygous samples as part of the 
PCR reaction (as soon as the efficiency of amplification 
starts to plateau) and can be artificially created from two 
different homozygote PCR products by mixing, denaturation and 
renaturatio·n. A modification of this method was used to 
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detect the 3 b. p. deletion in exon 4 of the LDL receptor 
commonly found in Ashkenazi Jews (Meiner 1991). (See Section 
2A. 9. 5.) 
2B.1.2 Introduction to the Single-Stranded Conformational 
Polymorphism (SSCP} method for detecting point 
mutations. 
Recently, a method has been developed that relies on the 
observation that the electrophoretic mobility on non-
denaturing gels of single-stranded DNA i~ determined by its 
conformation that is in turn a function of both the size and 
sequence of the molecule. This technique uses PCR spiked 
with [a32pJ-dCTP or a kinased oligonucleotide to generate DNA 
sequences that are then denatured in a formamide buffer prior 
to electrophoresis in non-denaturing gels under a variety of 
conditions (Orita et al. 1989a, Orita et al. 1989b). The 
temperature of electrophoresis, the concentration of TBE in 
the running buffer and in the gel, and the glycerol 
concentration in the gel can all be varied to change and 
optimise the banding patterns resulting from the single 
stranded DNA. 
SSCP is one of the easiest and quickest methods available to 
detect point mutations, but not much work has been done to 
ascertain its sensitivity. This technique was investigated 
as it would be potentially of use in the initial detection of 
point mutations in the Indian FH homozygotes and subsequent 
population .screening. 
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The apo E polymorphisms were used to test the sensitivity of 
point mutation detection of SSCP gels. The apo E gene has 3 
common alleles. The commonest allele E3 allele has a 
cysteine at codon 112 and an arginine at codon 158, the E4 
allele has arginines at both codons and the E2 allele has 
cysteines at both sites. We had been using the Hha 1 
restriction digestion system (Hixson and Vernier 1990) to 
distinguish genotypes and combinations of the apo E2, E3, E4 
alleles from each other (see Section 2A.9.8, and Fig. 2A.6}. 
HhaI recognises the sequence GCGC that is present when either 
codon 112 or 158 are arginines (GCG} but not when they are 
cysteines (TGC). Unfortunately this method was designed to 
detect polymorphisms at codons 112 and 158 in the apo E gene, 
and does not detect mutations at many other sites. In 
addition to the potential of developing a system for rapid 
apo E genotyping, we also wanted to develop a system to 
distinguish the Arg145-cys and Lys146-Gln mutations that had 
been identified in our laboratory (W.J.S. de Villiers, G.A. 
Coetzee, D.R. van der Westhuyzen, personal communication) 
from the common apo E alleles E2, E3 and E4 as this could not 
be accomplished by Hha I restriction isotyping. 
Single-stranded versions of the different apo E alleles at 
our disposal and combinations thereof were electrophoresed on 
various types of SSCP gels in order to see which gel (s) 
resolved the polymorphisms best and whether it would be 
feasible to use SSCP as an apo E genotyping system and as a 
means of identifying mutations in our Indian FH patients. 
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2B.2 Methods 
A 244 b.p. fragment of the apo E gene that encompassed the 
polymorphic sites at codons 112 and 158 was amplified using 
oligonucleotides G23 and G24 (see Table 2A.1). The PCR was 
labelled by adding 1-10 µCi (0.1 - 1 µl) [a-32pJ-dCTP 
(Amersham, UK) to the mix. On certain occasions the PCR 
product was labelled by kinasing one of the oligonucleotides 
in the mix with [T-32pJ-ATP. One to three µl of the PCR 
product was mixed with 9 µl of 95% deionised formamide, 20 mM 
EDTA, 0.05% bromophenol b~ue, 0.05% xylene cyanol. This was 
heated at 95°C for 3-5 minutes, placed immediately on ice and 
then loaded onto the gel. 
Gels were run on a conventional sequencing apparatus (40 mm x 
20 mm x 0.4 mm) with a cooling plate. The gels were cooled 
with a fan when run at room temperature. Gels were composed 
of 6 or 8% acrylamide, 0.5x or lxTBE, and 0%, 5% or 10% 
Glycerol. These gels were made as 50 ml solutions. Five ml 
was taken to form a plug and was polymerised with 500 µl 3% 
ammonium persulphate and 5 µl TEMED. After the plug had set, 
the remaining 45 µl was polymerised with 2.5 ml 3% ammonium 
persulphate and 25 µl TEMED. Gels were pre-electrophoresed 
for an hour at the desired temperature (4°C in the cold room, 
or room temperature) and power prior to loading samples. 
Gels were run at constant power as shown in Table 2B.1. The 
samples were normally electrophoresed at least until the 
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Fig. 2B.l; Comparison of sscp patterns of PCR products of ape 
E genotypes labelled either with [a-llPJ-dCTP or with a 
kinased primer. PCR of the apo E gene was performed as 
described using G23 and G24 (see table 2A.l ). PCR products 
were radioactively labelled either by the addition of (a-
32P]-dCTP or some kinased oligonucleotide G24 to the PCR mix. 
PCR products were denatured in formamide and were 
electrophoresed at 4°c at 8 W on a SSCP g~l containing 8% 
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Fig. 2B. 2: Diagnosis of the Apo E Arg145-cys mutation on a 
SSCP gel. PCR of the ape E gene was performed as described 
using oligonucleotides G23 and G24 (see table 2A.l). The PCR 
products. were radioactively labelled by the addition of (a-
32p]-dCTP to the PCR mix. PCR products were denatured in 
formamide and · were electrophoresed at 40 W at room 
· temperature on a 6% gel containing 5% glycerol and o.s x TBE. 
The lane labelled 145/145 + 3/3 is a mix of PCR products from 
a 145/145 and a 3/3 homozygote. The proband was a 145/145 
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Fig. 2B.J: Diagnosis of the Apo E Lys:lJ.2-Gln mutation on sscp 
gels. Radiolabelled PCR products of the above apo E 
genotypes were generated by PCRing genomic DNA with 
oligonucleotides G23 and G24 (see table 2A. l.) and (a-32p]-
dCTP. PCR products were denatured in form.amide and were 
electrophoresed at 4 Wat room temperature on a 6% acrylamide 
gel containing 1 x TBE and 10% glycerol. 145 • Arg145-cys; 
146 = Lys 146-Gln. 
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In some cases, hydrolink gels (MDEtm, AT Biochem Inc, Malvern 
PA, USA) were used instead of conventional acrylamide. The 
hydrolink gel was made in a final volume of 60 ml consisting 
of 15 ml Hydrolink, 41 ml H2o, 3.6 ml lOx TBE and was 
polymerised with O. 3 ml ammonium persulphate and O. 03 ml 
TEMED. 
Gels were dried at 80°C for 1-2 hours and then were exposed 
to X-ray film (Kodak X-OMAT-AR). 
2B.3 Results and Discussion 
Table 2B. 1 summarises our experience in distinguishing the 
apo E2, E3, E4 alleles and the Arg145 to Cys mutation from 
each other. The most successful gels are shown in figs. 
2B.1, 2B.2 and 2B.3. It was clear from this series of gels 
that the sharpness/smudginess of the banding patterns and the 
ability to differentiate between different alleles varied 
from gel to gel (see Table 2B.1 and Figs. 2B.1, 2B.2, 2B.3). 
SSCP patterns obtained from PCRs of a given genotype labelled 
with (a32pJ-dCTP were compared to those obtained when the PCR 
was labelled by the incorporation of a kinased primer (Fig. 
2B.1). The a-labelling incorporates radioactivity into both 
strands synthesized in the PCR reaction; in the ideal 
situation 2 bands should be visible in a homozygote subject 
and 4 bands from a heterozygote. The PCR reaction labelled 
with a kinased · oligonucleotide primer only incorporates 
radioactivity into the strand primed by that oligonucleotide. 
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Consequently, in this scenario one expects one band from a 
homozygote and 2 bands from a heterozygote. Unfortunately, 
the number of bands seen is confounded by 2 situations. 
Firstly, a given single strand can migrate at more than one 
mobility, presumably due to folding into more than one stable 
conformation {Orita 1989a). Secondly, 2 complementary 
strands can run with the same electrophoretic mobility. 
None of the SSCP gels tested allowed absolutely successful 
apo E isotyping when the PCR products were labelled ·with 
(a32pJ-dCTP {Table 2B.l). Many of the gels could 
successfully differentiate the homozygotes from each other. 
However, the distinction of heterozygotes from the 
homozygotes that had one of the alleles of the heterozygote 
was often impossible. In Fig. 2B.l, for example, it was 
impossible to distinguish a 2/4 from a 4/4 in the (a32pJ-dCTP 
labelled samples. 
PCR was labelled 
The results were more promising when the 
with kinased G24. This approach 
differentiated between most of the apo E variants in both 
homozygous and heterozygous forms (Fig. 2B.l). 
An interesting feature emerged when the same DNA, PCRed 
either with (a32pJ-dCTP, or with a kinased oligonucleotide, 
was electrophoresed on the same gel (Fig. 2B.l). The 
mobilities of the PCR products labelled with a kinased 
oligonucleotide were not the same as those of the 
corresponding (a32pJ-dCTP-labelled samples. The addition of 
a 5' phosphate and the resulting extra negative charges 
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probably result in different single stranded conformations 
and/or the extra charge contributes to an increased 
electrophoretic mobility. 
One of the useful applications of this work on SSCP of apo E 
was the development of assays that differentiated the Arg145-
Cys and Lys146-Gln mutations from the wild type alleles E2, 
E3 and E4. Hha I analysis of the Arg145-cys mutation (when 
it occurs on an E3 allele) is undistinguishable from E3, 
since this mutation does not create or destroy a Hha 1 
restriction site. A patient homozygous for the Arg145-cys 
mutation, originally described by Rall et al. (1982), was 
detected in our laboratory (W.J.S. de Villiers, personal 
communication). It was important for us to know whether the 
3 children of this patient had the mutation or not in order 
to establish the dominant or recessive nature of this 
mutation. All three children's DNA typed as E3 /E3 when 
analysed by Hha I digestion. The SSCP analysis of the 3 
children (Fig. 2B.2) showed clearly that these 3 children 
were E3/Arg145-cys heterozygotes. 
A similar situation arose with a patient who was heterozygous 
for the Lys146-Gln mutation initially described by Rall et 
al. (1983). He typed as an E3/4 on the Hha 1 system (W.J.S. 
de Villiers, personal communication). SSCP analysis of this 
patient (Fig. 2B.3) demonstrated that this mutation created a 
pattern distinct from those of the 3 common alleles and the 
Arg145-cys · mutation. Since two of the bands from this 
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subject ' s DNA were the same as those from the E4 / 4 PCR 
product, one could conclude that this mutation occurred on an 
E3 background allele. The examples in Fig. 2B.2 and 2B.3 can 
be extended in relevant situations for rapid screening of 
selected patients for these mutations. 
The SSCP technique has been refined and a number of 
modifications have been attempted in order to increase the 
sensitivity of the system. Kovar and co-workers (1991) 
developed a two-dimensional system for mutation analysis of 
long DNA fragments. They first restricted the desired 
fragment with a frequent-cutter restriction endonuclease and 
separated the resultant fragments under denaturing conditions 
in the 1st dimension. The single-stranded fragments were 
then electrophoresed in a 2nd dimension on non-denaturing 
gels to determine their single-stranded conformations. 
This approach can 
products that are 
optimal for SSCP, 
be simplified when dealing with PCR 
larger than the 100-200 b.p. that are 
by digesting the PCR product with a 
restriction enzyme that results in fragments of a size more 
appropriate for SSCP analysis (Iwanhara et al. 1992). 
Another approach, that allows the analysis of many different 
regions of a gene concurrently, is to first amplify the 
different areas simultaneously with a multiplex PCR and then 
to electrophorese on an SSCP system (Runnebaum et al. 1991). 
This method is attractive, but it can be difficult to 
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optimize conditions for multiplex PCR so that each of the 
products amplify purely and to a similar extent. In 
addition, the SSCP patterns of the different PCR products 
must not overlap. 
Another group used 12 % minigels and silver-staining of DNA 
(non-isotopic) to detect mutations causing phenylketonuria 
(Dockhorn-Dworniczak et al. 1991). Ethidium bromide staining 
of SSCP gels on standard electrophoresis equipment has also 
been reported (Yap and McGee 1992). This approach is 
potentially cheaper, quicker, easier and safer than the 
conventional systems. However, it might not be as reliable 
in detecting subtly different bands due to the decreased 
resolution on minigels and the silver staining might not be 
as sensitive in detecting minor bands as 32p . 
• 
In summary, SSCP is easy to perform in the conventional 
isotopic mode on sequencing apparatus. It has limited 
sensitivity in differentiating heterozygotes from homozygous 
apo E genotypes on many systems even though the PCR product 
is relatively small (244 bp). Perhaps the sensitivity of a 
particular sequence to SSCP analysis is not only a function 
of its length but also of its base composition. The region 
of the apo E gene that was analysed is about 70% GC rich. 
SSCP is very easy and should be considered if close to 100% 
detection of mutations is not a priority. A particularly 
useful application of this technique is in population 
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screening for known mutations. Here the conditions that best 
distinguish between the wild-type and mutant alleles can be 
optimised and large numbers of patients can be screened at 
once (see Fig. 4.13). 
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CHAPTER 3 
PRELIMINARY CHARACTERISATION OF 2 MUTATIONS THAT RESULT IN 
DECREASED LDL-RECEPTOR PROTEIN SYNTHESIS 
3.1 INTRODUCTION 
This chapter describes the initial work on mutations that 
result in decreased LDL-receptor synthesis in the 2 FH 
homozygotes NS (an Indian) and JL (a Pedi). 
NS is an Indian boy who was diagnosed as an FH homozyyote on 
clinical grounds. His fibroblasts express no detectable LDL-
receptor protein and therefore he has a "Null" mutation. 
In contrast to the South African Indian population that seems 
to have a high prevalence of hypercholesterolemia (Seedat et 
al. 1990), this problem seems to be relatively rare in the 
South African Blacks (Marais and Berger 1986). This can be 
explained by the observation that this population eats foods 
that are low in saturated fats and cholesterol (Marais and 
Berger 1986) or by a decreased frequency of mutant genes that 
predispose to this disorder. Alternatively, hyperlipidemias 
are not being recognised in the Black population. 
At least 2 different FH mutations have been identified in 
South African Blacks (van Wingerden 1981, Leitersdorf et al. 
1988). The mutation in TT, a Xhosa, has been fairly 
extensively characterised. He was a homo-allelic homozygote 
whose receptors had 2 amino acids deleted from the first 
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cysteine-rich repeat of the ligand-binding domain. This 
resulted in the non-recognition of these receptors by IgG-C7, 
the monoclonal antibody directed to that epitope. His 
receptors bound LDL with normal affinity and when his 
fibroblasts were maximally upregulated they bound 30% of the 
maximum amount of LDL bound by normal fibroblasts. This 
confirmed findings that the first repeat of the LDL receptor 
is not necessary for normal LDL recognition (van Oriel et al. 
1987). TT' s receptors also manifested slow transport from 
the ER to the Golgi (Leitersdorf et al. 1988). 
JL, a Pedi from Lebowa, was the first Black FH homozygote 
characterised in South Africa (van Wingerden 1981). He was 
admitted to hospital at age 19 with painless swellings on 
both knees that turned out to be xanthomata. Besides the 
presence of extensive xanthomata, corneal arci and an early 
systolic murmur compatible with aortic stenosis, the patient 
appeared healthy. JL's total cholesterol readings around the 
time of presentation were 6,26, 5,64 and 8,87 mmol/1 (van 
Wingerden 1981). The normal cholesterol levels reported for 
Black men were 3, 18 ± 1, 25 (Bronte-Stewart 1985) . These 
levels in JL are particularly low for a homozygote and are 
similar to those found in heterozygotes in more affluent 
societies (Thompson et al. 1989). The clinical diagnosis of 
homozygous FH was confirmed in 1985 by comparing the receptor 
number on JL's fibroblasts and EBV transformed 
lymphoblastoid cells to normal values. 125r-LDL metabolism 
at 37°C in ·both cell types from JL were less than 15% normal 
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values, as was 125I-LDL and 125I-IgG C7 binding at 4°C. The 
low LDL-receptor status in this patient was confirmed further 
by the demonstration of very low ACAT stimulation by LDL in 
this subject's cells (Coetzee et al. 1985). This study 
concluded that JL's cells manifested the "receptor-defective" 
phenotype. The last sentence of this paper reads: "The 
exact nature of the mutant allele awaits clarification" 
(Coetzee et al. 1985). In this chapter the inability of JL's 
mutant alleles to synthesize LDL receptors will be discussed. 
JL died suddenly in 1985 aged 24 while doing a job at a 
neighbour's house (H. Marabe, personal communication). The 
severe clinical course of this untreated FH homozygote 
possibly illustrates an important clinical lesson: In spite 
of only moderately elevated cholesterol levels ( 6, 5 - 8, 9) 
more consistent with those of a FH heterozygote, this FH 
homozygote still manifested early xanthomata, an aortic 
stenosis murmur and premature sudden death (probably an MI). 
Presumably, this implies that cholesterol levels in Black 
homozygotes, even if partially normalised by a prudent diet 
and other genetic factors (Vermaak et al. 1991), are not 
necessarily a reliable predictive factor for the critical 
pathology of FH homozygotes, coronary artery disease. 
3 • 2 RESULTS: NS 
3.2.1 Clinical Presentation 
NS presented at the age of 4 years with the characteristic 











Xanthomata-tendon and cutaneous from 
4yrs 
MURMUR compatible with aortic stenosis 
Fig. 3.1: Family tree and clinical f~atures 6f NS. 
TC= Total cholesterol; TG = Triglycerides; 
HDL = HDL-cholesterol; LDL = LDL cholesterol; 
all measured in mmol/1. 
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the behaviour of LDL receptors in his fibroblasts were 
undertaken in order to confirm the diagnosis of FH and 
characterise the type of mutation. 
3.2.2 Ligand Binding to NS Fibroblasts 
In order to determine the size of the pool of LDL receptors 
on his fibroblasts, ligand binding to these receptors was 
determined at 4°C. LDL-receptor specific binding was 
determined in each case by subtracting binding values 
obtained either in down-regulated cells or in cells 
simultaneously incubated with excess unlabelled ligand from 
total binding. No receptors were detected above background 
levels by the anti-LDL receptor monoclonal antibodies IgG-C7 
or IgG- HLl (Table 3. 1) . IgG-C7 and IgG-HLl have distinct 
epi topes in ligand binding repeat 1 and the hinge-region 
between ligand binding repeats 4 and 5, respectively. 
These findings were confirmed by more sensitive assays for 
LDL and B-VLDL metabolism at 37°C (Table 3.2). The 125r-LDL-
bound, intracellular or degraded after 4 hours was <5% of 
normal values as was the amount of 125r-B-VLDL degraded 
(Table 3.2). LDL binding at 37°C was examined by using the 
dI-LDL technique. This fluorescent ligand serves as a very 
sensitive means of detecting LDL-receptor activity in cells. 
Even small amounts of dI-LDL when trapped in lysosomes give 
off a detectable fluorescent signal. While this was clearly 
evident in normal fibroblasts, no fluorescence was detected 
in NS fibroblasts. 
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Table 3.1: 125r-IgG-C7 and 125r-IgG-HL1 binding to NS 
fibroblasts at 4°C 
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Antibody binding to fibroblasts was performed at 0.9 - 1 µg/ml 
125r-IgG-C7 and 2 - 2. 5 µg/ml 125r-IgG-HL1 as described in 
general methods. Non-specific binding was determined in cells 
down-regulated with 1 or 2 µg/ml 25-0H cholesterol (2) or in 
cells to which 50 µg/ml unlabelled Ig-G-C7 was added to the 
cells along with the labelled antibody {1). (3) Values 
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Table 3.2: 1251-LDL and 125r-B-VLDL metabolism in 
NS 
.=.... ................ --............a _____ _ 
fibroblasts at 37°c 
125r-LDL and 125r-B-VLDL metabolism was determined 
in 
fibroblasts as described in the general methods. Non-specif
ic 
binding was either determined in cells down-regulated with
 1 
µg/ml 25-0H cholesterol (2) or in cells to which an excess 
of 
unlabelled LDL {200 µg/ml or 300 µg/ml) or B-VLDL {100 µg/m
l) 
was added along with the labelled ligand {10 µg/ml) (1). (
3) 
Values expressed as mean ± standard deviation of 
4 
experiments. 
Cell strain 125I-LDL 125I-B-VL
DL 
Bound Intracellular Degraded Degraded 
ng/mg cell protein 
Normal 233±1643 1319±5573 4511±27643 1820±9093 
% normal 
NS o2 o2 12 
32 
ol 41 0.31 31 
4.21 71 2.91 ol 
__ 61_ __ 41 __ 1.51 _ 2.51 
2.6±33 3.8±2.93 1.4±1.13 2.1±1.43 
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N 0 - 0 3 6 g 12 
12sr-LDL (pg/ml) 
Fig. 3.2: 4°C binding of 125r-LDL to Normal and NS 
fibroblasts. Upregulated cells were incubated at 4°C for 2 
hours and the total 125r-LDL bound was determined as 
described in the general methods. The normal cells bound 
125r-LDL with a B of 78 ng/mg protein and a Ka of 1.5 max 
µg/ml as determined using commercial software (Enzfitter, 
Elsevier Biosoft) using one site of specific binding and non-
specific processes. NS fibroblasts yielded a linear 
relationship of total ligand bound vs. ligand concentration 
that suggested predominantly non-saturable (i.e. non-
receptor) binding. Each point represents the mean value 
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125I-.BvLDL (pg/ml) 
Fig. 3. 3: Cell associated B-VLDL determined at 37 °C for 30 
minutes in normal and NS fibroblasts. 
incubated for 30 minutes with the 
Upregulated cells were 
indicated 125r-BVLDL 
concentrations at 37°C. The cells were then washed 4x with 
PBS-albumin and 3x with PBS at 4°C. 0.6 ml PBS were added to 
the dishes and the cells were scraped and collected in 
microfuge tubes. This process was repeated on each dish to 
ensure that most of the cells were collected. The cells were 
centrifuged at 12 ooo g for 2 minutes. The supernatant was 
discarded and the pellet was counted. The normal cells 
"bound" 125r- B-VLDL with a Bmax of 117 ng/mg protein and a 
Ka of o. 08 µg/ml. NS fibroblasts yielded a predominantly 
linear relationship of cell-associated ligand to ligand 
concentration that suggested that the binding was 
predominantly a non-specific (non-receptor) process. (Total 
binding was analysed using commercial software as described 
in general methods. ) Each point is the mean value from 
duplicate dishes. 
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An outside chance remained that the low binding values were 
the result of the putative mutant receptors having an 
impaired affinity for their ligands. This possibility was 
excluded in Fig. 3.2 and Fig. 3.3 that demonstrated no 
specific LDL binding or B-VLDL association with NS 
fibroblasts in the face of high-affinity processes occurring 
in the normal control cells. 
3.2.3 Immunoprecipitation of NS Receptors 
As no receptors were detectable on NS fibroblasts we had to 
make the distinction between 3 scenarios: mutations that 
synthesise no detectable receptors (Class 1 mutations), those 
where there is a complete block in receptor processing (Class 
2A mutations) or mutations that result in secretion of 
receptors (that can be placed in Class 4). The absence of any 
immunoprecipitable receptors in NS cells after metabolic 
labelling fibroblasts for 1 hour or after a subsequent chase 
for 5. 5 hours suggested that NS harboured a "Null" mutation 
that resulted in no detectable protein synthesis (Fig. 3.4). 
Since these assays might not detect less than 5% of normal 
LDL receptor synthesis the distinction between very low and 
completely absent LDL receptor synthesis in NS cannot be 
made. 
3.2.4 mRNA Levels in NS 
"Null" mutations can result from defects at many different 
levels. The analysis of mRNA levels and mRNA size can help 
eliminate some of the possibilities. The mRNA levels in NS 
seemed to be very low in comparison to normal on Northern 
Blot analysia but the transcript was approximately the 
correct size (Fig. 3.5). There was also some evidence that 
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labelled LDL receptors from normal and NS fibroblasts. Up-
regulated fibroblasts were pulse labelled with [35s]-
methionine for 1 hour and chased in DMEM/LPDS for the 
indicated times . LDL-receptors were immunoprecipitated and 
visualised on autoradiographs as indicated in the methods. 
The apparent molecular weights of the precursor {120 kDa) and 
mature { 160 kDa) receptors are indicated. The absence of 
immunoprecipitable LDL receptors in NS was confirmed in 
another similar experiment. 
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Fig. 3.5: Northern Blot of LDL-receptor mRNA from normal and 
NS cells. Cells were grown for 5 days · in Dulbecco' s MEM 
containing 10% fetal calf serum {DMEM/FCS). The cells marked
 
+ were then upregulated for 1 day by changing the medium to 
DMEM containing lipoprotein deficient serum (5 mg 
protein/ml). The cells marked - were grown for all 6 days in
 
DMEM/ FCS. 3 o µg of total RNA was electrophoresed in each 
lane of a 1% agarose gel containing lxMOPS and 1% 
formaldehyde. The RNA was blotted onto HYBOND-N and 
hybridised with a probe to the LDL-receptor as described in
 
general methods and X-ray film was exposed to this membrane. 
N NS 
· 5.3 kb> 
REGULATION: + + 
size of NS mRNA has been confirmed to be grossly normal by
 
comparing the size of PCR products of overlapping regions of
 
the cDNA that encompass the translated message with normal
 
(results not shown). 
3.2.5 LDL-receptor haplotype of NS 
Haplotype analysis was then undertaken to determine whether
 
NS was maybe a heteroallelic homozygote. NS was homozygous
 
at the 4 sites examined (Ava II++, Taq 1--, Stu I++,
 
Nco I++) • This result is consistent with NS being a true
 
homozygote. It is, howev~r, not an absolute result since the
 
heterozygosity index of these sites is not 100%. The 10 RFLP
 
sites that are presently most informative only have a
 
heterozygosity index of 86% (Hobbs et al. 1990). 
3.2.6 Promoter Sequence of NS 
Low mRNA levels are either the result of impaired
 
transcription or due to message instability. The promoter 
region of NS' DNA was sequenced and was normal from the
 
translation start site upstream to beyond the first Spl
 
binding repeat (Fig. 3. 6). This region includes all the
 
regions of the promoter thought to be necessary for adequate
 
transcription. NS did not have the mutations that we have
 
detected thus far in South African Indians (Results not
 
shown). The exact nature of the mutation in NS has not yet 
been characterised at the DNA level, as only limited
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3 . 3 RESULTS: JL 
3.3.1 Ligand Binding to JL Fibroblasts 
We aimed to determine the mechanisms underlying the decreased 
surface expression of LDL receptors in JL's cells. It was 
possible that the low IgG-C7 and LDL binding previously 
reported in JL' s cells (Coetzee et al. 1981} was due to 
mutations that affected the receptor's ability to recognise 
these ligands effectively. The low surfac~ receptor number 
was confirmed by the similarly low levels of IgG-C7 and B-
VLDL that bound to JL's fibroblasts at 4°C (Table 3.3). 
3.3.2 Processing of JL's LDL receptors 
The biosynthesis and processing of receptors in JL's cells 
was examined next (Fig. 3.7). JL's cells synthesised 
precursor and mature receptors of normal size. The 
conversion of precursor to mature receptors proceeded at the 
normal rate with complete conversion of precursor to mature 
receptors within a half-hour chase period. In addition, the 
expression of JL's receptors was appropriately down-regulated 
by sterols (Fig. 3.7). JL's cells produced very few LDL 
receptors as judged by the amount of immunoprecipitate 
compared to normal cells after a 1 hour labelling period. 
This will be systematically investigated in 3.3.4. 
3.3.3 Stability of JL's LDL receptors 
A low receptor population can either be due 
synthesis or decreased stability of receptors. 
to impaired 
We initially 
examined the latter scenario. JL's cells were metabolically 
101 
Table 3.3: 125r-IgG-C7 and 125r-B-VLDL binding to normal and 
JL fibroblasts at 4°C 
Upregulated fibroblasts were incubated with 0.1 µg/ml 125r-
IgG-C7 with/without 50 µg/ml unlabelled Ig-G-C7 or with 3 
µg/ml 1251-B-VLDL with/without 100 µg/ml unlabelled B-VLDL. 
Specific binding was determined by subtracting the binding 
obtained in the presence of unlabelled ligand from the total 
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Fig. 3.7: Autoradiographs of immunoprecipitated [35sJ-labeled 




were grown for 5 days in Dulbecco's MEM 
fetal calf serum. The cells were then 
changing the medium to Dulbecco's MEM 
containing lipoprotein deficient serum (5 mg protein/ml) for 
24 hours. The cells were then either upregulated for a 
further 24 hours {+) or were downregulated {-) by adding 12 
ug/ml cholesterol and 1 ug/ml 25-0H cholesterol to the 
upregulation medium. The cells were pulsed with [35sJ-
methionine for 1 hand were chased for the indicated times. 
The LDL receptors were immunoprecipitated and visualised on 
autoradiographs as described in general methods. The 
apparent molecular weights of the precursor ( 120 kDa) and 
mature {160 kDa) receptors are indicated. Please take care 
not to confuse the band of the mature LDL receptor with "band 
X" that runs just above 160 kDa. 
labelled with [35sJ-methionine and were chased for different 
periods of time up to 10 hours. The half-life of JL's mature 
160 kD receptors was not noticeably decreased and a 
significant pool of receptors remained after 10 hours of 
chase (Fig. 3.8). 
3.3.4 Synthetic Rates of JL's LDL receptors 
The synthesis rates of normal and JL's receptors were 
determined by comparing the amount of immunoprecipitable LDL-
receptor protein (mature and precursor forms), after a\ hour 
and a 1 hour pulse with [35sJ-methionine, to total protein 
synthesis and/or transferrin receptor synthesis (Fig. 3.9). 
These synthetic rates were measured at similar cell 
densities. ( As fibroblasts reach confluency in culture they 
stop dividing rapidly and their demand for cholesterol for 
membrane synthesis decreases. Their LDL receptor expression 
decreases in concert.) In each of 3 experiments where JL's 
receptor synthesis was determined it was decreased to below 
25% of normal levels. 
Impaired LDL-receptor synthesis as determined in Fig. 3.9 can 
either be the result of true decreased protein synthesis or 
due to instability of the precursor. Precursor degradation 
can hypothetically occur either before or after the receptor 
is recognisable by antibodies. If the latter case were 
operative, the degradation rate of these putatively unstable 
precursors would have to be rapid in relation to the rate of 
conversion · to mature receptors. The total half-life of 
104 
Fig. 3. 8: Half-life of LDL-receptors 
from normal and JL 
cells. Up-regulated cells were pulse
-labeled with (35s]-
methionine for 2 hours and chased for 
a further 1 hour in 
order to convert all the LDL-receptors 
to the mature form. 
LDL receptors were then chased for the
 indicated times and 
then immunoprecipitated and visualised o
n autoradiographs as 
described in the general methods. 
Each time point is 
represented by duplicate results from bo
th cell types. JL's 
receptors exhibited a normal half-life in
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Regulation Up I Non 
Fig. 3.10: Northern Blot of LDL-receptor mRNA from normal 
and JL cells. Cells were grown for 5 days in Dulbecco's MEM 
containing 10% fetal calf serum. The cells were either grown 
in the same medium for an additional day (non-regulated) or 
were up-regulated in Dulbecco' s MEM containing lipoprotein 
deficient serum (5 mg protein/ml). 30 ug of total RNA was 
electrophoresed in each lane of a 1% agarose gel containing 
lx MOPS and 1% formaldehyde. The RNA was blotted onto 
HYBOND-N and hybridised with a probe to the LDL-receptor as 
described in the general methods and X-ray film was exposed 
to this membrane. 
precursor receptors (degradation plus maturation half-lives) 
would therefore be grossly decreased. Thus the ratio of 
precursor to mature receptors would be less than normal in 
JL's cells. (This is not obvious in Fig. 3.9). 
3.3.5 LDL-receptor mRNA in JL's Fibroblasts 
The LDL-receptor mRNA levels were then determined in JL' s 
cells (Fig. 3.10). These low message levels could account 
for the decreased protein synthesis in JL' s cells. The 
message seemed to be of approximately nc..rmal size . and was 
regulated by sterols (Fig. 3.10). 
3.3.6 DNA Sequence of JL's LDL-receptor Promoter 
Analysis of the sequence of the promoter of JL's LDL receptor 
has yielded interesting findings (Fig. 3.11). JL is a 
heteroallelic homozygote and one of his alleles is missing 
two C's and one Tin Repeat one of the promoter (G. Zuilani, 
H.Hobbs and L.F. de Waal personal communication). It is not 
possible to say exactly which three bases have been deleted. 
This might affect the transcription of LDL-receptor mRNA and 
further studies are in progress to determine what the 
consequences of this deletion are. The nature of the 
mutation in JL's other allele is not known. 
108 
109 
Fig. 3.11: Comparison of various LDL-Receptor promoter 
sequences with the GC box consensus sequence 
1 GC BOX CONSENSUS : 5 I 
1 NORMAL HUMAN REPEAT 1: 5' 
2 JL REPEAT 1 5' 
3 XENOPUS 1 REPEAT 1 51 
3 XENOPUS 2 REPEAT 1 . 5' . 
4 HAMSTER REPEAT 1 . 5' . 
4 RAT REPEAT 1 . 5' . 
1 NORMAL HUMAN REPEAT 2: 5 I 
1 MUTANT -203 TO -194 5' 
1 MUTANT -195 TO -186 5' 
1 MUTANT -186 TO -177 . . 
Footnote: 
G C C C 
A T T C C G C C C A 
A A A C T C C '.r C C T C 
A A A C T C C '.r C '.r T ~ 
T A G C T C C T C C C T 
T A G C T C C T C C C C 
A A G C T C C T C C C C 
AA G C T C C T C C C C 
A A A A T C A .Q C C C A 
G C G C T C C T C C '.r C 
A C .Q TATGCATG C 
A A A C T C C '.r C C GT 
T T G C 
C 
G C T G 
T G C C 
G G C C 
G C A C 
C T G C 
T T G C 
T T G C 
G C A T 
1 Sequences from Sildhof et al. (1987); Mutant sequences were 
from constructs described in the paper. The activity of 
those constructs is represented in Fig. 3.12. 
2 G. Zuilani, H. Hobbs and L.F. de Waal, personal 
communication 
3 Mehta et al. (1991) 
4 Bishop (1992) 
3.4 DISCUSSION 
In this chapter the phenotypes of the LDL receptors produced 
by 2 FH homozygotes have been characterised as defects of 
LDL-receptor protein synthesis. 
3.4.1 NS 
NS presented with a "Null" mutation ( s) that resulted in no 
detectable LDL receptor synthesis. His mRNA was present at 
very low steady state levels but showed no evidence of any 
major rearrangements. 
"Null" mutations with low levels of mRNA often result from 
the following types of defects: 
1. Very large deletions generally involving the whole 
promoter region (e.g. French Canadian major founder mutation 
(Hobbs et al. 1987) result in no detectable mRNA being 
synthesized. 
2. Mutations that create premature termination codons very 
often have decreased message levels (Hobbs et al. 1990 ) . 
This is thought to be due to lack of ribosomal binding to a 
large stretch of mRNA that predisposes the message to 
degradation (Trecartin et al. 1981). Nonsense point 
mutations frequently result in decreased amounts of normal-
sized mRNA. Alternatively, low levels of abnormal sized mRNA 
can arise from premature termination codons being created by 
deletions or splicing errors (Hobbs et al. 1990). An example 
of such a mutation is the single b.p. deletion in codon 743 
in exon 15 that introduces a stop at the adjacent codon (Webb 
110 
et al. 1992). It is likely that the mutation in NS resulted 
from a nonsense point mutation or a small deletion that 
created a termination codon, since the low level of mRNA was 
of approximately normal size and the promoter sequence was 
normal. 
3.4.2: JL 
JL, a Pedi homozygote, had an early death presumably from a 
heart attack and extensive xanthomata, in spite of lower than 
expected cholesterol levels. Detailed discussio:.1 of this 
phenomenon is not possible as, to our knowledge, no autopsy 
was perf armed and other important parameters such as JL' s 
apo E genotype and HDL cholesterol level were not available. 
Unfortunately JL died before simvastatin was introduced in 
South Africa. The mutation(s) in JL present with a very 
interesting phenomenon. JL's fibroblasts have low LDL-
receptor mRNA levels and synthesise receptor protein at low 
but detectable rates. This implies that the low synthetic 
rate is the result of decreased but partially effective 
transcription. Despite this low transcription rate, LDL-
receptor mRNA levels and receptor synthesis are regulated by 
sterols. Virtually all of the Class 1 mutations that have 
been described result in complete abolition of LDL-R 
synthesis (Hobbs et al. 1990) . It is possible that the 
control of LDL receptor synthesis in the liver might be 
different to that in fibroblasts. Such a difference might 
contribute to the lower than expected total cholesterol level 
found in 'JL. JL' s one LDL-receptor allele has a 3 bp 
111 
deletion in the first Spl-binding repeat of the promoter 
(G.Zuilani, H.Hobbs and L.F. de Waal, personal 
communication). The sequence of the promoter of JL's other 
allele is normal. The three direct repeats in the LDL-
receptor promoter each include a 10 bp sequence homologous to 
the GC-box sequence (see Fig. 3.11) that is thought to be the 
consensus sequence for the transcription factor Spl (Kadonaga 
1986) . Repeats 1 and 3 that deviate from this consensus 
sequence at the 2 and 1 sites respectively, both bind Spl in 
vitro (Dawson et al. 1988). However, repeat 2 that deviates 
at 3 sites does not bind Spl. The sequences of repeat 1 in 
Xenopus, the hamster and the rat never deviate by more than 2 
bp from the consensus sequence {Fig 3.11). The sequence of 
JL that harbours the deletion deviates by four bp from the 
consensus sequence and it is thus possible that this results 
in impaired Spl binding leading to decreased transcription. 
In vitro mutagenesis experiments on the LDL-receptor promoter 
region have been performed by Sildhof et al. {1987). A vector 
was constructed that contained the LDL-receptor promoter 
region linked to the coding region of the bacterial 
chloramphenicol acetyltransferase gene. Each of the fifteen 
mutations that were created in the LDL-receptor promoter 
region of this vector had a cassette of 10 base pairs that 
was scrambled. These cassettes of mutations overlapped and 
spanned the three imperfect direct repeats and the TATA like 
sequences. A summary of the results is shown in Fig. 3.12. 
The mutations that pertain to repeat 1 are shown in Fig. 
3 .. 11. These experiments suggest that mutations in repeat 1 
112 
affect transcription less severely {50% 90%) than 
mutations in the other 2 repeats. It is also interesting 
that transcription is not abolished when bp -195 to -186, 
that comprise almost the entire Spl consensus sequence {Fig. 
12) of repeat 1, are scrambled. When only 3 bp {bp -203 to -
194 {see Fig. 3.11)) were scrambled a significant reduction 
of transcription occurred {Fig. 3. 12) suggesting that the 
entire repeat and not only the consensus sequence is probably 
recognised by the transcription factor {Stidhof et al. 1987). 
These experiments suggest that transcription of the LDL-R 
gene is sensitive to mutations in repeat 1. However it would 
seem that mutations in repeat 1 do not entirely abolish 
transcription. These experiments did not address the effects 
of deletions in repeat 1. Studies are currently being 
pursued to determine whether the deletion in JL affects 
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Fig, J.12 Ctrom sUdhof et al,, 19871 
A fragment of the human LDL-receptor promoter from -58 to -
234 (the A of the ATG initiation codon is +l) was inserted 
into pSVO-CAT(a). The sequence of a portion of this promoter 
is shown at the top of (b) and the important transcriptional 
elements are labelled. Fifteen different overlapping 
mutations, where 10 b.p. were scrambled, were introduced into 
this plasmid. The 10-bp sequence that was scrambled is shown 
on the left of (b) and is shown in lower case letters below 
the nor111al sequence. 
The nor111al and the mutated plasmids were co-transfected along 
with a control plasmid, pHSVTK-CAT into CHO cells (pHSVTK-CAT 
contains a part of the herpes simplex virus thymidine kinase 
promoter). The relative transcription activity of the nor111al 
and mutant LDL-receptor promoters was expressed as the ratio 
(x/y) of the amounts of primer extension products of the 
mRNAs from the transfected LDL-receptor-CAT gene ' (x) and from 
the HSVTK-CAT gene (Y). The nor111al LDL-receptor promoter 
activity was nor111alised to the value of 1. The ratios of the 
activities of mutant promoters relative to the nor111al 
promoter (1) was plotted (c). The locations of the mutations 
are shown on the x axis (c). A diagram of the nor111al LDL 
receptor promoter is at the bottom of (c). 
These figures are reproduced with 
authors and the American Society 
Molecular Biol·ogy. 





THE LDL-RECEPTOR MUTATIONS IND 
4.1 INTRODUCTION 
A practical prerequisite for undertaking an investigation of 
FH in any population is to have access to patient material. 
Skin fibroblasts from 4 different unrelated homozygote South 
Africans of Indian origin provided a starting point for the 
study of FH in this group. Two of the patients, AV and AA, 
were from the Transvaal Province and NS and D came from 
Pietermaritzburg and Durban, respectively, in the Natal 
Province of South Africa. Preliminary findings allowed us to 
conclude that there were at least three different LDL 
receptor mutations in South African Indians: NS manifested a 
"Null" mutation; 2. AV and AA were indistinguishable and 
were characterised as being receptor defective expressing 
about 25% the normal number of receptors on their 
fibroblasts; 3. D also expressed around 25% the normal 
number of receptors. However, in contrast to AV and AA, his 
receptors did not bind LDL to the same extent as B-VLDL and 
IgG-C7. 
Subsequently two different LDL receptor mutations were 
detected in D. The path taken in the discovery of the 
mutations in D, from the protein phenotype to the genotype, 
will be outlined in this chapter. 
115 
4. 2 RESULTS 
4.2.1 Clinical Background 
The patient D was originally recognised as a FH homozygote by 
Dr I. Jialal. 
in Fig. 4.1. 
D's genogram and clinical features are shown 
It is clear that the index patient and his 
sibling have classic features of homozygous FH. D's father 
seems to have had raised lipid levels and an early death from 
an MI compatible with his obligate heterozygote genotype, but 
his mother has very low cholesterol levels for an obligate 
heterozygote. Unfortunately fibroblasts and DNA from D' s 
parents were not available and contact with this family seems 
to have been lost. 
4.2.2 Ligand Binding and Metabolism by D's LDL Receptors 
The ability of D's fibroblasts to bind and metabolise various 
ligands was initially examined (Table 4.1). D's upregulated 
fibroblasts consistently bound, internalised and degraded 
less than 10% of the normal amount of 125I-LDL when incubated 
with 10 µg/ml 125I-LDL for 4 hours at 37°C. However his 
cells seemed to express around 30% the normal number of LDL 
receptors as determined by their ability to bind B-VLDL and 
IgG-C7 (Table 4.1). One or both of the following scenarios 
could explain this discrepancy between the IgG-C7 and B-VLDL 
binding on the one hand and the LDL binding on the other. 
The receptors produced by D's mutant alleles might be 
expressed at about 30% the normal level on the surface of his 
cells but have a lower affinity for LDL. Alternatively, 
there might be at least two populations of receptors on his 
116 
fibroblasts: one population that recognises LDL, B-VLDL and 
antibody normally and another population that has a very low 
affinity for LDL, but a normal affinity for the other two 
ligands. 
Binding isotherms established that the number of receptors on 
D's cells determined in Table 4. 1 was not a falsely low 
estimate due to the receptors having an impaired affinity for 
antibody binding. D's fibroblasts or normal cells were 
incubated with increasing concentrations of 125r-IgG-C7 and 
it was determined that his cells indeed expressed about 30% 
the normal number of receptors that had a normal affinity for 
this antibody (Fig. 4.2). 
The ability of D's receptors to recognise LDL was then 
determined by incubating normal and D's fibroblasts with 
varying concentrations of 1251-LDL at 37°C for 4 hours 
(Fig. 4.3). The normal cells yielded saturable binding 
isotherms and were analysed 
(Enzfitter Elsevier Biosoft) 
binding site and non-saturable 
concentrations that resulted 
using commercial software 
assuming one high-affinity 
processes. The 1251-LDL 
in half-maximal binding, 
internalization and degradation at 37°C in the normal cells 
was 11 µg/ml, 8 µg/ml and 6 µg/ml respectively. In contrast, 
the shape of the curve in mutant cells was a straight line 
implying that the predominant process that was being measured 
was non-saturable binding. This suggested that the affinity 







HDL 0.8 LDL 3.9 
Xanthomata - -
0(11) sen ....... 8(9) PC14) ........ 
TC 19.5 16.9 4.7 
TG 1.9 1.3 1.2 
HDL 0.4 0.6 0.8 
LDL 18.8 15.7 3.4 
Xanthomata +++ +++ -
Fig. 4.1: Family tree and clinical features of D. 






HDL = HDL-cholesterol; LDL = LDL cholesterol; all measured 
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0.0 0.3 0.6 0.9 
12e1-IgG-C7 (ug/ml) 
Fig. 4.2: 4°C Binding of 125r-IgG-C7 to Normal and D 
fibroblasts. Upregulated cells were incubated at 4°C for 2 
hours with varying concentrations of 125r-IgG-C7 and the 
total 125r-ligand bound was determined as described in the 
general methods. Each value represents the average of a 
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Fiq. 4.3 125r-LDL metabolism in normal and D fibroblasts at 
37°C. Upregulated normal and D fibroblasts were incubated 
with the indicated 125r-LDL concentrations for 4 hours at 
37°C. Then the 125r-bound, intracellular and degraded were 
determined as described in the general methods. When these 
total activities were analysed using commercial software 
(Enzfitter, Elsevier biosoft) assuming one specific site plus 
non-specific processes, the normal cells yielded apparent 
Kd' s of 11 ug/ml, 8 µ.g/m and 6 ug/ml for 125I-LDL bound, 
intracellular and degraded, respectively. D's fibroblasts 
yielded virtual straight lines for these processes suggesting 
that the activity in these dishes was mainly due to non-
specific (non-receptor) processes. Each point represents the 
average value obtained from duplicate dishes. 
40 
do not rule out the 2 population model but do suggest that if 
this is the case, then the proportion of receptors on D's 
cells that recognise LDL normally is very low. 
4.2.3 LDL-Receptor Biosynthesis and Stability in D's 
Fibroblasts 
The cause of the receptor-defective phenotype was 
investigated in experiments where D's cells and normal 
controls were metabolically labelled with [35s)-methionine 
for an hour and then chased for varying periods. The 
synthesis of receptors in D's cells was determined to be 
grossly normal since the amount of [35s)-methionine 
incorporated into LDL receptors as a proportion of total 
protein synthesis was similar in D's and normal fibroblasts 
(Fig. 4 . 4} . The majority of the receptors synthesised by 
normal cells were of the mature type (160 kDa} after 1 hour 
of labelling and the residual precursor (120 kDa} receptor 
pool in these cells was converted to the mature form after a 
further 4 hours of chase (Fig. 4.4). In D's cells, however, 
the majority of the receptors were still in the precursor 
form (correct size of 120 kDa} after 1 hour of metabolic 
labelling (Fig. 4.4). Some of this precursor receptor pool 
was still present in D's cells after a further 4 hours of 
chase (Fig. 4. 4}. The mature receptors in D were of the 
correct size (160 kDa} (Fig. 4.4). These results suggest 
that there was slowed transport of D's receptors from the ER 





CHASE (H) 0 4 0 4 
Fig. 4. 4 LDL-Receptor processing in N and D cells. 
Upregulated fibroblasts were pulse-labeled with [35s]-
methionine for 1 hour and chased in DMEM/LPDS for the 
indicated times. LDL-receptors were immunoprecipitated and 
visualised on autoradiographs as indicated in the Methods. 
The apparent molecular weights of the precursos (120 kDa) and 




CHASE (H) 0 12 0 12 
NORMAL 
a 
0 12 0 12 
D 
Fig. 4.5 Degradation of Normal and D's LDL-receptors. 
Upregulated fibroblasts were pulse-labelled with (35sJ-
methionine for 1 hour and chased in DMEM/LPDS for the 
indicated times. LDL-receptors were immunoprecipitated and 
visualised on autoradiographs as described in the general 
Methods. The apparent molecular weights of the precursor 
(120 kDa) and mature (160 kDa) receptors are shown. 
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5.3 kb > 
NORMAL D 
Fig. 4.6 Northern blot of LDL-receptor mRNA from normal and D 
fibroblasts. 3 O ug of total mRNA from UJ?regulated 
fibroblasts was electrophoresed in each lane of a 1% agarose 
gel contaning lx MOPS and 1% formaldehyde. The RNA was 
blotted onto HYBOND-N and hybridised to a probe to the LDL 
receptor as described in the general methods. This membrane 
was then used for autoradiography. 
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The stability of D's receptors was then examined by pulsing 
the cells with ( 35sJ-methionine for 1 hour and then chasing 
them in the absence of methionine for 12 hours. The ratio of 
the receptors in the normal cells before and after the 12 
hour chase was consistent with a normal mature receptor half-
life of around 10-12 hours (Casciola et al. 1988, Knight et 
al. 1989). D's receptors almost completely disappeared after 
the 12 hour chase (Fig. 4.5). This suggested that the low 
steady-state level of LDL receptors in D was largely the 
result of their instability. 
4.2.4 mRNA Levels in D 
Northern Blot analysis of the mRNA in upregulated cells 
showed that D had normal sized transcript present at 
approximately normal steady state levels (Fig. 4.6). 
4.2.5 The Approach to the LDL-receptor Mutations in D 
Haplotype analysis of PCR products of genomic DNA determined 
that this subject was a heteroallelic homozygote since he was 
a heterozygotye at both the Ava II and Hine II RFLP sites 
(results not shown). Since the mutations in D · impaired LDL 
binding, these were sought in the ligand-binding domain and 
EGF-precursor homology repeat A (Esser et al. 1989, Russell 
et al. 1990). Overlapping PCR products obtained from first 
strand cDNA comprising the ligand-binding domain and part of 
the EGF-precursor domain were analysed on single-strand 
conformational polymorphism (SSCP) gels (Fig. 4.7). The band 
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Fig. 4. 8: LDL-receptor PCR products of cDNA made from D's 
mRNA. cDNA was reverse-transcribed from mRNA extracted from 
D's upregulated fibroblasts as described in the general 
methods. This cDNA was amplified in PCR reactions that 
contained oligonucleotides AR12 and AR13, AR14 and AR15, AR16 
and AR17, AR6 and AR7, ARB and AR9 that spanned exons 1-4, 5-
8, 9-12, 13-15 and 16, 17 and part of 18 of the LDL-receptor 
respectively. The major bands gave the expected sizes of 718 
b.p., 541 b.p., 726 b.p., 533 b.p. and 355 b.p. PCR 
conditions are outlined in table 
methods. 
2A.1 of the general 
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exons 1 to 3 and that spanning exon 4 were different for D 
and the normal control (Fig. 4.7). This suggested that one 
of D's mutations was in exons 1-3 and the other in exon 4. 
Overlapping regions of the coding region of the cDNA from D 
were amplified by PCR (Fig. 4.8). The one set of primers 
amplified exons 1-4 (lane 1). The bands were cut out from 
the gel and were subsequently crushed and eluted into TE. 
The primers for the exon 1-4 product were created with Barn HI 
(AR12) and Sph I (AR13) restriction sites closet~ their 5' 
ends. This allowed us to insert the PCR product into the 
polylinker of pUC 118 and generate clones for DNA sequencing. 
The main reason for opting for cloning was that direct DNA 
sequencing can be difficult to interpret in heteroallelic 
genes. 
DNA sequence analysis yielded different mutations in clones 1 
and 2. Clone 1 had a G-A mutation at codon 119 (GAG(Glu)-
AAG (Lys)) in the ligand-binding repeat 3 in exon 4 (Fig. 
4. 9) . Clone 2 had a G-T mutation at codon 69 (GAT (Asp) -
TAT(Tyr)) in ligand-binding repeat 2 in exon 3 (Fig. 4.10). 
To confirm that these mutations were true mutations and not 
errors introduced by the PCR reaction, one or both of the 
following methods were used: the mutation in exon 3 was 
confirmed by direct sequencing of a second PCR product 
prepared from a second cDNA preparation (Fig. 4 .11). The 
mutation identified in exon 4 eliminated an Mnl 1 restriction 
site. This was demonstrated by Mnl I restriction digestion 
128 
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Fig. 4.9: DNA sequence of mutation in codon 119 of D. D's 
cDNA was PCR-amplified by AR12 and AR13 · (see Table 2A. l), 
inserted into pUC 118 and sequenced with the Tag Track kit 
(Promega) using (r32p]-ATP-kinased AR12 (see general 
methods). Exons 1-4 of the normal LDL receptor cDNA sequence 
in pLDL-R2 was subcloned in M13mpl9 by restriction digestion 
with Eco RI and XbaI. This was sequenced with the Tag Track 
Kit using s•-32p-labelled universal primer. The site of the 
mutation is indicated. 
C GATC GATC C Ser C C Ser 
T T 
C C 
Ala C C Ala 
G G 
G G 
Lys A A Glu 
A __ G 
C C 
Asp A A Asp 






Fig. 4.10: DNA sequence of mutation in codon 69 of D's LDL-
receptor. D's cDNA was PCR-amplified by AR12 and AR13 (see 
Table 2A.1) and inserted into pUC 118. Clones 1 (normal 
sequence) and 2 (D's mutant sequence) were sequenced with 
the TaqTrack kit using (T-32p]-ATP-kinased AR12 (see general 
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Fig. 4.11: Direct sequencing of the codon 69 mutation in D. 
cDNA from D was amplified using oligonucleotides AR12 and G14 
using the conditions of the G13-Gl4 PCR (see table 2A. i). 
The PCR product was electrophoresed on 6% acrylamide and the 
correct size band was cut out and eluted. This fragment was 
sequenced with the fmol kit (Promega) using kinased AR12 as 
described in the general methods. The cDNA preparation used 
for this direct sequencing was made independently from the 
preparation that was cloned and sequenced in Fig. 4.10. 
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Fig. 4 .12: Diagnosis of codon 119 mutation in D by Mnl I 
digestion. The 5' end of exon 4 of genomic DNA from a normal 
subject and D was amplfied by PCR using oligonucleotides G31 
and 4.3 (see table 2A.1, general methods). The PCR product 
was radiolabelled by (a32p] dCTP incorporation. This was then 
digested overnight with Mnl I (4u) and electrophoresed on 12% 
polyacrylamide. The gel was dried and autoradiographed. Note 
that there is a fragment in D that is resistant to Mnl I 
digestion that is not present in the normal control. The 
fragment sizes in D are consistent with one of his alleles 





of the appropriate PCR product prepared from genomic DNA 
(Fig. 4.12). The resistance of part of the PCR product of D 
to normal Mnl I digestion was evidence that this was a true 
mutation. 
4.2.6 Population Analysis of Mutations in D 
Twelve apparently unrelated Indian families with unequivocal 
FH (raised total cholesterol> 7.5 mmol/1 or LDL-cholesterol 
> 5 mmol/1 plus xanthomata or thickened Achilles tendons) and 
28 hypercholesterolemic patients without xanthomata were made 
available to us by the main lipid clinics in the provinces of 
the Cape, Transvaal and Natal. (There are virtually no 
Indians in the Orange Free State Province of South Africa). 
Since these mutations did not create or delete any 
restriction sites that were appropriate for population 
screening (Mnl I is very expensive), an SSCP diagnostic assay 
was established for these mutations. The SSCP assay that 
initially allowed us to detect the presence of these 
mutations (see Fig. 4.7) was based on PCR products of cDNA, 
not genomic DNA, and was rather crude. For the screening 
assay, PCR products were prepared using one pair of 
oligonucleotides that amplified exon 3 and another pair that 
amplified the 5' region of exon 4 from genomic DNA. PCR 
products from D gave different patterns to the PCR products 
from normal controls on the SCP gels (Fig. 4.13a and 4.13b). 
Note that the gel in Fig. 7 was a 6% acrylamide, 10% glycerol 
gel run at room temperature in 1 x TBE while that in Fig. 
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~ x TBE. Fig. 4.13b shows SSCP results for these mutations 
on a 50% Hydrolink gel run in 0.6 x TBE. The conditions of 
Fig. 4.13a were used for the population screening. None of 
the 36 patients screened had either of the mutations detected 
in D (see Table 7.1). 
4.3 DISCUSSION 
Patient D has been characterised as a heteroallelic FH 
homo zygote with point mutations at highly conserved amino 
acids in repeats 2 and 3 of the ligand-binding domain of the 
LDL receptor (Fig. 4.14). The mutation in repeat 3 could be 
particularly deleterious as it replaces the negatively 
charged glu with the positively charged lys in the triplet 
Ser-Asp-Glu near the car boxy terminus of the repeat. This 
triplet of negatively-charged amino acids is conserved in 
each of the ligand-binding repeats and is thought to be the 
ligand-binding site in each repeat. Ligand binding to the 
receptor is thought to involve an ionic interaction 
(Innerarity 1990). The substitution of the negatively 
charged Aspartyl residue with the aromatic Tyrosine residue 
in repeat 2 is also unlikely to be a neutral mutation. 
These mutations were not detected in 72 alleles screened by 
SSCP (Table 7.1) and it is therefore unlikely that they are 
polymorphisms. Further evidence for the dysfunctional nature 
of these mutations is provided by analyses of mutations at 
homologous sites in different ligand-binding repeats. The 
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Fig. 4.14: A comparison of the amino acid sequences of the 
ligand-binding repeats in human. rabbit. hamster. rat and 
.::.:X=e=n __ o--p....._u=s'--'s:ah=o"-"w,._.i::..::na.:.;g::i.....-=t:::.h.:..:e=---=s""'i:..:t::..:e::.:s:;_...a:o=f---t ......... h___ e.........,.m __u ____ t ...... a __ t__ 1 ___ · o __ n==s--'1=· n=-~D (from Mehta 
et al. 1991a). The arrows show the sites of the Asp69-Tyr 
and Glu119-Lys mutations 
amino acids within each 








consensus among the 7 repeats across the different species is 
noted at the bottom of the figure. The Asp that is mutated 
is present in 38 of the 42 positions while the Glu is present 
at the homologous position in each repeat in all the species 
examined here. Reproduced with permission of the authors and 
the American Society for Biochemistry and Molecular Biology. 
(E. Leitersdorf, personal communication) is in the same site 
in repeat 4 as is D's Asp69-Tyr mutation in repeat 2. The 
Sephardic mutation is clearly significant as the receptors 
are slowly processed, unstable and do not bind LDL but do 
recognise IgG-C7 (F. Graadt van Roggen, D.R. van der 
Westhuyzen, G.A. Coetzee and E. Leitersdorf, personal 
communication). A point mutation in repeat 2 that is thought 
to be functionally significant is the Trp66-Gly French 
Canadian-4 mutation (Leitersdorf et al. 1990). 
The French canadian-3 mutation (Hobbs 1990), Glu207-Lys 
(Repeat 5), (Leitersdorf 1990), is the exact parallel of D's 
Glu119-Lys mutation in repeat 3. The French Canadian-3 
mutation results in a slowly processed receptor (Leitersdorf 
et al. 1990) that does not bind B-VLDL (Hobbs et al. 1990). 
The FH Lancashire mutation, Glu80-Lys (Webb et al. 1992) 
occurs at the homologous site in repeat 2 to D's Glu119-Lys 
mutation in repeat 3. This Glu80-lys mutation results in a 
slowly processed (Type 2B) phenotype that forms a normal 
sized protein under reducing conditions, but an abnormally 
slowly migrating protein on non-reducing gels (Webb et al. 
1992). The dysfunctional nature of these mutations at 
homologous sites in different repeats suggests that these 
sites are critical in maintaining the correct structure of 
the repeat and may therefore play the same role in different 
repeats. 
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Site-directed mutagenesis at these particular sites has not 
yet been performed, but the experiments of Russell et al. 
(1990) can be used to predict the effects of these mutations 
on ligand binding. Table 4.2 summarises the effects on LDL 
and B-VLDL binding of the point mutations or the deletions in 
repeats 2 or 3 . It should be noted that the Asp118 that was 
mutagenised in repeat 3 is adjacent to the Glu119 that is 
mutated in D. 
These mutagenesis experim~nts yield 3 important findings 
relevant to D's mutations. 
1. None of the point mutations or the deletions of repeats 
2 or 3 affected B-VLDL binding to the LDL receptor. 
2. The mutations in a given repeat had a similar effect on 
LDL binding whether a single amino acid was mutated or if the 
whole repeat was deleted. This result did not only hold true 
for LDL binding but also for B-VLDL binding in parallel 
mutations from repeat 1 to repeat 7 in the ligand binding 
domain (Russell et al. 1990). This suggested that the 
individual binding repeats function in a modular manner. If 
a point mutation in a particular repeat disturbs binding then 
that repeat is functionally eliminated from the receptor but 
the other repeats can function undisturbed. 
3. Mutations in repeat 2 caused a moderate reduction 
while mutations in repeat 3 result in severe impairment of 
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Thus, it is likely that neither of D's mutations will affect 
B-VLDL binding. However, LDL binding to receptors with the 
Asp69 -Tyr mutation will probably be mildy reduced and LDL 
will probably be only very poorly recognised by receptors 
with the Glu119-Lys mutation. Thus, the reduced LDL binding 
affinity in the face of normal B-VLDL and IgG-C7 binding that 
was observed in D's fibroblasts was in accord with the 
results predicted by the mutagenesis experiments of Russell 
et al. (1990), especially if the codon 119 mutants comprise a 
significant proportion of the ~urface receptors in this 
patient. 
The normal cholesterol levels in the obligate heterozygote 
mother of patient D is a stimulus for speculation that I 
cannot resist. Unfortunately, unless this family can be 
tracked down the following hypotheses are not likely to be 
testable. The one possibility is that D's mother carries a 
cholesterol-lowering gene that compensates for the effects of 
her mutant LDL-receptor allele {Hobbs et al. 1989). Another 
possibility is that the mutation in repeat 2 (Asp69-Tyr) 
might be functionally mild like FH-Tonami-2, a deletion of 
repeats 1 and 2 that results in a 40% reduction in LDL 
affinity. Heterozygotes for FH-Tonami-2 have normal to only 
moderately raised (315 ± 80 µg/dl) total cholesterol levels. 
Four true homozygotes have been detected and are alive at 33, 
48, 51 and 62 ! The FH-Tonami-2 heterozygotes also seem to 
live longer than "classical" heterozygotes (Kajinami, 1988). 
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The combination of such a mild mutation (repeat 2) with a 
more severe defect (repeat 3) predicted from the mutagenesis 
experiments discussed earlier, would probably result in a 
homozygote with typical features. A similar situation of 
unusually low cholesterol levels in the obligate heterozygote 
parents, especially the mother, of severely 
hypercholesterolemic FH homozygote monozygote twins, has been 
described (Vauy et al. 1991). This study suggested that the 
co-inheritance of mild to moderate defects of LDL-receptor 
function from both parents caused the FH homozygote phenotyJe 
in the twins. 
The single-strand conformational polymorphism technique of 
detecting point mutations was used in two different ways in 
D. Initially it allowed us to detect the regions of the gene 
where the mutations were. In a sense this was fortunate, as 
this method does not detect all point mutations especially 
when the fragments are much longer than 200 b.p .. Since no 
cheap restriction sites were created or deleted by these two 
mutations (Mnl I is very expensive), easy and reliable SSCP 
assays were established. Neither of the mutations were 
detected in 36 hyperlipidemic patients (including 8 patients 
with definite FH) that were tested (see Table 7 .1). This 
result was not that surprising as the majority of Indians in 
South Africa came from many regions all over India and have 
only been resident in South Africa for about 3 generations. 
Dis from a Hindu family. About 80% of South Africa's Indian 
population are Hindu whose marriage choices would have been 
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and are still constrained by the caste system. Therefore, 
any type of recent founder effect for this mutation in South 
Africa would be unlikely due to the large size of the 
founder population (150 000), the lack of time (3 
generations) and the caste barriers that prevented the 
mutations from spreading throughout the population. 
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CHAPTER 5 
IDENTIFICATION AND PROPERTIES OF THE PROLINE664 -LEUCINE 
MUTANT LDL RECEPTOR IN SOUTH AFRICANS OF INDIAN ORIGIN 
5.1 INTRODUCTION 
In the initial phases of these studies of familial 
hypercholesterolemia in South Africans of Indian origin, it 
was found that the LDL receptors from two homozygous 
patients, AV and AA, behaved very similarly. One of the LDL-
receptor mutations that had been characterised in som~ depth 
at about the time this project was started was the FH Zambia 
mutation, so named because it was initially identified in MM, 
a Zambian of Indian origin (Soutar et al. 1989, Knight et al. 
1989). This mutation results in a C to T transition in codon 
664 that causes the substitution of proline by leucine. This 
single amino acid change occurs in the C repeat of EGF-
precursor homology domain of the LDL receptor, distant from 
the repeats known to be essential for ligand binding. 
Interestingly, however, it was reported that this mutation 
markedly diminished the affinity of the receptor for LDL, and 
to a lesser extent B-VLDL (Knight et al. 1989, Soutar et al. 
1989) . 
We subsequently · identified this same mutation in AA and AV 
(both homo-allelic homozygotes) and two other heterozygote 
subjects. The families of all four probands are unrelated 
and trace their origin to the vicinity of Surat in the 
Gujerat province of India. The availability of two subjects 
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homozygous for this mutation enabled us to re-examine its 
phenotype particularly with regard to ligand binding. When 
fibroblasts from AA and AV were studied, the mutant LDL 
receptors were found to have normal affinities for the 
ligands LDL and B-VLDL. The disease FH in these subjects can 
be explained by low steady-state levels of receptor molecules 
that are functionally normal but exhibit accelerated 
turnover. 
5. 2 RESULTS 
5.2.1 Identification of Pro664 -Leu Mutation 
The CCG (proline) to CTG ( leucine) mutation at codon 664 
creates a Pst I restriction site in the LDL-receptor gene 
(Soutar et al. 1989). This mutation was detected by 
amplifying genomic DNA by PCR using primers flanking exons 13 
and 14, and digesting the 496 bp product with Pst 1 (Fig. 
5. 1) • The generation of a 381 bp and a 115 bp fragment 
indicated the presence of the mutant sequence CTG in exon 14· 
at codon 664. The possibility that two such fragments 
resulted from a mutation that created a Pst I site in exon 13 
(i.e. at the 5'-end of the amplified fragment), rather than 
in exon 14, was ruled out: when genomic DNA was amplified 
using an upstream primer within rather than flanking exon 13 
and the same downstream primer flanking exon 14, the Pst I 
digest of this product again released a 115 bp fragment. We 
have identified the proline664 -leucine mutation in FH 
patients from 4 unrelated families of Indian origin (Table 





Fig. 5. 1 
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(a) Diagram of the LDL-receptor gene showing the positions 
of oligonucleotides 541 and 542 and the Pst 1 site created by 
the Leu664 mutation. 
(b) Polyacrylamide gel stained with ethidium bromide showing 
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Fig. 5. 2: DNA sequence of the Pro664 -Leu mutation in AV. 
DNA from AV and N cells was amplified using oligonucleotides 
541 and 542. The PCR products were electrophoresed on 1% 
Agarose gels and the bands were eluted using Geneclean II. 
These PCR products were sequenced using kinased 542 and the 
fmol sequencing kit (Promega). This mutation was also 
confirmed in AA by direct sequencing (result not shown). 
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Table 5.1: Biochemical and clinical data for patients and affected 
relatives. 
Individual Sex Age TC LDL-C HDL-C TG FH664 Sequelae 
status 
Family: V 
AV (proband) M 10 21.6 20.1 0.9 1.3 homo- Arcus 
zygote Xanthomata 
{at age 3) 
Xanthelasmata 
Mrs SV F 42 7.6 5.8 1.4 0.6 hetero- Nil 
(mother) zygote 
Mr MV M 47 7.1 5.7 1.1 0.7 hetero- Arcus, 
(father) zygote Xanthomata 
Family: A 
AA (proband) F 16 17.7 16.3 0.9 1.1 homo- Xanthomata 
zygote (at age 5) 
Bruits 
Mrs HA F 43 8.0 6.1 1.1 1.8 hetero-
(mother) zygote 
Family: MA 




AMT M 36 9.2 7.3 1.2 1.7 hetero- Arcus 
zygote Xanthlasmata 
I.H.D. 
TC= Total cholesterol, LDL-C = LDL-cholesterol, HDL-C = 
HDL-cholesterol, TG = triglyceride, all measured in mmol/1. 
I.H.D. = ischaemic heart disease. 
vicinity of Surat in the Gujerat province on the west coast 
of India. The unrelated homozygous probands AV and AA are 
offspring of different consanguinous marriages between first 
cousins. This mutation was confirmed in the homozygotes AV 
and AA by direct sequencing of the above PCR products (Fig. 
5. 2) . 
5.2.2 Haplotype of LDL-receptor Alleles in AV 
More recently, the FH Zambia mutation has been identified in 
a Norwegian family on the same LDL-reccptor haplotype as MM 
and, interestingly, in a number of English subjects in which 
the mutation was on a different LDL-receptor haplotype (King-
Underwood et al. 1991). The five-enzyme haplotype of both LDL 
receptor genes in the FH patient, AV, was the same as that of 
MM (Ava II++, HincII--, Stu 1++. Taq 1--, Nco 1++) and 
distinct from the haplotype of the English subjects, 
suggesting that AV and MM inherited the same mutant LDL-
receptor alleles. The haplotype of the British subjects 
differed from that of AV and MM at three restriction sites. 
5.2.3 LDL receptor Synthesis, Processing and Turnover in 
AV's Fibroblasts 
LDL receptor synthesis and processing was studied using 
(35s]-methionine pulse-chase experiments in cultured 
fibroblasts. The precursor receptors in AV cells were 
abnormally slowly processed to mature forms with a half-life 
of conversion of about 2 hours (Figs. 5.3 and 5.4). Most of 
these precursor receptors were converted to the mature form 
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Fig. 5.3: Decay of radioactivity from pulse-labeled LDL-
receptor protein. 
Up-regulated fibroblasts from AV were pulse-labeled with 
[35sJ-methionine for 1.5 h and chased in DMEM/LPDS for the 
indicated times. The radioactivity in the 120 kDa precursor 
and 160 kDa mature receptors was quantified by densitometric 
scanning of autoradiographs of gels of immunoprecipi tated 
LDL-receptors. All the values except those at 30 minutes are 
means of 2 experiments done in duplicate dishes. The values 
at 30 minutes are from 1 experiment only. In each experiment 
the intensity of the bands was expressed relative to the 
precursor band at 2.5 hours. In the same and other control 
experiments,. normal receptor precursors were rapidly and 
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Fig. 5.4: Autoradiographs of immunoprecipitated r35s1-
labeled LDL-receptors from normal. AV and AA fibroblasts. 
Up-regulated fibroblasts were pulse-labeled with (35sJ-
methionine for 1 hour and chased in DMEM/LPDS for the 
indicated times. . LDL-receptors were · immunoprecipi tated and 
visualised on autoradiographs as indicated in the Methods. 
The apparent molecular weights of the precursor (120 kDa) and 
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Fig. 5.5: Half-lives of mature LDL receptors from normal and 
AV fibroblasts 
Normal and AV upregulated fibroblasts were pulse labeled with 
[35sJ-methionine for 40 minutes and 90 minutes respectively. 
The medium was then changed to DMEM/LPDS and the normal cells 
were chased for a\ hour and the AV cells were chased for 6.5 
hours before starting to measure the half-life of mature LDL 
receptors at time o. LDL receptors were immunoprecipitated, 
run on 7% acrylamide and visualised on autoradiographs as 
indicated in the Methods. The points are the mean values 
from 2 experiments. Normal and AV fibroblasts were compared 
in each experiment in which each point was the mean of the 
values obtained in duplicate dishes. The half-lives of the 
mature LDL receptors from normal and AV fibroblasts were 
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Fig. 5. 6: Effect of B-VLDL and NHi. Cl on turnover of normal 
and AV. Upregulated cells were pulsed with [35sJ-methionine 
for 1 hour. Normal cells were pre-chased for 2 hours and AV 
cells were pre-chased for 6 hours in DMEM/LPDS in order to 
convert most of the receptors to the mature form. The cells 
were then chased for the indicated times in DMEM/LPDS 
supplemented where . indicated with either 10 mM NH4Cl or 10 
µg/ml B-VLDL, before immunoprecipitation. The 
immunoprecipi tates were electrophoresed on 7% SOS-PAGE and 
were visualised as described in the general methods. 
(Fig. 5.4) although the possibility that some precursor 
degradation may have occurred could not be ruled out. By 
contrast, in the same experiments, normal receptor precursors 
(120 kDa) were rapidly and completely converted to the mature 
form ( 160 kDa) within 30 min of a chase period (data not 
shown). The retarded processing of the mutant receptors was 
presumably a consequence of a structural abnormality. We 
determined whether such an abnormality would affect the 
stability of the mature mutant receptors. The half-life of 
the AV's mature LDL receptors was about 3.5 hours, in 
comparison to a half-life of about 9 hours for normal 
receptors (Fig. 5.5). 
Some mutations in the EGF-precursor homology domain result in 
impaired acid-dependent ligand-receptor dissociation (Davis 
et al. 1987a). Such mutant receptors are trapped in the cell 
in the presence of ligand and are subsequently rapidly 
degraded (Davis et al. 1987a). Since the degradation rate of 
AV's receptors was not abnormally enhanced when B-VLDL 
(10 ug/ml) was added to the chase medium (Fig. 5.6), it was 
unlikely that this mutation resulted in impaired acid-
dependent ligand-receptor dissociation. The inability of the 
lysosomotropic agent, NH4 Cl, to protect these mutant 
receptors from enhanced degradation suggested that the first 
steps in their degradation pathway were non-lysosomal (Fig. 
5. 6) . 
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5.2.4 Ligand Binding and Metabolism in FH-664 Fibroblasts 
AV and AA fibroblasts were able to sustain internalisation 
and degradation of 1251-LDL at 37°C 
commensurate with their steady-state 
about 25% of normal levels (Table 5.2). 
for 4 h at rates 
binding activity of 
The internalization 
index for the mutant cells was normal, therefore indicating 
that the mutant cells internalised and degraded LDL normally 
and that their receptors recycled back to the surface 
appropriately. The rapid degradation of mutant receptors 
(see above) was therefore not further acce.,,.erated by the 
presence of B-VLDL or LDL. Therefore, the FH Zambia mutation 
does not affect acid-dependent ligand-receptor dissociation. 
The 1251-LDL concentrations that resulted in half-maximal 
1251-LDL degradation were similar in normal and mutant cells 
(Fig. 5.7). This suggested that the mutation does not affect 
the affinity of the receptor for LDL at 37°C. The maximum 
binding of AV cells at ligand saturation was 23% of normal. 
The binding of 1251-LDL and 125r-IgG-C7 to AV cells was also 
studied at 4°C. The maximum number of surface receptors on 
the mutant fibroblasts that bind these ligands was about 20% 
of that in normal cells (Fig. 5.8). These binding curves 
indicated that the affinity of AV's 
ligands was normal (Fig. 5.8). 
receptors for both 
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Table 5.2: High-affinity binding, intracellular content and rates 
of degradation of 125I-LDL in cultured fibroblasts 
LDL metabolism at 37°C was done at 10 µg/ml 125I-LDL as described 
in the Methods. Values are the means of 3 experiments each done in 
duplicate dishes. The internalisation index was calculated by 
dividing the sum of the 125I-LDL degraded in 4 hours and the 
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Fig. 5.7: 125r-LDL degradation in normal and AV fibroblasts 
Normal and AV upregulated fibroblasts were incubated with the 
indicated concentrations of 125r-LDL for 4 hours at 37°C. 
The medium was collected and its content of non-iodide 
trichloroacetic acid-soluble radioactivity was determined and 
considered as the 125r-LDL degraded in 4 hours (each point is 
the mean value of duplicate incubations}. AV's fibroblasts 
degraded 125r-LDL with a Bmax of 23% normal. The 125r-LDL 
concentration that resulted in half-maximal 1251-LDL 
degradation was 5.1 µg/ml and 3.6 µg/ml in the mutant and the 
normal fibroblasts, respectively. 
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The Kd values for 1251-LDL binding to normal and AV receptors 
were 1.8 ± 0.4 µ.g/ml and 1.8 ± 0.9 µ.g/ml, respectively. 
Cells from the other patient (AA) who was homoallelic for the 
FH Zambia mutation bound 1251-LDL with an affinity similar to 
that of AV and normal fibroblasts (results not shown). 
These values were calculated by non-linear regression 
analysis of the total ligand binding values assuming one 
specific high-affinity binding site and a non-saturable 
component. Similar Kd values for normal and mutant cells 
were obtained when s~cific receptor binding was determined 
by two alternative approaches: non-specific binding was 
measured either in the presence of excess unlabelled ligand 
or in down-regulated cells and subtracted from total binding 
values. In these cases the calculated specific binding 
values were plotted and analyzed as single component curves 
(Fig. 5.9). The binding of an alternate lipoprotein ligand, 
B-VLDL, was also examined. The B-VLDL concentration required 
for half-maximal inhibition of 1251-LDL binding at 4 °C was 
similar in normal and AV cells, indicating that the affinity 
of the mutant receptor for this ligand was also normal (Fig. 
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Fig. 5.8: 4°C binding of 125r-LDL and 125r-IgG-C7 to Normal 
and AV fibroblasts 
Upregulated cells were incubated with varying concentrations 
of these ligands at 4°C for 2 hours and the total 125r-ligand 
bound was determined as described in the Methods. Each value 
represents the average of duplicate incubations. AV 
fibroblasts bound IgG-C7 with a Bmax of 2 0% of the normal 
fibroblasts and with a Kd of 0.05 µ.g/ml (Normal Kd = 0.04 
µ.g/ml). AV fibroblasts bound 125r-LDL with a Bmax of 25% of 
the normal fibroblasts and with a Kd of 1.97 µ.g/ml (Normal Kd 
= 1. 81 µ.g/ml). When these results were pooled with those 
from 2 other similar experiments, AV fibroblasts bound 125r-
LDL with a Bmax of 20±9% of normal fibroblasts and with a Kd 
of 1.8±0.9 µ.g/ml as compared to 1.8±0.4 µ.g/ml in normal 
fibroblasts (mean± standard deviation values). 
Fig. 5.9: Comparison of specific binding of 125r-LDL at 4°C 
derived by 3 different methods. 
Fibroblasts, in a single experiment, were upregulated as 
described in the Methods and incubated at 4°C for 2 hours 
with varying concentrations of 125r-LDL. 
a. Total binding values were analysed using non-linear 
regression analysis assuming one specific binding site and a 
non-specific component (Enzfitter, Elsevier biosoft}. 
Specific values are plotted. The calculated Ka values for 
the normal and mutant cells were 1.81 µg/ml and 1.97 µg/ml, 
respectively. 
b. Non-specific binding was determined in the presence of 
excesd unlabelled LDL (200 µg/ml). Non-specific binding was 
subtracted from total binding and the resultant specific 
binding values are plotted. The calculated Ka values of 
specific binding for normal and mutant cells were 1.99 µg/ml 
and 2.5 µg/ml, respectively. 
c. Non-specific binding was measured in cells which had been 
down-regulated with 25-0H cholesterol for 48 h. Non-specific 
binding values were subtracted from total binding and the 
resultant specific binding values are plotted. The 
calculated Ka values of specific binding for normal and 
mutant cells were 1.84 µg/ml and 1.35 µg/ml, respectively. 
The bottom panel in this figure shows the Scatchard plots of 
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Fig. 5.10: B-VLDL competition for 125r-LDL bound to normal 
and AV fibroblasts. 
AV and normal fibroblasts were incubated for 2 hours at 4°C 
with 2 ,ug/ml 125r-LDL plus the indicated concentration of 
unlabelled B-VLDL. Heparin-releasable 125r-LDL binding was 
determined as in the Methods. Each value is the mean of 
duplicate incubations. Similar results were obtained in a 
separate experiment. The mean concentration of B-VLDL 
required for - h~lf-maximal inhibition of 125r-LDL binding to 
AV' s fibroblasts calculated by non-linear regression (from 
two experiments) was o. 44 ,ug/ml as compared _to o. 32 ,ug/ml in 
the normal fibroblasts. 
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5.3 DISCUSSION 
The EGF-precursor homology domain of the LDL receptor is so-
named because it encodes a sequence that is 33% identical to 
a part of the mouse epidermal growth factor-precursor gene 
(Stidhof et al. 1985). Within this domain are 3 cysteine-rich 
40 amino acid sequences, the first two (repeats A and B) that 
are contiguous and separated from the third (repeat C) by 280 
amino acids (Stidhofet al. 1985). These repeats are distinct 
from those in the ligand-pinding domain and are found in a 
wide variety of extrace11.ular proteins in humans and lower 
eukaryotes (Davis et al. 1987a). 
The EGF precursor-like repeat C contains 6 cysteines that are 
thought to be disulphide-bonded to each other. It is likely 
that the first and third, the second and fourth, and the 
fifth and sixth cysteine within each of the repeats are 
covalently bonded, since this is the pattern that was found 
in other proteins with growth-factor repeats (Esser and 
Russell 1988). The three disulphide bonds in this 40 amino 
acid repeat probably result in a highly compact structure. 
The abnormal function of many mutant LDL receptors can be 
predicted from the known structure/function correlations in 
the normal receptor (Hobbs et al. 1990). 
Mutations in the EGF-precursor like domain seem to affect 
four distinct functions of the LDL receptor. Receptor 
transport from the ER to the Golgi is particularly sensitive 
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to major conformational changes. The most severe transport-
defective mutations (Class 2A) produce receptors that are 
completely blocked from reaching the Golgi (Hobbs et 
al.1990). All five of the Class 2A mutations reviewed by 
Hobbs et al. (1990) occur in the EGF-precursor homology 
domain. These authors suggested that this domain probably 
has a highly compact structure that is easily disturbed by 
single point mutations. This may explain why this domain has 
been so highly conserved in evolution (Mehta et al. 1991). 
Since receptor stability is likely to be at least partly 
determined by protein 3° structure, it is not surprising that 
mutations in the EGF-precursor homology domain affect LDL 
receptor turnover. At least two different mutations in this 
region, FH Cape Town-2 (van .der Westhuyzen et al. 1991), and 
FH-Afrikaner-2 (Leitersdorf et al. 1989), are inherently 
unstable. The Asp412 -His mutation (Miyake et al. 1992) in 
exon 9 was processed normally, however no detectable 125I-LDL 
or 125I-C7 binding was detected on the surface of this 
subject's fibroblasts. It is likely that this mutation 
results in mature receptors that are very rapidly degraded 
and thus the pool size of surface receptors is very small. It 
is interesting to speculate about the possibility that the 
predominant effect of mutations in the EGF-precursor domain 
might be to affect the stability of mature receptors. If one 
had mutant receptors that were so unstable that the half-life 
of the mature forms was much shorter than the half-time of 
the rate of conversion of precursor to mature receptors 
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(assuming that conversion did occur, even if more slowly than 
normal) , then one would probably not be able to detect 
mature receptors 
Such a mutation 
being formed in pulse-chase experiments. 
would be classed as type 2A, a complete 
block in transport! There is one way to possibly determine 
whether type 2A mutations are really the result of complete 
block in transport or a consequence of hyper-instability of 
mature LDL receptors. The degradation of normal receptors is 
inhibited by cycloheximide, and therefore is probably 
mediated by a short-lived protein(s) (Casciola et al. 1988) 
and is not affected by lysosomotropic agents (Casciola 1989). 
The degradation of certain mutant receptors might be 
lysosomal, however. If one re-examined all of the class 2A 
mutations by pulsing their cells for enough time to label a 
significant precursor receptor pool and then added 
cycloheximide and/or lysosomotropic agents, one might find 
that the extremely unstable putative mature forms would be 
protected from degradation and thus become detectable. 
Unfortunately, a negative result in such an experiment would 
not be informative. 
One of the crucial features of the LDL receptor is its 
ability to separate from internalised ligand as a result of 
the decreased pH in the endosomes. The freed receptor can 
thus recycle to the cell surface. Deletion of repeats A and 
B or the entire EGF-precursor domain seem to affect this 
acid-dependent receptor-ligand dissociation in both natural 
(Miyake et · al. 1989) and artificial mutants (Davis et al. 
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1987a}. This deficiency results in rapid disappearance of 
mutant receptors from the cell surface in the presence of 
ligand, with subsequent intracellular trapping and 
degradation of receptors. 
The EGF-precursor homology domain also plays a role in ligand 
binding. A mutant receptor that had this entire domain 
deleted bound both B-VLDL and LDL on nitrocellulose blots but 
in intact cells only bound with high affinity to B-VLDL, not 
LDL (Dav1.s et al .1987a} . It was suggested tllat the EGF-
precursor domain positions the ligand-binding domain in a 
conformation that allows it to bind LDL on the cell surface. 
A similar reduction of LDL binding in the face of normal B-
VLDL binding was observed in naturally occurring mutants 
where either the entire EGF-precursor homology domain (Miyake 
et al. 1989} or just repeats A and B (van der Westhuyzen et 
al. 1991} were deleted. Artificial mutants, where either 
repeat A alone or both repeats A and B are deleted, 
demonstrate the same apo B-100-binding deficiency (Esser et 
al. 1989} . However, deletion of repeat B alone does not 
affect LDL or B-VLDL binding to the LDL receptor (Esser 
1989). These results suggest that repeat A is the critical 
region of the EGF- precursor homology domain that determines 
LDL binding. The findings of Sou tar and Knight on the MM 
mutation in repeat c were therefore of considerable interest 
{Soutar et al. 1989, Knight et al. 1989}. 
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The proline at amino acid 664 is in a highly conserved region 
between cysteine 3 and cysteine 4 (Mehta et al. 1991) in 
repeat C. The subs ti tut ion of leucine for pro line at this 
site presumably results in aberrant folding of the mutant 
protein since proline causes fixed kinks in polypeptide 
chains and therefore probably plays an important role in 
determining conformation. 
the slow processing and 
This, in turn, could account for 
instability of this 
features common to other mutations in this domain 
receptor, 
(van der 
Westhuy~en et al. 1991, Leitersdorf et al. 198 9). However, 
the report that this point mutation, more than 350 amino 
acids away from the ligand binding domain, affected the 
affinity of ligand binding, was unexpected (Soutar et al. 
1989, Knight et al. 1989) . It suggested a new role for 
repeat C either in the . maintenance of the correct 
conformation of the binding domain or in controlling 
appropriate interactions between LDL-receptor molecules. The 
identification of 2 patients who were homozygous for this 
mutation allowed us to re-examine its phenotype. 
Our results differ in one fundamental respect from those 
previously reported: Knight and coworkers reported that MM's 
receptors exhibited a decreased affinity for the ligands B-
VLDL (Soutar et al. 1989) and LDL (Soutar et al. 1989, Knight 
et al. 1989). The decreased affinity for LDL was apparent 
both at 37°C and particularly at 4°C, where the mutant 
receptor's Kd was 5 times the value obtained for normal 
receptors . . · Our affinity measurements indicate that the 
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mutant receptors have a normal affinity for IgG-C7, LDL and 
B-VLDL at 4°C. The 1251-LDL concentration that resulted in 
half-maximal 125r-LDL degradation at 37°C was similar in 
normal and in mutant fibroblasts. This suggested that the 
affinity of these receptors for LDL at 37°C was also normal. 
The reason for the differences between our results and those 
previously reported is not clear. 
The low number of surface receptors in AV's fibroblasts is at 
least - partially due to the increased ra~e of receptor 
turnover. The enhanced degradation rate, also reported by 
Knight and coworkers (1989), was observed in the absence of 
lipoprotein ligand. The abnormally fast degradation rate of 
the mutant receptors was not further enhanced by the presence 
of LDL or B-VLDL, since there was no gross depletion of 
mutant receptors after 4 hrs of incubation of cells with 
either ligand at 37 °C. Therefore an impairment of acid-
dependent ligand-receptor dissociation and the consequent 
trapping of receptors in endosomes does not explain the 
accelerated receptor degradation. 
The absence of any inhibition of the degradation of these 
mutant receptors by the lysosomotropic agent, NH4 Cl, 
suggested that these receptors are initially degraded in a 
non-lysosomal compartment, like normal receptors (Casciola et 
al. 1989). 
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The diagnosis of this mutation in AV and AA relied on the 
creation of a Pst 1 restriction site and direct sequencing of 
exon 14. It is unlikely, but possible that another LDL-
receptor mutation might co-exist on the same allele(s) as the 
FH Zambia mutation in our patients. We have established that 
our subject AV has the same haplotype as MM. It is unlikely 
that a second mutation could correct for a defect in binding 
caused by an initial mutation at amino acid 664. 
The pro664 -leu mutatim1 was originally identified in MM, a 
Zambian who originated from Gujerat on the West Coast of 
India. Subsequently this mutation was identified in another 
family of the same racial and geographical origin (King-
Underwood et al. 1991). We have identified this mutation in 
four families. They are all of Gujerati Muslim origin from 
the vicinity of Surat. The frequent identification of this 
mutation in Indian emigrants of Gujerati/Surat origin 
suggests that this mutation might be very common in this area 
of India. 
Muslim Gujeratis, until 
descendants from their own 
very recently, only married 
village or locality in India. 
Therefore this group was genetically isolated both in India 
and abroad. It is thus unlikely that this mutation would 
have been uniformly distributed among all Indians in south 
Africa of which the majority are Hindus. However, since 
Muslim Gujeratis comprise less than 1/5 of South Africa's 800 
000 - 1 ooo ooo Indians (Lazarus 1976), the finding of 4 
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unrelated kindreds with this mutation suggests that this 
mutation is indeed very common in this group. 
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CHAPTER 6 
FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100 (FOB) IN 
SOUTH AFRICA 
6.1 INTRODUCTION 
Familial Defective Apolipoprotein B-100 (Arg3500-Gln) and 
LDL-receptor mutations are the known causes of monogenic 
hypercholesterolemia and are often clinically 
indistinguishable (Rauh et al. 1982, Tybjaerg-Hansen et al. 
1990; see 1.8 for review). The Afrikaner, Jewish and Indian 
populations in South Africa each have a particularly high 
incidence of monogenic hypercholesterolemia (MH) ( Seftel et 
al. 1980; Seftel et al. 1989; Seftel Hand Asvat M, personal 
communication). Although major founder LDL-receptor 
mutations account for most of this condition in Afrikaners 
(Leitersdorf et al. 1989, Kotze et al. 1989) and South 
African Jews (Meiner et al. 1989) , these mutations did not 
account for all of the monogenic hypercholesterolemia in the 
lipid clinics (Graadt van Roggen et al. 1991) and the 
question remained whether FOB was present in these 
populations. 
The so-called Coloured population in South Africa is of mixed 
indigenous African, Indonesian and North European ancestry. 
Due to the significant input of European genes into the 
Coloureds' gene pool, as evidenced by the presence of FH 
Afrikaner-1 and FH Afrikaner-2 LDL-receptor mutations (M 
Kotze, F Graadt van Roggen, personal communication), the 
possibility existed that FOB might be found in this group. 
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Most of the Indian patients who were referred to us with the 
diagnosis of FH were negative for the LOL-receptor mutations 
that we had identified in this population. Therefore, we 
investigated this group for the presence of FOB, as most 
studies have only looked for this disorder in European/North 
American Caucasians. 
Hypercholesterolemic patients with or without thickened 
Achilles tendons or xanthomata were screened for FOB. 
Initially these patients were analysed for the relevant 
common/founder LOL-receptor mutations. If the frequencies of 
the non-founder LOL-receptor mutations (Goldstein and Brown 
1989) and FOB (Innerarity et al. 1990) were both 1/500, as is 
the case in Europe and North America, then one would expect 
equal numbers of LOL-receptor and FOB mutations in the 
patients with xanthomata or thickened Achilles tendons who 
did not have the founder mutations. This would of course 
only be the case if the two conditions were clinically 
identical. 
Although no patients with FOB were identified in the above 
populations, two families (Mand W) each of mixed Afrikaner 
and British ancestry were identified with this mutation. The 
M family that has FOB was initially screened along with the 
Jewish group as the proband (non-Jewish) had a Jewish 
husband/surname. The W family is unique to our knowledge as 
the pedigree contains both the FH Afrikaner-1 and FH 
Afrikaner-2 · mutations and FOB in different combinations. 
170 
There are subjects with each of the individual gene defects 
but there are also 4 individuals that are mixed heterozygotes 
for FH Afrikaner-! and FOB and one "complex" heterozygote 
that has both FH Afrikaner-! and FH Afrikaner-2 LOL-receptor 
defects and FOB! This large pedigree allows the clinical 
comparison of the various genotypes and their combinations. 
6. 2 RESULTS 
6.2.1 FOB in hypercholesterolemic Afrikaners, "Coloureds", 
Indians and Jews in South Africa 
The results of our initial screening of the various South 
African populations for FOB are shown in Table 6.1. Patients 
were placed in 6 categories. Subjects that had total 
cholesterol> 7.5 mmol/1 or LOL-cholesterol > 5.2 mmol/1 were 
called definite monogenic hypercholesterolemics (MH) if they 
had evidence of xanthomata or thickened Achilles tendons. 
Patients with similarly elevated total- and LOL-cholesterol 
levels and triglyceride concentrations <2. 3 mmol/1 with no 
xanthomata or thickened Achilles tendons were considered to 
have possible MH. The patients from the Tygerberg, Groote 
Schuur, Johannesburg General and R.K. Khan Hospital clinics 
were assessed by physicians for the presence of xanthomata 
and thickened Achilles tendons, features that are 
pathognomonic for heterozygous MH in the context of the 
appropriate lipid profile. The Afrikaners from Potchefstroom 
were unfortunately not assessed for . these features and are 
therefore listed separately as there might be patients in the 
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possible MH group that would qualify for the definite MH 
group. 
Patients with total cholesterol > 7.5 mmol/1 or LDL-
cholesterol > 5.2 mmol/1 and triglyceride concentrations of 
2.3-4.5 mmol/1 were called type IIb. They could also have 
LDL receptor mutations or FDB. If patients with similarly 
elevated cholesterol levels had triglyceride levels > 4. 5, 
that make it impossible to determine LDL levels using the 
Friedewald equation (Thompson 1989), they were called mixed 
hyperlipidemics. 
Mildly hypercholesterolemic subjects (total cholesterol 
> 6 mmol/1) were also analysed for FDB as some of the 
patients that were initially described with this condition 
manifested a milder disease than that caused by LDL-receptor 
mutations (Innerarity et al. 1990). 
The patients in the Afrikaner and Jewish groups were all pre-
screened for the presence of relevant LDL-receptor founder 
mutations (FH Afrikaner-!, -2 and -3 and FH Piscataway) . 
Coloured patients were tested for the Afrikaner founder 
mutations. Patients who tested positive for these mutations 
were nevertheless screened for FDB but were placed in a 
separate category aside from those who were negative. Some 
of the patients in the Indian population were screened for 
the FH Zambia mutation and the two mutations we identified in 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































screened for all three of these mutations ( in addition to 
FDB) are in brackets. 
The rationale for screening for these LDL-receptor mutations 
was to eliminate the founder mutations that resulted in the 
increased FH frequency in these groups from our analysis. 
The remaining sporadic LDL-receptor mutations presumably 
exist at a frequency of 1/500 (Goldstein and Brown 1989). 
Thus the frequency of FDB in the groups with definite MH 
would allow some estimate of the population frequency as the 
definite MH groups probably contain only LDL-receptor 
mutations and FDB. 
Although FDB was not detected in any of the true Afrikaners, 
Jews, Indians and so-called "Coloureds" listed in Table 6.1, 
this mutation was identified in two families each of mixed 
Afrikaner and British ancestry. 
6.2.2 THEM FAMILY 
The genogram of the M family is shown in Fig. 6 .1. The 
proband, her child and grandchild are heterozygous for FDB. 
The proband's father died from an M.I. at 42 and premature 
coronary artery disease seems to have affected at least one 
of his siblings and nephews. The absence of heart disease in 
the proband' s mother and siblings suggests that the mutant 
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analysis does not help elucidate the origin of FDB in this 
family as the proband' s father had British and Afrikaner 
parents. 
A comparison of lipid levels in the unaffected and FDB 
subjects from this family (Table 6.2) suggests that the LDL-
cholesterol levels in the affected individuals are higher 
than those in the normals. Each of the FDB subjects has a 
type IIa lipid profile. The only peripheral stigmata of 
hyperlipidemia were noted in the proband 2M, who had a mild 
arcus cornealis that regressed subsequent to treatment with 
simvastatin. Her response to simvastatin treatment (up to 40 
mg/day) was compatible with that reported in the literature 
(Maher et al. 1991). Her total cholesterol levels dropped 
from 8.02 mmol/1 to 5.06-5.59 mmol/1 and her LDL-cholesterol 
concentration dropped from 6.4 mmol/1 to 3.6-4.1 mmol/1. 
6.2.3 THEW FAMILY 
The proband (CW) in the W family (Fig. 6. 2) was initially 
considered to be an FH heterozygote . Her DNA was analysed 
for the FH Afrikaner-1 LDL-receptor mutation and for FDB 
since she was referred to us with high total cholesterol 
levels (15-18 mmol/1) and had an Afrikaner father. When both 
of these mutations were identified in cw, her very large 
family was recruited for further investigation (Table 6.3). 
Each member of the W family that was recruited was screened 
for FH-Afrikaner-1 and FDB and most of the hyperlipidemic 















































































































































































































































Ii:\ble 6. J: ~linical. Qgtail!i! Qf w r~mih:: 
Initials Sex FDB FH-1 FH-2 FH-3 Age at Corneal Xanthe- Xanthomata CHO TCP TG HDL LDL Apof<! 
am12l1ng Ats.!.!s lHH As:.bill~!i! Qttu::i;: 
HQ tfi.!IAIIQH~ QCE!;IE;Q 
GBW M 56 N N N N N 7.29 1.36 1.09 5.6 ND 
CWJ F 30 N N N N N 6.36 0.93 1.36 4.6 ND 
HK M 34 N N N N N 5.91 2.55 0.88 3.9 ND 
PK F 7 N N N N N 4.29 0.56 1.53 2.5 ND 
MD F 35 N N N N N 7.3 0.69 1.34 5.6 ND 
JD F 12 N N N N N 5.65 0.77 1.63 3.7 ND 
WO F 8 N N N N N 5.91 0.48 1.66 4,0 ND 
PZ M 23 N N N N N 7.05 2.24 0.99 5 ND 
.JKK M 45 N N N N N 5.88 1.24 1.5 3.8 ND 
BKK F 41 N N N N N 4.81 3.2 0.73 2.6 ND 
HKK M 24 N N N N N 4.8 5.0 0.73 ND 
GKK M 23 N N N N N 4.51 1.05 1.05 2.97 ND 
AKK F 10 N N N N N 3.69 0.8 1.01 2.J ND 
MAB F ___li_ N N N N N ~.fifi 12,2! 1,22 !,12 ND 
28±14 ca 5.7 1.0 1.2 3.9h) 
db ±1.1 ±0.4 ±0.3 ±1.2ik 
tll-Af'RIJCANER-1 (FH-1) 
JAB M + 5 N N N N N 7.18 0.65 1.39 5.5 3/3 
BK M + 51 N N N N N 9.89 1.27 1.56 7.7 3/3 
KK F + 21 N N N N N 10.78 1.01 1.88 8.4 3/3 
.JK M + 17 N N N N N 7.85 1.47 1.18 6 3/3 
KB M ... -2..Q._ N N N N N 2,2fi !!,2fi !!,!!2 fi,2 2/3 
23:tl 7 a 8.7 1.1 1.4 6.9 h 
• ±1.5 ±0.3 ±0.4 ±1.21 
tll -ArBIKANEB-2 (FH-2) 
NM F + 50 N N N N N 13.12 3.65 1.06 10 3/3 
MK M + -1.L N N N N N !!,ZJ 1,Jfi 1,2J fi,2 3/3 
FH-AFRIKANER-1 26±18 a 9.4 1.5 1.3 7.J k. 
+ FH-AFRIKANER-2 COMBINED AVERAGES t ±2.1 ±1.0 ±0.3 ±1.5 m 
.EQI1 
GW M + 31 N N N N N 7.49 1.54 0.94 5.8 2/3 
SW M + 23 N N N N N 5,69 0,94 0.7 4,5 3/3 
MH F + 30 N N N N N 9,54 0.56 2.5 6,8 3/3 
co F + ~ N N N N N 2,!7 l.,!!i l.di 7d ,3/3 
28±4 b 8,0 1.02 1,4 6.1 1. 
g ±1,8 ±0.4 ±0.8 ±l.3n 
roa + rHi. 
cw r F + + 48 N y y N N 15.3 0.63 1.4 13.6 3/3 
RB F + + 26 N N y N N 15.59 0.93 1.35 13.8 3/3 
MZ F + + 21 N N N N N 11,86 2.16 0.8 10 3/3 
MB F + + __u_ N N y N N 1§,!!J l.,i l.,!1 Udi!! 3/3 
35±13 C 14, 7 1.4 1, 0 13. 0 Jk 
gte ±1.9 ±0,7 ±0.4 ±2 • 0 lmn 
rt!ll + flil + rH2 
knees 
JJK s M + + + 12 y N y elbows AESM 21.66 1.74 0.52 20.79 3/3 
hands (2/6) 
in 1979 in 






in all ace ghijklmn = Values in the designated groups compared by unpaired two tailed t-tests; p<0.005 
cases except for (i) where p = o.0053. All values expressed as mean ±s.o. 
p TC (total cholesterol), TG (triglycerides), HDL (HDL-cholesterol) and LDL (LDL-cholesterol) concentrations 
expressed as mmol/1 
q Apo E genotypes determined as described by Hixson and Vernier (1990) 
r CW was the only patient receiving treatment at the time ot sampling. Her sole treatment was plasma 
apharesis. This sample was taken >4 weeks after a plasma apharesis. 
s JJK underwent a partial ileal bypass in 1981, His lipid biochemistry values are pre-bypass values. 
AESM = Aortic ejection systolic murmur. 
Two clearly hyperlipidemic subjects, NM and MK, were negative 
for these mutations. We then screened NM and her children 
for the FH Afrikaner-2 and FH Afrikaner-3 mutations. NM and 
MK were found to be heterozygotes for the FH Afrikaner-2 
mutation and JJK was a triple heterozygote for both the FH 
Afrikaner-1 and FH Afrikaner-2 mutations and FOB. NM's 
deceased husband must therefore have been an obligate 
compound heterozygote for FH Afrikaner-1 and FOB. (I 
subsequently screened all the W family members that had been 
recruited for the FH Afrikaner -2 and -3 mutations but jid 
not discover any additional cases.) 
The availability of such large numbers of individuals with 
various combinations of LOL receptor mutations and FOB 
allowed us to examine and compare the clinical and 
biochemical features of these genetic disorders {Table 6.3). 
Total cholesterol levels were similar in the FH Afrikaner-1 
(8.7±1.5 mmol/1) and FOB heterozygote groups {8.0±1.8 mmol/1) 
and were clearly higher than normal (5.7±1.1 mmol/1). The 
LOL-cholesterol levels in the FH Afrikaner-1 (6.9±1.2 
mmol/1), FOB (6.1±1.3 mmol/1) and normal groups(3.9±1.2 
mmol/ 1) followed the same trend as the total cholesterol 
levels. One FDB heterozygote SW had a relatively normal 
lipid profile with total- and LDL-cholesterol levels of 5.69 
mmol/1 and 4.5 mmol/1, respectively, at age 23. The total-
and LOL-cholesterol levels of the FH-Afrikaner-1/FOB compound 
heterozygotes of 14.7±1.9 mmol/1 and 13.0±2.0 mmol/1, 
respectively, were higher than those of individuals who had 
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Table 6.4: Response of CW (a compound heterozygote with FOB 
and the FH Afrikaner-1 LDL-receptor mutation} to 
Simvastatin therapy 
Date coosage bTc TG LDL-C HDL-C 
16.03.92 15.3 0.63 13.6 1.4 
(pre-treatment) 
20 mg/day 
15.06.92 11.34 0.26 9.6 1.58 
a(-26%) (-58%) (-29%) ( +:.3%) 
40 mg/day 
27.07.92 9.36 0.58 
a(-39%) {-8%) 
a Percentage change in lipid level compared to starting value. 
b All lipid levels are in mmol/1 
c Drug was Simvastatin (Zocor, Logos Pharmaceuticals) 
just one of the mutations. None of the heterozygotes for 
either FH Afrikaner-1, FH Afrikaner-2 or FDB had xanthomata 
or Achilles tendon thickening (Table 6.3) but 3 of the 4 FH 
Afrikaner-1/FDB compounds had these stigmata. This might be 
significant as these three compounds were of similar ages to 
some of the patients with just one mutation. The youngest 
person in this category, MZ, 21 y, who had the lowest lipid 
levels, did not exhibit these stigmata. 
One of the FH Afrikaner-1/FDB subjects, the proband CW, had 
been undergoing plasma aphoresis that was stopped before 
January 1992. on 16. 3. 92 she was put on Simvastatin (20 
mg/day) that was increased 40 mg/day on 15.6.92. Her 
response to this drug (Table 6. 4) was good as far as the 
percentage drop in total- and LDL-cholesterol was concerned 
(39%), when compared to that observed in FH and other 
patients (reviewed by Todd and Goa 1990). However, the final 
total cholesterol level after 4. 5 months of treatment was 
9.6 mmol/1, which is the type of total cholesterol 
concentration that would be expected in an untreated FH 
heterozygote (Thompson 1989) . FH patients on Simvastatin 
treatment often reduce their total cholesterol levels to 65% 
or 70% of this value (Todd and Goa 1990). 
The clinical features of JJK, the "complex heterozygote" with 
PH-Afrikaner 1, FH Afrikaner-2 and FDB seem to be similar to 
those of an FH homozygote. Prior to his partial ileal bypass 
in 1981 (age 14) he had LDL-cholesterol levels of more than 
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20 mmol/1 (age 12), a corneal arcus and extensive planar and 
tendon xanthomata. His total cholesterol levels have dropped 
to 13. 7 mmol/ 1 ( age 24) and his xanthomata have largely 
regressed since the partial ileal bypass. He was not on any 
lipid-lowering medication for at least a year prior to this 
examination. However, although he is asymptomatic at 
present, he has a 2/6 aortic ejection systolic murmur and 
carotid bruits that are evidence of premature atherosclerosis 
(Table 6.3). 
6.3 DISCUSSION 
In a North American or European population the frequencies of 
LDL-receptor mutations and FDB are both about 1/500 
(Goldstein and Brown 1989, Innerarity et al. 1990). Thus one 
would expect to find equal numbers of the two types of 
defects in hypercholesterolemic patients with xanthomata or 
thickened tendons from these populations, as both conditions 
present with similar clinical features (Rauh et al. 1992, 
Tybjaerg-Hansen et al. 1990). 
Three founder LDL receptor mutations account for 74-98% of 
clinical monogenic hypercholesterolemia (MH) in the 
Afrikaners (Graadt van Roggen et al. 1991). Although the 
overall frequency of FH in Afrikaners is about 1/100 (Seftel 
et al. 1980), the frequency of non-founder LDL receptor 
mutations is approximately 1/500 ([100 - 74 to 98%] x 1/100), 
the same as . the frequency of FH in most other populations 
(Goldstein and Brown 1989). One would have expected to find 
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equal numbers of FDB and LDL receptor mutations in the 
patients with non-founder mutations with definite MH 
(hypercholesterolemia with xanthomata or thickened Achilles 
tendons) if the frequency of FDB in these populations was 
1/500. FDB was not detected in 7 Afrikaners with definite MH 
in our study and a further 13 such patients tested previously 
(Graadt van Roggen et al. 1991) or in 33 Afrikaners with 
possible MH or in any of the 
hyperlipidemic Afrikaners screened. 
other categories of 
Thus we feel that FDB is 
at best only a rare cause of monogenic hypercholesterolemia 
in this population. 
No cases of FDB were detected in the so-called Coloured or 
Indian populations. The same arguments that were used in the 
Afrikaners apply here and suggest that FDB is only a rare 
cause of hypercholesterolemia in these groups. 
The FDB mutation probably occurred once on a Caucasian 
ancestral chromosome and is not the result of multiple 
mutational events at a CpG dinucleotide (Ludwig and McCarthy 
1990). The frequency of this mutation probably varies in 
different populations as the allele's frequency was likely to 
have been amplified or reduced by founder effects and random 
genetic drift. The frequency of FDB in North American and 
European-Caucasian populations has been estimated to be 1/500 
(Innerarity et al. 1990). Although the frequency of this 
mutation has not been investigated extensively in non-
Caucasian populations (Ludwig and McCarthy 1990), FDB has not 
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been detected in Finns (Hamalainen et al. 1990) or in 
Japanese people (Hosking et al. 1991). 
There are a number of reasons why FDB might not have been 
frequently detected in the populations we screened. Firstly, 
the mutant allele might have been diluted by random drift. 
Alternatively, in the case of the Indians, it might not be 
present at all if it is an allele confined to European and 
North American Caucasians. In the Coloured population the 
mutant allele might not have bee!l present in the gene pools 
of their non-Caucasian ancestors and any FDB that might have 
been introduced from their European ancestors would have been 
dramatically diluted. 
One might argue that FDB is a milder disease than the FH 
caused by LDL-receptor mutations. Al though this was the 
impression initially (Innerarity et al. 1990), subsequent 
studies incorporating large numbers of FDB subjects suggest 
that the two diseases are generally clinically 
indistinguishable in presentation (Rauh et al. 1992; 
Tybjaerg-Hansen et al. 1990) and clinical response to lipid 
lowering therapy (Maher et al. 1991). In any case, FDB was 
not detected in any of the patients with possible MH or in 
any of the other hypercholesterolemic groups that were 
screened in this study. 
Two families each of mixed British and Afrikaner origin had 
FDB. (Because of the uncertain origin of this mutant gene 
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they were not considered to be Afrikaner). The FDB patients 
in both families had lipid levels compatible with FH. One 
patient, SW, in the W family had relatively normal levels, 
however. Perhaps this is support for the argument that there 
might be some patients with this mutation that have a milder 
disease (Innerarity et al. 1990). The variability in the 
expression of FDB in this subject cannot be explained by the 
apo E phenotype (see Table 6.3). Perhaps other genetic and 
environmental influences play a greater role in determining 
the lipid levels in FDB than in LDL-receptor deficiency, 
since the former mutation presumably only interferes with LDL 
clearance, while the latter set of defects affects IDL 
clearance, LDL production and LDL clearance. Consequently, 
since FDB presumably affects only the final step of this 
pathway, it is likely that the variability in the efficiency 
of the upstream steps is of greater consequence in FDB. 
Alternatively, the variability of FDB might be modified by 
polymorphisms in the "normal" apo B allele that affect the 
clearance rate of the normal LDL. The XbaI polymorphism in 
the apo B gene has been correlated with differing LDL 
clearance rates in vivo. The presence of cutting at this 
site in an individual is associated with increased LDL levels 
due to decreased catabolism of LDL. Subjects homozygous for 
XbaI cutting clear autologous LDL 22% less efficiently than 
their counterparts who are homozygous for apo B alleles that 
don't have the XbaI site (Houlston et al.1988, Demant et al. 
1988) . 
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The most interesting feature of the W family was the presence 
of 4 patients (+ 1 deceased) that were compounds for FH 
Afrikaner-1 and FDB. Only 1 case of a compound of an LDL-
receptor mutation and FDB has been to my knowledge previously 
reported (Rauh et al.1991). This group diagnosed LDL-
receptor deficiency by determining HMG-CoA reductase 
activity in skin fibroblasts, thus the genetic nature of the 
LDL-receptor mutation was not revealed. The conclusion of 
that group was that the compound was clinically very similar 
to patients with either defect. The ii family allowed the 
comparison of 4 such compounds with a similar number of FH 
Afrikaner-1 and FDB heterozygotes. 
The clinical features of the FH Afrikaner-1 and FDB 
heterozygotes were very similar and were clearly less severe 
than those of the compounds of FH Afrikaner-1 and FDB, both 
in terms of lipid levels and clinical features. The typical 
compound seems to have lipid levels that fall between the 
average levels found in FH heterozygotes (8.9 - 10.8 mmol/1) 
and those in homozygotes (18.8 to 20.3 mmol/1) (Thompson et 
al. 1989) . The range of total cholesterol concentrations 
quoted by Goldstein and Brown (1989) are 6.5 - 12.9 mmol/1 
and 15. 5 - 25. 8 mmol/ 1 for heterozygous and homozygous FH 
respectively. The total cholesterol values of our compounds 
were 11.86, 15.3, 15.6 and 16.0 mmol/1. Intuitively one 
would expect this to be the case: These compounds should be 
worse off than the FDB heterozygotes since there are not the 
normal number of receptors present to clear the normal apo-
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BlOO-LDL particles. Similarly they should be worse off than 
FH heterozygotes as only about 30% of the LDL particles at 
steady state are competent ligands (Innerarity et al. 1990) 
for the already reduced receptor complement. However, one 
would not expect these compounds to be as severely affected 
as FH homozygotes as a significant proportion of the LDL 
particles and LDL receptors are normal. 
Further evidence for the observation that these FH Afrikaner-
1/FDB compounds have a disease that is intermedia·.:e in 
severity between heterozygote and homozygote FH was revealed 
by one of these patient's responses to Simvastatin therapy. 
Al though her response was good and her total cholesterol 
levels dropped by 40%, her post-treatment levels were 
equivalent to those of an untreated FH or FDB heterozygote 
and certainly higher than one would expect from a treated FH 
or FDB subject (Todd and Goa 1990, Maher et al. 1991) (Table 
6. 4) • 
The clinical presentation of the "complex" heterozygote that 
had both FH Afrikaner-1 and -2 mutations and FDB was similar 
to that of a normal homozygote with LDL-receptor mutations 
(Thompson et al. 1989). It is not possible at present to say 
whether this subject is worse off with the apo B mutation 
than he might have been without it. The FH Afrikaner-1 
mutation does express a significant number of functional 
receptors on human skin fibroblasts but the FH Afrikaner-2 
mutation is practically a null mutation due to its very short 
188 
half-life (Fourie et al. 1988). Thus, a heteroallelic 
heterozygote for these two mutations would have some residual 
LDL-receptor activity (Fourie et al. 1988). The greater the 
residual LDL receptor activity is, the greater will be the 
liability of the additional presence of the FDB mutation. In 
theory, this could be assessed by comparing the ratio of 
mutant apo B to normal apo Bin LDL particles from the FDB, 
FDB/FH Afrikaner-1 and FH Afrikaner-1/FH Afrikaner-2/FDB 
subjects. (This type of experiment could be enhanced by 
treatment of this subject with Simvastat~n that would 
theoretically upregulate his residual functional receptors.) 
If the ratio of mutant to normal apo B were still 
significantly greater than 1: 1 in the patient with 2 LDL-
receptor mutations and FDB, then one would assume that there 
was residual LDL-receptor activity and that he was worse off 
having the additional apo B defect. The clinical sequelae 
would probably not be more severe than those in a patient 
with 2 null LDL-receptor alleles, as it is unlikely that any 
significant normal apo B-100-mediated LDL clearance occurs in 
the absence of LDL receptors. 
The presence of the combination of both apo B and LDL-
receptor gene defects in individuals in this family 
underlines the importance of testing for both classes of 
defects in the appropriate populations and patient groups at 
risk. Populations that have a particularly high frequency of 
either FDB or LDL-receptor mutations are more likely to 
contain individuals with both types of defect. This scenario 
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should be considered in "FH heterozygotes" with slightly 
higher than expected lipid levels that do not drop as close 
to normal as one would expect on Simvastatin or similar 
therapy. The identification of one of these 2 causes of 
monogenic hypercholesterolemia should not be considered 
completely diagnostic unless the other class of defect has 




One of the hallmarks of progress in medical science has been 
in the way the concept of disease has been understood. 
Initially, most diseases were merely symptom complexes that 
behaved distinctly. Then followed a mechanistic elucidation 
of the pathological processes that caused the symptom 
complexes. In certain cases, it was found that different and 
distinct pathological processes resulted in final symptom 
complexes that were similar. The fact that two or more 
distinct "diseases" can cause similar symptom complexes was 
an important step forwards. Often the different "diseases" 
had different cures and/or prognoses. The converse situation 
also arose where two seemingly unrelated symptom complexes 
had the same pathological cause and could be treated 
together. Thus, it was important to understand diseases as 
pathological processes and not merely as symptom complexes. 
The recent explosion in the knowledge of the molecular basis 
of disease has introduced a further level of understanding of 
many disease processes: the precise mutations and the genes 
involved in diseases can be identified. 
The understanding of 
followed this pathway. 
familial hypercholesterolemia has 
In 1873 Fagge ( 1873) described FH 
associated with xanthomas in a multigenerational family and 
hypothesised that the fatty deposits in the skin were related 
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to those in the arteries. In 1939 Carl Muller (1939) 
consolidated the understanding of this symptom complex in his 
description of Familial Hypercholesterolemia as a fairly 
common dominant inborn error of metabolism that resulted in 
xanthomata, raised plasma cholesterol concentrations and an 
increased frequency of early heart attacks. The work of 
Khachadurian in the 1960s (Khachadurian 1964) elucidated 
further aspects of this disease by clearly demonstrating 
differences in clinical severity between homozygotes and 
heterozygotes. 
(1934) that an 
The observations of Gofman and colleagues 
elevation of LDL particles caused the 
hypercholesterolemia in FH and 
Fredrickson et al. (1967) that this 
the demonstrations by 
was due to impaired LDL 
catabolism, marked the stage when the pathological processes 
underlying FH began to be understood. 
The work of Brown and Goldstein that showed that FH was 
caused by mutations in the gene coding for the cell-surface 
receptor for LDL, led to the understanding of this 
pathological process at the genetic level (Brown et al. 1974, 
Brown and Goldstein 1974). Today we know that many different 
mutations in the LDL-receptor gene (Hobbs et al. 1990) and 
the mutation at codon 3500 in apo BlOO (Rauh et al. 1992) 
cause this clinical picture. One could argue that the 
importance today of knowing the precise nature of the 
mutations involved in individual patients is probably only of 
academic int~rest . However, considerable heterogeneity of 
FH exists ·and is perhaps most clearly demonstrated by the 
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susceptibility to heart disease of patients homozygous for 
null mutations relative to those with receptor-defective LOL 
receptor mutations (Yamamoto et al. 1989, Goldstein and Brown 
1983). There also seems to be considerable heterogeneity in 
the expression of FOB that is as yet unexplained (Innerarity 
et al. 1990). Although at the moment there does not seem to 
be much difference in the therapeutic response of FOB and 
LOL-receptor mutations to cholesterol-lowering therapy (Maher 
et al. 1991), such a difference might exist with newer drugs 
that are developed since these "diseases" cause 
hypercholesterolemia through subtly distinct mechanisms. 
Perhaps the next step in the understanding of disease is 
going to be progress in the elucidation of gene-gene and 
gene-environment interactions that result in variation in 
disease expression and cause polygenic conditions. 
The main aim of this thesis was to try to identify and 
understand the mutations responsible for familial 
hypercholesterolemia in the South African Indian population. 
At least four different LOL receptor mutations have been 
identified: The Pro664 -Leu, Asp69-Tyr, Glu119-Lys point 
mutations and the "Null" mutation in NS. 
The Pro664 -Leu mutation, FH Zambia, was initially described 
and characterised by Soutar and Knight as a mutation that 
resulted in the LOL receptor having an impaired affinity for 
both LDL and B-VLDL (Knight et al. 1989, Soutar et al. 1989). 
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This finding seemed very interesting as the point mutation 
was in Repeat c in the EGF-precursor homology domain, more 
than 300 amino acids away from the ligand-binding domain of 
the receptor. The availability of fibroblasts from two 
patients who were homozygous for this mutation allowed us to 
re-examine this mutant protein's behaviour. Our studies 
suggested that this mutation does not affect the mutant 
receptor's ability to bind either B-VLDL or LDL. The 
mutation resulted in the rapid degradation of mature 
receptors that could account for the decreased cell-surface 
population of normally functional receptors. This presumably 
caused FH in these subjects. 
The patient D was a heteroallelic homozygote with the Asp69 -
Tyr (ligand-binding repeat 2) and Glu119-Lys (repeat 3) point 
mutations (both at highly conserved sites). The impaired 
ability of mutant receptors on his fibroblasts to bind LDL 
was consistent with the results of experiments done using 
artificial constructs with nearby mutations or deletions of 
the same ligand-binding repeats (Russell et al. 1990). 
Natural mutations at homologous sites in different ligand-
binding repeats suggest that both asp69 and glu119 play 
important functional or structural roles within their repeats 
(Leitersdorf et al. 1990; Leitersdorf E, Graadt van Roggen F, 
van der Westhuyzen D and Coetzee G, personal communication.) 
Thus, these amino acid substitutions are believed to be the 
mutations causing FH in this patient. 
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The patient NS did not express any detectable LDL-receptor 
protein. The mRNA levels from his fibroblasts were low when 
compared to normal but the message size was approximately 
normal. The absence of any abnormality in the promoter of 
his gene suggests that this mutation is probably a point 
mutation or a small insertion or deletion that creates a stop 
codon. 
JL, a Black patient belonging to the Pedi tribe, was also 
investigated as an FH homozygote whose fibroblasts expressed 
very low numbers of LDL-receptors. The underlying cause for 
the receptor deficiency in this patient was shown to be at 
the synthetic level. This was confirmed by the finding of 
low LDL-receptor mRNA levels. DNA sequence analysis of JL's 
LDL-receptor promoter revealed that he was a heteroallelic 
homozygote and that one of his alleles had a 3 b.p. deletion 
in the Spl repeat 1 (G.Zuilani, H.Hobbs and L.F. de Waal, 
personal communication). 
Indian patients referred to us by Lipid clinics from all over 
the country were screened for the three point mutations that 
were identified in this group and for FDB (Fig. 7.1). It was 
not surprising that we detected no major founder LDL-receptor 
mutation in the Indians, as they are descended from a large 
initial immigrant population (150 000) of diverse 
geographical, cultural and religious origins and have only 
been in South Africa for 3-4 generations. However, it was 










































































































































































































































































































































































































































































































































































































































































































































































































Pro664 -Leu mutation. All four families were Muslim and 
traced their origins to the vicinity of Surat in the Gujerat 
province of India. The patient MM that was described by 
Soutar and Knight (Soutar et al. 1989, Knight et al. 1989) 
and the subsequent Indian identified with this mutation in 
London (King-Underwood et al. 1991) were also of Gujerati 
Muslim origin. It is thus likely that there is a founder 
pocket of this mutation in that area of India. 
The SSCP technique was used 
subsequently to screen for the 
initially 
Asp69-Tyr 
to c..etect and 
and Glu119-LYS 
mutations among Indian lipid clinic patients. Except for the 
index case, no other patients with these mutations were 
identified. There are still a few Indian families with 
definite FH (raised cholesterol levels and xanthomata) whose 
defects are not known. It is possible that some of them have 
the as yet unidentified "Null" mutation found in NS but the 
more likely scenario is that there are many different LDL-
receptor mutations in this group reflecting their diverse 
geographical origins. 
To the best of my knowledge, there have been no previous 
studies that have investigated FDB in South Africa. No FDB 
was detected in any of the Indian patients that were 
screened. The absence of this mutation in these patients 
suggests that the majority of clinical FH in South African 
Indians can probably be accounted for by mutations in the 
LDL-receptor gene and that the frequency of FDB is probably 
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lower than that found in European and North American 
Caucasians. 
We also screened a number of Afrikaner, so-called Coloured 
and Jewish patients for the FDB mutation. Patients who were 
positive for founder LDL-receptor mutations were considered 
separately from those who were negative. The absence of FDB 
in the FH patients who didn't have the LDL-receptor founder 
mutations was evidence that this mutation is not a major 
contributor to clinical FH in the Afrikaner.; and the so-
called Coloureds. The frequency of both FH and FDB in 
European populations have both been estimated at 1/500 
(Goldstein and Brown 1989, Innerarity et al. 1990). We thus 
would have expected similar numbers of LDL-receptor mutations 
and FDB to cause "FH" in our subjects that did not have 
founder mutations. It is thus possible that FDB might be 
under-represented in the Afrikaners and so-called Coloureds 
compared to the European populations. (The number of definite 
Jewish FH patients that were screened for FDB that were 
negative for the FH Piscataway mutation was too small to 
allow us to comment). 
As part of this screening program we identified two families 
of mixed English and Afrikaner descent that had the FOB 
mutation. One of the families was particularly interesting, 
as in addition to subjects who were heterozygous for FOB, 
there were heterozygotes for the FH Afrikaner-1 and FH 
Afrikaner-2· LDL receptor mutations, a number of compound 
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heterozygotes for FDB and FH Afrikaner-! mutations and one 
subject who was a heteroallelic homozygote for the FH 
Afrikaner-! and FH Afrikaner-2 mutations and heterozygous for 
FDB. The availability of such a diversity of mutations in 
one family allowed us to compare the clinical severity of 
each alone and in combination. The subjects who were 
heterozygous for LOL-receptor mutations were clinically 
similar to those with FOB. The subjects who had a 
combination of an LOL-receptor defect and FDB were clearly 
worse off than those with either defect, in contrast to ~he 
previous report of such a patient (Rauh et al. 1991). 
However these subjects were not as severely affected as 
typical FH homozygotes. The co-inheritance of both ligand 
and receptor defects might be more common than one might 
imagine especially in populations that have an enrichment of 
one or both of these causes of monogenic 
hypercholesterolemia. 
In conclusion, 4 different LOL-receptor mutations were 
identified in South Africans of Indian origin. There was no 
evidence of a founder effect amplifying the frequency of any 
of these mutations in South Africa. However, the FH Zambia 
mutation is likely to be common in Muslims of Guj era ti 
origin. FOB was not detected in any Indian, Afrikaner or 
Coloured patients with Monogenic Hypercholesterolemia and is 
probably not as prevalent in these populations as it is in 
European and North American Caucasians. 
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